UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 6, 2014

 


 

PHYSICIANS REALTY TRUST

(Exact name of registrant as specified in its charter)

 


 

Maryland
(State or other jurisdiction of
incorporation or organization)

 

001-36007
(Commission File Number)

 

46-2519850
(I.R.S. Employer Identification No.)

 

735 N. Water Street, Suite 1000
Milwaukee, Wisconsin
(Address of principal executive offices)

 

53202
(Zip Code)

 

Registrant’s telephone number, including area code: (414) 978-6494

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 2.02 Results of Operations and Financial Condition.

 

On May 7, 2014, Physicians Realty Trust (the “Company”) issued a press release that announced operating results for its first quarter ended March 31, 2014. The press release refers to a supplemental information package that is available on the Company’s website (www.docreit.com), free of charge.  Copies of the press release and supplemental information package have been furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report, and are incorporated herein by reference.

 

The information included in Item 2.02 of this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On May 6, 2014, the Company and each of John Thomas, Chief Executive Officer, John Sweet, Chief Investment Officer, John Lucey, Senior Vice President and Principal Accounting and Reporting Officer and Mark Theine, Senior Vice President Asset and Investment Management (the “Executive Officers”) entered into amended employment agreements (the “Amended Agreements”), which provide for the Compensation and Nominating Governance Committee (the “Committee”) of the Board of Trustees of the Company to use its discretion in setting the amount of annual bonus to be paid to each Executive Officer and to make other administrative changes to the agreements.

 

On May 6, 2014, the Committee approved the Physicians Realty Trust Incentive Bonus Plan, effective for the 2014 fiscal year and future fiscal years (the “Bonus Plan”). The Bonus Plan provides for the payment of annual cash bonuses to eligible key employees. The performance goals under the Bonus Plan may include any one or any combination of financial, operational, sales or other goals, which may be Company-wide, on a business unit or individual basis or otherwise, and may be expressed, for example, in terms of return on invested capital, revenue, net income or loss, real estate investments, funds from operations, or the attainment of various growth objectives.

 

On May 6, 2014, the Committee approved an amendment to the Physicians Realty Trust 2013 Equity Plan (“Amendment No. 1 to the 2013 Plan”) removing certain limitations on required periods for time vesting of awards and granting to the Committee the authority to administer and amend the 2013 Equity Plan.

 

The foregoing description of certain terms of the Amended Agreements, the Bonus Plan and the Amendment No. 1 to the 2013 Plan do not purport to be complete and are qualified in their entirety by reference to the full text of the Amended Agreements, the Bonus Plan and Amendment No. 1 to the 2013 Plan, copies of which are attached as Exhibits 10.1, 10.2, 10.3, 10.4, 10.5 and 10.6 to this Current Report and are incorporated in this Item 5.02 by reference.

 

Item 9.01. Financial Statement and Exhibits.

 

(d) Exhibits

 

10.1* Amended and Restated Employment Agreement dated as of May 6, 2014, between the Company and John T. Thomas.

 

10.2* Amended and Restated Employment Agreement dated as of May 6, 2014, between the Company and John Sweet.

 

10.3* Amended and Restated Employment Agreement dated as of May 6, 2014, between the Company and John Lucey.

 

10.4* Amended and Restated Employment Agreement dated as of May 6, 2014, between the Company and Mark D. Theine.

 

10.5* Physicians Realty Trust Incentive Bonus Plan.

 

2



 

10.6* Amendment No. 1 to the Physicians Realty Trust 2013 Equity Plan.

 

10.7* Form of Restricted Share Award Agreement - Executive (Time Vesting).

 

10.8* Form of Restricted Share Award Agreement - Trustees (Time Vesting).

 

10.9* Form of Restricted Share Unit Award Agreement (Performance Units).

 

99.1 Press Release, dated May 7, 2014, issued by Physicians Realty Trust.

 

99.2 Supplemental Operating & Financial Information, First Quarter 2014.

 


*Indicates a management contract or compensatory plan or arrangement.

 

3



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: May 7, 2014

PHYSICIANS REALTY TRUST

 

 

 

 

 

 

 

By:

/s/ John T. Thomas

 

 

John T. Thomas

 

 

President and Chief Executive Officer

 

4



 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

 

 

10.1*

 

Amended and Restated Employment Agreement dated as of May 6, 2014, between the Company and John T. Thomas.

 

 

 

10.2*

 

Amended and Restated Employment Agreement dated as of May 6, 2014, between the Company and John Sweet.

 

 

 

10.3*

 

Amended and Restated Employment Agreement dated as of May 6, 2014, between the Company and John Lucey.

 

 

 

10.4*

 

Amended and Restated Employment Agreement dated as of M May 6, 2014, between the Company and Mark D. Theine.

 

 

 

10.5*

 

Physicians Realty Trust Incentive Bonus Plan.

 

 

 

10.6*

 

Amendment No. 1 to the Physicians Realty Trust 2013 Equity Plan.

 

 

 

10.7*

 

Form of Restricted Share Award Agreement - Executive (Time Vesting).

 

 

 

10.8*

 

Form of Restricted Share Award Agreement - Trustees (Time Vesting).

 

 

 

10.9*

 

Form of Restricted Share Unit Award Agreement (Performance Units).

 

 

 

99.1

 

Press Release, dated May 7, 2014, issued by Physicians Realty Trust.

 

 

 

99.2

 

Supplemental Operating & Financial Information, First Quarter 2014.

 

 


*Indicates a management contract or compensatory plan or arrangement.

 

5


Exhibit 10.1

 

AMENDED AND RESTATED

EMPLOYMENT AGREEMENT

 

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) by and between PHYSICIANS REALTY TRUST, a Maryland trust, (the “Company”), and JOHN T. THOMAS (the “Executive”) is entered into this 6th day of May, 2014, but effective as of the 24th day of July, 2013 (the “Effective Date”).

 

WHEREAS , the Company and the Executive entered into an Employment Agreement (the “Original Agreement”) dated the Effective Date, providing for the Executive’s employment and setting forth the terms and conditions for such employment; and

 

WHEREAS , the Company and the Executive desire to amend and restate the Original Agreement to provide for certain changes to the terms and conditions of the Executive’s employment by the Company, as reflected in this Agreement.

 

NOW THEREFORE , in consideration of the mutual covenants herein contained, the parties, intending to be legally bound, hereby agree as follows:

 

1.                                       EMPLOYMENT

 

The Company hereby agrees to employ the Executive as its President and Chief Executive Officer (the “CEO”) upon the terms and conditions herein contained, and the Executive hereby agrees to accept such employment and to serve in such position. As CEO, the Executive will have those duties which can reasonably be expected to be performed by a person in such position and shall undertake such other responsibilities as may be assigned to the Executive by the Company’s Board of Trustees from time to time. For purposes of this Agreement, all references to the “Board” shall mean the Board of Trustees, excluding the Executive. In such capacity, the Executive shall report to the Company’s Board and shall have such powers and responsibilities consistent with his position as may be assigned. The Company agrees to nominate the Executive to be a member of the Board and any Executive Committee (or similar Committee) of the Board for the Employment Term (as defined below) at the next regularly scheduled meeting of the Board that occurs after the Effective Date of this Agreement. Throughout the Employment Term, the Executive shall devote his best efforts and all of his business time and services to the business and affairs of the Company.

 

2.                                       TERM OF AGREEMENT

 

Subject to earlier termination as herein provided, the Executive’s employment under this Agreement shall begin on the Effective Date and shall continue in effect until the third anniversary of the Effective Date (the “Initial Term”). The Agreement will automatically renew, subject to earlier termination as herein provided, for successive one (1) year periods (the “Additional Terms”), unless either the Executive or the Company provide notice of non-renewal at least sixty (60) days prior to the expiration of the Initial Term or the then Additional Term, whichever is applicable. The Initial Term and any Additional Term(s) shall be referred to collectively as the “Employment Term.”

 

Notwithstanding the foregoing, the Company shall be entitled to terminate this Agreement immediately, subject to a continuing obligation to make any payments required under Section 5 below, if the Executive (i) incurs a Disability as described in Section 5(b) , (ii) is terminated for Cause, as defined in Section 5(c) , or (iii) voluntarily terminates his employment without Good Reason (as defined below) during the Employment Term, as described in Section 5(d) .

 



 

3.                                       SALARY AND BONUS .

 

The Executive shall receive a base salary during the Employment Term at a rate of $300,000 per annum for 2013 (the “Base Salary”), payable in substantially equal semi-monthly installments. The Compensation Committee of the Board shall consult with the CEO and review the Executive’s Base Salary at annual intervals, and may increase the Executive’s annual Base Salary from time to time as the Committee deems to be appropriate.

 

Subject to Section 12 , the Executive will have an annual cash bonus opportunity for each calendar year during the Employment Term (the “Annual Bonus”) based upon performance goals that are established by the Board or the Compensation Committee of the Board, as the case may be, in its sole discretion.  In the event an Annual Bonus is payable pursuant to this Section 3 , such bonus shall be paid to the Executive no later than March 15th of the year after the year to which the bonus relates.

 

On or as soon as administratively practicable after the date of an Initial Public Offering (as defined below) (but in no event later than sixty (60) days after the date of an Initial Public Offering), the Executive shall receive a grant of restricted shares of the Company’s common shares having a value of $1,000,000 based on the public offering price per share of the Company’s common shares offered for sale at the Initial Public Offering (the “Restricted Shares”). The Restricted Shares shall be subject to the restrictions set forth in the restricted share agreement between the Company and the Executive and the terms of an equity incentive plan adopted by the Company prior to the grant of the Restricted Shares (the “Plan”). The Restricted Shares shall vest over a three-year period, with one-third of the Restricted Shares vesting equally on the first, second, and third anniversary of the Effective Date, subject to any forfeiture or acceleration provisions set forth in the restricted share agreement and the Plan. For purposes of this Agreement, “Initial Public Offering” means any underwritten sale of the Company’s equity securities pursuant to an effective registration statement under the Securities Act of 1933 filed with the Securities and Exchange Commission on Form S-1 or any other eligible form (or a successor form thereto adopted by the Securities and Exchange Commission).

 

4.                                       ADDITIONAL COMPENSATION AND BENEFITS

 

The Executive shall receive the following additional compensation and welfare and fringe benefits during the term of the Agreement:

 

(a)                                  Options and Other Long-Term Incentives . During the Employment Term, any options, restricted shares or other awards granted under the Plan shall be at the discretion of the Compensation Committee of the Company’s Board.

 

(b)                                  Vacation . The Executive shall be entitled to up to four (4) weeks of vacation during each year during the Employment Term and any extensions thereof, prorated for partial years.

 

(c)                                   Business Expenses . The Company shall reimburse the Executive for all reasonable expenses he incurs in promoting the Company’s business, including expenses for travel and similar items, upon presentation by the Executive from time to time of an itemized account of such expenditures. Any reimbursement of expenses made under this Agreement shall only be made for eligible expenses (including transportation and cellular service expenses as set forth above) incurred during the Employment Term, and no reimbursement of any expense shall be made by the Company after December 31st of the year following the calendar year in which the expense was incurred. The amount eligible for reimbursement under this Agreement during a taxable year may not affect expenses eligible for reimbursement in any other taxable year, and the

 

2



 

right to reimbursement under this Agreement is not subject to liquidation or exchange for another benefit. The Executive will comply with the Company’s policies regarding these benefits, including all Internal Revenue Service rules and requirements.

 

(d)                                  Professional Expenses . Each calendar year during the Employment Term, the Company agrees to reimburse the Executive for up to $10,000 of reasonable professional expenses (i.e., accounting, financial planning, estate planning expenses) incurred by the Executive during such year for personal advice rendered to the Executive.

 

(e)                                   Other Benefits and Perquisites . The Executive shall be entitled to participate in the benefit plans provided by the Company for all employees, generally, and for the Company’s executive employees. The Company shall be entitled to change or terminate these plans in its sole discretion at any time.

 

5.                                       PAYMENTS UPON TERMINATION

 

(a)                                  Involuntary Termination . If the Executive’s employment is involuntarily terminated by the Company during the Employment Term, the Executive shall be entitled to receive his Base Salary accrued through the date of termination, any accrued but unpaid vacation pay, plus any bonuses earned but unpaid with respect to fiscal years or other periods ending before the termination date (collectively, the “Accrued Obligations”). Such payments shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of involuntary termination). The Executive shall also receive any nonforfeitable benefits payable to him under the terms of any deferred compensation, incentive or other benefit plans maintained by the Company, payable in accordance with the terms of the applicable plan.

 

If the termination is not (1) a termination for Cause (as defined below), as described in Section 5(c) ; (2) a voluntary termination by the Executive without Good Reason (as defined below) as described in Section 5(d) ; (3) a termination as a result of the Executive’s death or Disability (as defined below); or (4) a termination due to non-renewal of the then current term as described in Section 5(e) , then subject to compliance with the restrictive covenants in Section 9 and Section 10 and the execution and timely return by the Executive of a release of claims in a form and substance reasonably requested by the Company (the “Release”), and except as otherwise provided by Sections 12 and 18 , the Company shall pay severance to the Executive in accordance with its normal payroll practices, equal to the Executive’s Base Salary as in effect at the time his employment terminates for a period equal to the greater of (a) the remainder of the then current term of this Agreement or (b) twenty-four (24) months, with the first payment on the first payroll date after the revocation period for the Release has expired; provided, that if the time period for returning and revoking the release begins in one taxable year and ends in a second taxable year, the payments shall not commence until the first payroll date in the second taxable year.

 

In addition, if the termination is not (1) a termination for Cause, as described in Section 5(c) ; (2) a voluntary termination by the Executive without Good Reason as described in Section 5(d) ; (3) a termination as a result of the Executive’s death or Disability (as defined below); or (4) a termination due to non-renewal of the then current term as described in Section 5(e) , then, subject to compliance with the restrictive covenants in Section 9 and Section 10 , the execution and timely return by the Executive of the Release, and except as otherwise provided by Sections 12 and 18 , the Executive shall be entitled to the following:

 

3



 

(i)                                      Any options, restricted shares or other awards granted to the Executive under the Plan shall become fully vested and, in the case of options, exercisable in full;

 

(ii)                                   Provided that the Executive elects continuation of coverage under the Company’s group health plan pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1986, as amended (“COBRA”), the Executive shall be provided continued coverage at the Company’s expense under any health insurance programs maintained by the Company in which the Executive participated at the time of his termination for twelve (12) months, or until, if earlier, the date the Executive obtains comparable coverage under a group health plan maintained by a new employer. To the extent the benefits provided under the immediately preceding sentence are otherwise taxable to the Executive, such benefits, for purposes of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) (and the regulations and other guidance issued thereunder) shall be provided as separate monthly in-kind payments of those benefits, and to the extent those benefits are subject to and not otherwise excepted from Section 409A of the Code, the provision of the in-kind benefits during one calendar year shall not affect the in-kind benefits to be provided in any other calendar year; and

 

(iii)                                Any Annual Bonus(es) payable under Section 3 above that would have been earned based solely on continued employment for the remainder of the then current term, and if none, then an amount equal to fifty percent (50%) of the Executive’s then current Base Salary, payable at the same time as bonuses are paid to other active employees of the Company with respect to such performance period, and forfeited if the Executive violates any of the restrictive covenants in Section 9 and Section 10 .

 

(b)                                  Disability . The Company shall be entitled to terminate the Executive’s employment if the Board determines that the Executive has been unable to attend to his duties for at least ninety (90) days because of a Disability (as defined below), and has received a written opinion from a physician acceptable to the Board that such condition prevents the Executive from resuming full performance of his duties and is likely to continue for an indefinite period. Upon such involuntary termination, the Executive shall be entitled to receive the Accrued Obligations. Such payments shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of involuntary termination). In addition, subject to compliance with the restrictive covenants in Section 9 and Section 10 and the execution and timely return by the Executive of the Release, the Company shall pay severance to the Executive in accordance with its normal payroll practices, equal to twelve (12) months of the Executive’s Base Salary as in effect at the time his employment terminates, with the first payment on the first payroll date after the revocation period for the Release has expired; provided, that (i) if the time period for returning and revoking the Release begins in one taxable year and ends in a second taxable year, the payments shall not commence until the first payroll date in the second taxable year; and (ii) all such payments shall immediately terminate at an earlier date if the Executive returns to active employment, either with the Company or otherwise. Any amounts payable under this Section 5(b)  shall be reduced on a dollar-for-dollar basis by the amount of bona fide disability pay (within the meaning of Treas. Reg. section 1.409A-1(a)(5)) received or receivable by the Executive during such twelve-month period, provided such disability payments are made pursuant to a plan sponsored by the Company that covers a substantial number of employees of the Company and was established prior to the date the Executive incurred a permanent disability, and further provided that such reduction does not otherwise affect the time of payment of amounts pursuant to this Section 5(b) . For purposes of this Agreement, “Disability” means the Executive is incapacitated due to physical or mental illness and such incapacity, with or without reasonable accommodation, prevents the Executive from satisfactorily

 

4



 

performing the essential functions of his job for the Company on a full-time basis for at least ninety (90) days in a calendar year.

 

(c)                                   Termination for Cause . If the Executive’s employment is terminated by the Company for Cause, the amount the Executive shall be entitled to receive from the Company shall be limited to the Accrued Obligations. Such payments shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of termination).

 

For purposes of this Agreement, the term “ Cause ” shall be limited to the following:

 

(i)                                      the Executive engaging in any act of fraud, dishonesty, theft, misappropriation or embezzlement of funds or misrepresentation with respect to the Company;

 

(ii)                                   the Executive’s conviction or plea of no contest with respect to any felony or other crime involving moral turpitude;

 

(iii)                                the Executive’s material breach of his obligations under this Agreement, including, without limitation, breach of the covenants set forth in Section 9 and Section 10 below or the refusal of the Executive to perform his job duties as directed by the Board, which the Executive failed to cure within thirty (30) days after receiving written notice from the Board specifying the alleged breach;

 

(iv)                               violation of any material duty or obligation to the Company or of any direction or any rule or regulation reasonably established by the Board, which the Executive failed to cure within thirty (30) days after receiving written notice from the Board specifying the alleged violation; or

 

(v)                                  insubordination or misconduct in the performance of, or neglect of, the Executive’s duties which the Executive failed to cure within thirty (30) days after receiving written notice from the Board specifying the alleged insubordination, misconduct, or neglect.

 

(d)                                  Voluntary Termination by the Executive without Good Reason . If the Executive resigns or otherwise voluntarily terminates his employment before the end of the current Employment Term (other than in connection with a Change in Corporate Control, as described in Section 6 ), the amount the Executive shall be entitled to receive from the Company shall be limited to the Accrued Obligations. Such payment shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of resignation or voluntary termination).

 

For purposes of this Agreement, a resignation by the Executive shall not be deemed to be voluntary without Good Reason if, without the Executive’s prior consent, the Executive is (1) assigned to a position other than the CEO (other than for Cause or by reason of his Disability) or assigned duties materially inconsistent with such position if either such change in assignment constitutes a material diminution in the Executive’s authority, duties or responsibilities, or (2) directed to report to anyone other than the Board if such change in reporting duties constitutes a material diminution in the authority, duties or responsibilities of the supervisor to whom the Executive is required to report; provided that the Executive has notified the Company within the first ninety (90) days following the initial date of such change in assignment or reporting duties

 

5



 

that the Executive regards such change in assignment or reporting duties as grounds justifying resignation under this Section 5(d)  and the Company has failed to cure such change in assignment or reporting duties within ninety (90) days following its receipt of such notice from the Executive; and provided further that the Executive resigns under this Section 5(d) within six (6) months following the initial existence of a change in assignment or reporting duties described herein.

 

(e)                                   Non-Renewal . The Executive’s employment shall terminate in the event that the then-current Employment Term expires by reason of a party giving a notice of an election not to renew as provided in Section 2 . If the Executive’s employment terminates due to non-renewal of the Agreement, the amount the Executive shall be entitled to receive from the Company shall be limited to the Accrued Obligations. Such payment shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the expiration of the then-current term).

 

6.                                       EFFECT OF CHANGE IN CORPORATE CONTROL

 

(a)                                  Accelerated Vesting of Awards . In the event of a Change in Control (as such term is defined in the Plan), the vesting of any options, restricted shares or other awards granted to the Executive under the terms of the Plan shall be accelerated (to the extent permitted by the terms of the Plan) and such awards shall become immediately vested in full and, in the case of options, exercisable in full.

 

(b)                                  Severance Payment . If, during the Employment Term at any time during the period of twelve (12) consecutive months following the occurrence of a Change in Corporate Control, the Executive is involuntarily terminated (other than for Cause) or the Executive terminates his employment for Good Reason, then subject to compliance with the restrictive covenants in Section 9 and Section 10 and the execution and timely return by the Executive of the Release, the Executive shall be entitled to receive a lump sum severance payment equal to the present value of a series of monthly payments for twenty-four (24) months, each in an amount equal to one-twelfth (1/12th) of the sum of (i) the Executive’s Base Salary, as in effect at the time of the Change in Corporate Control, and (ii) the average of the annual bonuses paid to the Executive for the prior two fiscal years of the Company ending prior to the Change in Corporate Control, if any. Such present value shall be calculated using a discount rate equal to the interest rate on 90-day Treasury bills, as reported in the Wall Street Journal (or similar publication) on the date of the Change in Corporate Control. Such lump sum payment shall be made to the Executive within sixty (60) days following the date of such involuntary termination.

 

In addition, if during the Employment Term within twelve (12) months after a Change in Corporate Control the Executive is involuntarily terminated (other than for Cause) or the Executive terminates his employment for Good Reason, he shall be entitled to continued coverage at the Company’s expense under any health insurance programs maintained by the Company in which the Executive participated at the time of his termination, which coverage shall be continued for eighteen (18) months or until, if earlier, the date the Executive obtains comparable coverage under a group health plan maintained by a new employer. To the extent the benefits provided under the immediately preceding sentence are otherwise taxable to the Executive, such benefits, for purposes of Section 409A of the Code (and the regulations and other guidance issued thereunder) shall be provided as separate monthly in-kind payments of those benefits, and to the extent those benefits are subject to and not otherwise excepted from Section 409A of the Code, the provision of the in-kind benefits during one calendar year shall not affect the in-kind benefits to be provided in any other calendar year.

 

6



 

(c)                                   Definition of Change in Corporate Control . For purposes of this Agreement, a “Change in Corporate Control” shall include any of the following events:

 

(i)                                      The acquisition in one or more transactions of more than fifty percent (50%) of the Company’s outstanding Common Shares (or the equivalent in voting power of any class or classes of securities of the Company entitled to vote in elections of trustees) by any Company, or other person or group (within the meaning of Section 14(d)(3) of the Securities Exchange Act of 1934, as amended);

 

(ii)                                   Any transfer or sale of substantially all of the assets of the Company, or any merger or consolidation of the Company into or with another Company in which the Company is not the surviving entity;

 

Provided, however, that no event shall constitute a Change in Corporate Control unless such event is also a “change in ownership”, a “change in effective control” or a “change in the ownership of a substantial portion of the assets” of the Company, as determined in accordance with Section 409A of the Code, and the regulations and guidance issued thereunder.

 

7.                                       DEATH

 

If the Executive dies during the Employment Term, the Company shall pay to the Executive’s surviving spouse or if there is no surviving spouse, the Executive’s estate, a lump sum payment equal to the Accrued Obligations. Such payment shall be paid within the time period required by applicable law (and in all events within sixty (60) days following the date of the Executive’s death). In addition, the death benefits payable by reason of the Executive’s death under any retirement, deferred compensation, life insurance or other employee benefit plan maintained by the Company shall be paid to the beneficiary designated by the Executive, and the options, restricted shares or other awards held by the Executive under the Company’s equity incentive plans shall become fully vested, and, in the case of options, exercisable in full, in accordance with the terms of the applicable plan or plans.

 

8.                                       WITHHOLDING

 

The Company shall, to the extent permitted by law, have the right to withhold and deduct from any payment hereunder any federal, state or local taxes of any kind required by law to be withheld with respect to any such payment.

 

9.                                       PROTECTION OF CONFIDENTIAL INFORMATION

 

During the Executive’s employment with the Company, the Company shall grant the Executive otherwise prohibited access to its trade secrets and confidential information which are not known to the Company’s competitors or within the Company’s industry generally, which were developed by the Company over a long period of time and/or at its substantial expense, and which are of great competitive value to the Company, and access to the Company’s customers and clients. For purposes of this Agreement, “Confidential Information” includes all trade secrets and confidential and proprietary information of the Company, including, but not limited to, the following: financial models, financial information and data, business methods, electronic files, computer drives/disks, passwords, address and telephone lists, internal memoranda, correspondence, business strategies, business plans and/or projections, lease forms, construction contract forms, development and construction management service agreements, tenant lists, lease terms, rates, rent rolls, strategies, improvements, discoveries, plans for research or future business, infrastructure, marketing and sales plans and strategies, budgets, customer and client information, employee, customer and client nonpublic personal information, supplier lists,

 

7



 

business records, audit processes, management methods and information, reports, recommendations and conclusions, information regarding the names, contact information, skills and compensation of employees and contractors of the Company, other information not generally known to the public, and other business information disclosed to the Executive by the Company, either directly or indirectly, in writing, orally, or by drawings or observation.

 

The Executive acknowledges and agrees that Confidential Information is proprietary to and a trade secret of the Company and, as such, is a special and unique asset of the Company, and that any disclosure or unauthorized use of any Confidential Information by the Executive will cause irreparable harm and loss to the Company. The Executive understands and acknowledges that each and every component of the Confidential Information (i) has been developed by the Company at significant effort and expense and is sufficiently secret to derive economic value from not being generally known to other parties, and (ii) constitutes a protectable business interest of the Company. The Executive acknowledges and agrees that the Company owns the Confidential Information. The Executive agrees not to dispute, contest, or deny any such ownership rights either during or after the Executive’s employment with the Company. The Executive agrees to preserve and protect the confidentiality of all Confidential Information. The Executive agrees that the Executive shall not at any time (whether during or after the Executive’s employment), directly or indirectly, disclose to any unauthorized person or use for the Executive’s own account any Confidential Information without the Company’s consent. Throughout the Executive’s employment and at all times thereafter: (i) the Executive shall hold all Confidential Information in the strictest confidence, take all reasonable precautions to prevent its inadvertent disclosure to any unauthorized person, and follow all policies of the Company protecting the Confidential Information; (ii) the Executive shall not, directly or indirectly, utilize, disclose or make available to any other person or entity, any of the Confidential Information, other than in the proper performance of the Executive’s duties; (iii) the Executive shall not use the Confidential Information or trade secrets to attempt to solicit, induce, recruit, or take away clients or customers of the Company; and (iv) if the Executive learns that any person or entity is taking or threatening to take any actions which would compromise any Confidential Information, the Executive shall promptly advise the Company of all facts concerning such action or threatened action. The foregoing shall not apply to any information which is already in the public domain, or is generally disclosed by the Company or is otherwise in the public domain at the time of disclosure (other than through an unauthorized disclosure by the Executive or any other person).

 

Upon the termination of the Executive’s employment for any reason, the Executive shall immediately return and deliver to the Company any and all Confidential Information, software, devices, cell phones, personal data assistants, credit cards, data, reports, proposals, lists, correspondence, materials, equipment, computers, hard drives, papers, books, records, documents, memoranda, manuals, e-mail, electronic or magnetic recordings or data, including all copies thereof, which belong to the Company or relate to the Company’s business and which are in the Executive’s possession, custody or control, whether prepared by the Executive or others. If at any time after termination of the Executive’s employment he determines that he has any Confidential Information in his possession or control, the Executive shall immediately return to the Company all such Confidential Information in the Executive’s possession or control, including all copies and portions thereof.

 

The Executive recognizes that because his work for the Company may bring him into contact with confidential and proprietary information of the Company, the restrictions of this Section 9 are required for the reasonable protection of the Company and its investments and for the Company’s reliance on and confidence in the Executive.

 

8



 

10.                                RESTRICTIVE COVENANTS

 

In consideration for (i) the Company’s promise to provide Confidential Information to the Executive, (ii) the substantial economic investment made by the Company in the Confidential Information and goodwill of the Company, and/or the business opportunities disclosed or entrusted to the Executive, (iii) access to the Company’s customers and clients, and (iv) the Company’s employment of the Executive pursuant to this Agreement and the compensation and other benefits provided by the Company to the Executive, to protect the Company’s Confidential Information and business goodwill of the Company, the Executive agrees to the following restrictive covenants.

 

(a)                                  Non-Competition . The Executive hereby agrees that during the Restricted Period (defined below), other than in connection with the Executive’s duties under this Agreement, the Executive shall not, and shall not use any Confidential Information to, without the prior consent of the Company, directly or indirectly, either individually or as an owner, principal, partner, stockholder, manager, contractor, distributor, lender, investor, consultant, agent, employee, co-venturer or as a director or officer of any corporation or association, or in any other manner or capacity whatsoever, become employed by, control, carry on, join, lend money for, engage in, establish, perform services for, invest in, solicit investors for, consult for, do business with or otherwise engage in any Competing Business (defined below) within the Restricted Territory (defined below); provided however, that nothing in this Section 10(a)  shall prevent the Executive from owning a passive investment in up to two percent (2%) of the stock of a publicly traded corporation engaged in a Competing Business and such ownership shall not be considered to be a violation of Section 10(a) .

 

(i)                                      “Restricted Period” means during the Executive’s employment with the Company and for a period equal to the later of (i) one (1) year immediately following the date of the Executive’s termination from employment for any reason or (ii) the number of months for which the Executive is receiving monthly severance payments under Section 5 or Section 6 of this Agreement.

 

(ii)                                   “Competing Business” means any business, individual, partnership, firm, corporation or other entity that provides the same or substantially similar products or services as those provided by the Company during the Executive’s employment, which includes, without limitation, the business of buying, managing, holding and selling medical office buildings.

 

(iii)                                As CEO of the Company, the Executive has responsibility for the Company’s operations throughout the United States. Because the Company does business throughout the United States, the “Restricted Territory” means the United States and any other region or state in which the Executive performed services, was assigned responsibility for the Company, or about which the Executive received Confidential Information.

 

(b)                                  Non-Solicitation . The Executive agrees that during the Restricted Period, other than in connection with the Executive’s duties under this Agreement, the Executive shall not, and shall not use any Confidential Information to, directly or indirectly, either individually or as an owner, principal, partner, stockholder, manager, contractor, distributor, lender, investor, consultant, agent, employee, co-venturer or as a director or officer of any corporation or association, or in any other manner or capacity whatsoever, and whether personally or through other persons:

 

9



 

(i)                                      Solicit business from, interfere with, attempt to solicit business with, or do business with any customer or client of the Company with whom the Company did business or who the Company solicited within the preceding two (2) years, and who or which: (1) the Executive contacted, called on, serviced, or did business with during his employment with the Company; (2) the Executive learned of as a result of his employment with the Company; or (3) about whom the Executive received Confidential Information. This restriction applies only to business which is in the scope of services or products provided by the Company; or

 

(ii)                                   Solicit, induce, or attempt to solicit or induce, engage or hire, on behalf of himself or any other person or entity, any person who is an employee or full-time consultant of the Company or who was employed or retained by the Company within the preceding two (2) years.

 

(c)                                   Non-Disparagement . The Executive shall refrain, both during and after the Employment Term, from publishing any oral or written statements about the Company or any of the Company’s board of trustees, equity holders, members, shareholders, managers, officers, employees, consultants, agents or representatives that (i) are slanderous, libelous or defamatory; or (ii) place the Company or any of its trustees, managers, officers, employees, consultants, agents or representatives in a false light before the public. A violation or threatened violation of this prohibition may be enjoined by the courts. The rights afforded the Company under this provision are in addition to any and all rights and remedies otherwise afforded by law.

 

(d)                                  Tolling . If the Executive violates any of the restrictions contained in Section 10 , the Restricted Period shall be suspended and shall not run in favor of the Executive from the time of the commencement of any violation until the time when the Executive cures the violation to the satisfaction of the Company.

 

(e)                                   Reasonableness . The Executive hereby represents to the Company that he has read and understands, and agrees to be bound by, the terms of this Section 10 . The Executive acknowledges that the geographic scope and duration of the covenants contained in this Section 10 are fair and reasonable in light of (i) the nature and wide geographic scope of the operations of the Company’s business; (ii) the Executive’s level of control over and contact with the business in the Restricted Territory; and (iii) the amount of compensation, trade secrets and Confidential Information that the Executive is receiving in connection with his employment by the Company. It is the desire and intent of the parties that the provisions of Section 10 be enforced to the fullest extent permitted under applicable law, whether now or hereafter in effect and therefore, to the extent permitted by applicable law, the Executive and the Company hereby waive any provision of applicable law that would render any provision of Section 10 invalid or unenforceable.

 

11.                                INJUNCTIVE RELIEF

 

The Executive acknowledges that (a) compliance with the covenants set forth in Section 9 and Section 10 of this Agreement are necessary to protect the Company’s business and Confidential Information; (b) a breach or threatened breach of any of such covenants will irreparably harm the Company; and (c) an award of money damages will not be adequate to remedy such harm. Consequently, the Executive acknowledges and agrees that, in addition to other remedies, in the event the Executive breaches or threatens to breach any of the covenants contained in this Agreement, the Company shall be entitled to both a temporary and/or permanent injunction to prevent the continuation of such harm and enforce such provisions and money damages insofar as they can be determined, including, without limitation, all costs and reasonable attorneys’ fees incurred by or on behalf of the Company in the

 

10



 

enforcement of the terms of this Agreement. The Company may apply to any court of competent jurisdiction for a temporary restraining order, preliminary injunction or other interim or conservatory relief, as necessary or applicable. This provision with respect to injunctive relief shall not, however, diminish the Company’s right to claim and recover damages.

 

It is expressly understood and agreed that although the parties consider the restrictions contained in this Agreement to be reasonable, if a court determines that the time or territory or any other restriction contained in this Agreement is an unenforceable restriction on the activities of the Executive, no such provision of this Agreement shall be rendered void but shall be deemed amended to apply as to such maximum time and territory and to such extent as such court may judicially determine or indicate to be reasonable. By agreeing to this contractual modification prospectively at this time, the Company and the Executive intend to make this provision enforceable under the law or laws of all applicable jurisdictions so that the entire agreement not to compete and this Agreement as prospectively modified shall remain in full force and effect and shall not be rendered void or illegal.

 

12.                                CLAWBACK

 

Any compensation paid to the Executive shall be subject to recovery by the Company, and the Executive shall be required to repay such compensation, if (i) such recovery and repayment is required by applicable law or (ii) either in the year such compensation is paid, or within the three (3) year period thereafter the Company is required to prepare an accounting restatement due to material noncompliance of the Company with any financial reporting requirement under applicable securities laws and the Executive is either (A) a named executive officer or (B) an employee who is responsible for preparation of the Company’s financial statements. The parties agree that the repayment obligations set forth in this Section 12 shall only apply to the extent repayment is required by applicable law, or to the extent the Executive’s compensation is determined to be in excess of the amount that would have been deliverable to the Executive taking into account any restatement or correction of any inaccurate financial statements or materially inaccurate performance metric criteria.

 

13.                                MANDATORY MEDIATION AND ARBITRATION

 

In the event there is an unresolved legal dispute between the Executive and the Company that involves legal rights or remedies arising from this Agreement or the employment relationship between the Executive and the Company (“Dispute”), except as otherwise provided herein, before commencing an arbitration action or other legal proceeding, the parties shall promptly submit the Dispute to mediation, using a mediator jointly selected by the parties, or if the parties are unable to agree upon a mediator then the Dispute shall be submitted to non-binding mediation with the American Arbitration Association in Waukesha County, Wisconsin in accordance with its rules. The cost of the mediation shall be borne equally between the parties. If the parties are unable to achieve a mutually agreeable resolution of the Dispute through mediation, the parties agree to submit their Dispute to binding arbitration under the authority of the Federal Arbitration Act and/or the Wisconsin Uniform Arbitration Act; provided, however, that the Company may pursue a temporary restraining order, preliminary injunction and/or other interim or conservatory relief in accordance with Section 11 above, with related expedited discovery for the parties, in a court of law, and, thereafter, require arbitration of all issues of final relief. Insured workers compensation claims (other than wrongful discharge claims), and claims for unemployment insurance are excluded from arbitration under this provision. The Arbitration will be conducted by the American Arbitration Association pursuant to the American Arbitration Association’s National Rules for the Resolution of Employment Disputes. The arbitrator(s) shall be duly licensed to practice law in the State of Wisconsin. Each party will be allowed at least one deposition. The arbitrator(s) shall be required to state in a written opinion all facts and conclusions of law relied upon to support any decision rendered.

 

11



 

No arbitrator will have authority to render a decision that contains an outcome determinative error of state or federal law, or to fashion a cause of action or remedy not otherwise provided for under applicable state or federal law. Any dispute over whether the arbitrator(s) has failed to comply with the foregoing will be resolved by summary judgment in a court of law. In all other respects, the arbitration process will be conducted in accordance with the American Arbitration Association’s National Rules for the Resolution of Employment Disputes. The Company will pay the arbitration costs and arbitrator’s fees beyond $500, subject to a final arbitration award on who should bear costs and fees. All proceedings shall be conducted in Waukesha County, Wisconsin, or another mutually agreeable site. The duty to arbitrate described above shall survive the termination of this Agreement. Except as otherwise provided above, the parties hereby waive trial in a court of law or by jury. All other rights, remedies, statutes of limitation and defenses applicable to claims asserted in a court of law will apply in the arbitration.

 

14.                                NOTICES

 

All notices or communications hereunder shall be in writing and sent certified or registered mail, return receipt requested, postage prepaid, addressed as follows (or to such other address as such party may designate in writing from time to time):

 

If to the Company:

 

Physicians Realty Trust

735 North Water Street

Suite 1000

Milwaukee, Wisconsin 53202

(414) 978.6400

Attention: Corporate Secretary

 

If to the Executive:

 

John T. Thomas

c/o Physicians Realty Trust

735 North Water Street

Suite 1000

Milwaukee, Wisconsin 53202

(414) 978.6400

Attention: Corporate Secretary

 

The actual date of receipt, as shown by the receipt therefor, shall determine the time at which notice was given.

 

15.                                SEPARABILITY

 

If any provision of this Agreement shall be declared to be invalid or unenforceable, in whole or in part, such invalidity or unenforceability shall not affect the remaining provisions hereof which shall remain in full force and effect.

 

16.                                ASSIGNMENT

 

This Agreement shall be binding upon and inure to the benefit of the heirs and representatives of the Executive and the assigns and successors of the Company, but neither this Agreement nor any rights hereunder shall be assignable or otherwise subject to hypothecation by the Executive.

 

12



 

17.                                ENTIRE AGREEMENT

 

This Agreement represents the entire agreement of the parties and shall supersede any and all previous contracts, arrangements or understandings (whether oral or written) between the Company and the Executive with respect to the subject matter hereof. No oral statements or prior written material not specifically incorporated in this Agreement shall be of any force and effect. The Agreement may be amended at any time by mutual written agreement of the parties hereto. The Executive acknowledges and represents that in executing this Agreement, he did not rely on, has not relied on, and specifically disavows any reliance on any communications, promises, statements, inducements, or representation(s), oral or written, by the Company, except as expressly contained in this Agreement. The parties represent that they relied on their own judgment in entering into this Agreement.

 

18.                                SECTION 409A COMPLIANCE

 

This Agreement and the benefits or payments to be provided under this Agreement are intended to be exempt from with the requirements of Section 409A of the Code, and shall be interpreted and construed consistently with such intent, provided, that if the Agreement is not exempt, the Agreement is drafted in a manner to comply with the requirements of Section 409A of the Code. The payments to the Executive pursuant to this Agreement are also intended to be exempt from Section 409A of the Code to the maximum extent possible, under either the separation pay exemption pursuant to Treasury Regulation Section 1.409A-1(b)(9)(iii) or as short-term deferrals pursuant to Treasury Regulation Section 1.409A-1(b)(4). Each payment and benefit hereunder shall constitute a “separately identified” amount within the meaning of Treasury Regulation Section 1.409A-2(b)(2). In the event the terms of this Agreement would subject the Executive to taxes or penalties under Section 409A of the Code (“409A Penalties”), the Company and the Executive shall cooperate diligently to amend the terms of the Agreement to avoid such 409A Penalties, to the extent possible. To the extent any amounts under this Agreement are payable by reference to Executive’s “termination,” “termination of employment,” or similar phrases, such term shall be deemed to refer to the Executive’s “separation from service” (as defined in Treasury Regulation Section 1.409A-1(h) (without regard to any permissible alternative definition thereunder) with the Company and all entities treated as a single employer with the Company under Sections 414(b) and (c) of the Code but substituting a 50% ownership level for the 80% ownership level set forth therein). Notwithstanding any other provision in this Agreement, if the Executive is a “Specified Employee” (as defined in Treasury Regulation Section 1.409A-1(i) on December 31st of the prior calendar year), as of the date of the Executive’s separation from service, then to the extent any amount payable under this Agreement (i) constitutes the payment of nonqualified deferred compensation, within the meaning of Section 409A of the Code, (ii) is payable upon the Executive’s separation from service and (iii) under the terms of this Agreement would be payable prior to the six-month anniversary of the Executive’s separation from service, such payment shall be delayed and paid to the Executive, together with interest at an annual rate equal to the interest rate specified by Regions Bank for a six-month certificate of deposit, on the first day of the first calendar month beginning seven months following the date of termination, or, if earlier, within ninety (90) days following the Executive’s death to the Executive’s surviving spouse (or such other beneficiary as the Executive may designate in writing). Any reimbursement or advancement payable to the Executive pursuant to this Agreement shall be conditioned on the submission by the Executive of all expense reports reasonably required by the Company under any applicable expense reimbursement policy, and shall be paid to the Executive within thirty (30) days following receipt of such expense reports, but in no event later than the last day of the calendar year following the calendar year in which the Executive incurred the reimbursable expense. Any amount of expenses eligible for reimbursement, or in-kind benefit provided, during a calendar year shall not affect the amount of expenses eligible for reimbursement, or in-kind benefit to be provided, during any other calendar year. The right to any reimbursement or in-kind benefit pursuant to this Agreement shall not be subject to liquidation or exchange for any other benefit.

 

13



 

19.                                GOVERNING LAW

 

This Agreement shall be construed, interpreted, and governed in accordance with the laws of the State of Wisconsin, other than the conflict of laws provisions of such laws. Subject to Section 13, venue of any litigation arising from this Agreement or any disputes relating to the Executive’s employment shall be in the United States District Court for the Eastern District of Wisconsin, or a state district court of competent jurisdiction in Waukesha County, Wisconsin. The Executive consents to personal jurisdiction of the United States District Court for the Eastern District of Wisconsin, or a state district court of competent jurisdiction in Waukesha County, Wisconsin for any dispute relating to or arising out of this Agreement or the Executive’s employment, and Executive agrees that Executive shall not challenge personal or subject matter jurisdiction in such courts.

 

20.                                SURVIVAL

 

The Executive’s post-termination obligations in Section 9 and Section 10 shall continue as provided in this Agreement.

 

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

14



 

IN WITNESS WHEREOF , the Company has caused this Agreement to be duly executed, and the Executive has hereunto set his hand, as of the day and year first above written.

 

 

 

PHYSICIANS REALTY TRUST

 

 

 

 

 

By:

/s/ Tommy G. Thompson

 

Its:

Chairman, Board of Trustees, Physicians Realty Trust

 

 

 

 

 

 

 

 

EXECUTIVE:

 

 

 

 

 

 

 

 

/s/ John T. Thomas

 

 

John T. Thomas

 

15


Exhibit 10.2

 

AMENDED AND RESTATED

EMPLOYMENT AGREEMENT

 

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), by and between PHYSICIANS REALTY TRUST, a Maryland trust, (the “Company”), and JOHN SWEET (the “Executive”) is entered into this 6th day of May, 2014 but effective as of the 24th day of July, 2013 (the “Effective Date”).

 

WHEREAS , the Company and the Executive entered into an Employment Agreement (the “Original Agreement”) dated the Effective Date, providing for the Executive’s employment and setting forth the terms and conditions for such employment; and

 

WHEREAS , the Company and the Executive desire to amend and restate the Original Agreement to provide for certain changes to the terms and conditions of the Executive’s employment by the Company, as reflected in this Agreement.

 

NOW THEREFORE , in consideration of the mutual covenants herein contained, the parties, intending to be legally bound, hereby agree as follows:

 

1.                                       EMPLOYMENT

 

The Company hereby agrees to employ the Executive as its Executive Vice President and Chief Investment Officer (the “CIO”) upon the terms and conditions herein contained, and the Executive hereby agrees to accept such employment and to serve in such position. As CIO, the Executive will have those duties which can reasonably be expected to be performed by a person in such position and shall undertake such other responsibilities as may be assigned to the Executive by the Company’s Chief Executive Officer (“CEO”) and/or Board of Trustees from time to time. For purposes of this Agreement, all references to the “Board” shall mean the Board of Trustees. In such capacity, the Executive shall report to the CEO and shall have such powers and responsibilities consistent with his position as may be assigned. Throughout the Employment Term, the Executive shall devote his best efforts and all of his business time and services to the business and affairs of the Company.

 

2.                                       TERM OF AGREEMENT

 

Subject to earlier termination as herein provided, the Executive’s employment under this Agreement shall begin on the Effective Date and shall continue in effect until the third anniversary of the Effective Date (the “Initial Term”). The Agreement will automatically renew, subject to earlier termination as herein provided, for successive one (1) year periods (the “Additional Terms”), unless either the Executive or the Company provide notice of non-renewal at least sixty (60) days prior to the expiration of the Initial Term or the then Additional Term, whichever is applicable. The Initial Term and any Additional Term(s) shall be referred to collectively as the “Employment Term.”

 

Notwithstanding the foregoing, the Company shall be entitled to terminate this Agreement immediately, subject to a continuing obligation to make any payments required under Section 5 below, if the Executive (i) incurs a Disability as described in Section 5(b) , (ii) is terminated for Cause, as defined in Section 5(c) , or (iii) voluntarily terminates his employment without Good Reason (as defined below) during the Employment Term, as described in Section 5(d) .

 

3.                                       SALARY AND BONUS

 

The Executive shall receive a base salary during the Employment Term at a rate of $200,000 per

 



 

annum for 2013 (the “Base Salary”), payable in substantially equal semi-monthly installments. The Compensation Committee of the Board shall consult with the CIO and review the Executive’s Base Salary at annual intervals, and may increase the Executive’s annual Base Salary from time to time as the Committee deems to be appropriate.

 

Subject to Section 12 , the Executive will have an annual cash bonus opportunity for each calendar year during the Employment Term (the “Annual Bonus”) based upon performance goals that are established by the Board or the Compensation Committee of the Board, as the case may be, in its sole discretion. In the event an Annual Bonus is payable pursuant to this Section 3 , such bonus shall be paid to the Executive no later than March 15th of the year after the year to which the bonus relates.

 

On or as soon as administratively practicable after the date of an Initial Public Offering (as defined below) (but in no event later than sixty (60) days after the date of an Initial Public Offering), the Executive shall receive a grant of restricted shares of the Company’s common shares having a value of $800,000 based on the public offering price per share of the Company’s common shares offered for sale at the Initial Public Offering (the “Restricted Shares”). The Restricted Shares shall be subject to the restrictions set forth in the restricted share agreement between the Company and the Executive and the terms of an equity incentive plan adopted by the Company prior to the grant of the Restricted Shares (the “Plan”). The Restricted Shares shall vest over a three-year period, with one-third of the Restricted Shares vesting equally on the first, second, and third anniversary of the Effective Date, subject to any forfeiture or acceleration provisions set forth in the restricted share agreement and the Plan. For purposes of this Agreement, “Initial Public Offering” means any underwritten sale of the Company’s equity securities pursuant to an effective registration statement under the Securities Act of 1933 filed with the Securities and Exchange Commission on Form S-1 or any other eligible form (or a successor form thereto adopted by the Securities and Exchange Commission).

 

4.                                       ADDITIONAL COMPENSATION AND BENEFITS

 

The Executive shall receive the following additional compensation and welfare and fringe benefits during the term of the Agreement:

 

(a)                                  Options and Other Long-Term Incentives .  During the Employment Term, any options, restricted shares or other awards granted under the Plan shall be at the discretion of the Compensation Committee of the Company’s Board.

 

(b)                                  Vacation .  The Executive shall be entitled to up to four (4) weeks of vacation during each year during the Employment Term and any extensions thereof, prorated for partial years.

 

(c)                                   Business Expenses .  The Company shall reimburse the Executive for all reasonable expenses he incurs in promoting the Company’s business, including expenses for travel and similar items, upon presentation by the Executive from time to time of an itemized account of such expenditures. Any reimbursement of expenses made under this Agreement shall only be made for eligible expenses (including transportation and cellular service expenses as set forth above) incurred during the Employment Term, and no reimbursement of any expense shall be made by the Company after December 31st of the year following the calendar year in which the expense was incurred. The amount eligible for reimbursement under this Agreement during a taxable year may not affect expenses eligible for reimbursement in any other taxable year, and the right to reimbursement under this Agreement is not subject to liquidation or exchange for another benefit. The Executive will comply with the Company’s policies regarding these benefits, including all Internal Revenue Service rules and requirements.

 

2



 

(d)                                  Professional Expenses .  Each calendar year during the Employment Term, the Company agrees to reimburse the Executive for up to $10,000 of reasonable professional expenses (i.e., accounting, financial planning, estate planning expenses) incurred by the Executive during such year for personal advice rendered to the Executive.

 

(e)                                   Other Benefits and Perquisites .  The Executive shall be entitled to participate in the benefit plans provided by the Company for all employees, generally, and for the Company’s executive employees. The Company shall be entitled to change or terminate these plans in its sole discretion at any time.

 

5.                                       PAYMENTS UPON TERMINATION

 

(a)                                  Involuntary Termination . If the Executive’s employment is involuntarily terminated by the Company during the Employment Term, the Executive shall be entitled to receive his Base Salary accrued through the date of termination, any accrued but unpaid vacation pay, plus any bonuses earned but unpaid with respect to fiscal years or other periods ending before the termination date (collectively, the “Accrued Obligations”). Such payments shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of involuntary termination). The Executive shall also receive any nonforfeitable benefits payable to him under the terms of any deferred compensation, incentive or other benefit plans maintained by the Company, payable in accordance with the terms of the applicable plan.

 

If the termination is not (1) a termination for Cause (as defined below), as described in Section 5(c) ; (2) a voluntary termination by the Executive without Good Reason (as defined below) as described in Section 5(d) ; (3) a termination as a result of the Executive’s death or Disability (as defined below); or (4) a termination due to non-renewal of the then current term as described in Section 5(e) , then subject to compliance with the restrictive covenants in Section 9 and Section 10 and the execution and timely return by the Executive of a release of claims in a form and substance reasonably requested by the Company (the “Release”), and except as otherwise provided by Sections 12 and 18 , the Company shall pay severance to the Executive in accordance with its normal payroll practices, equal to the Executive’s Base Salary as in effect at the time his employment terminates for a period equal to the greater of (a) the remainder of the then current term of this Agreement or (b) twenty-four (24) months, with the first payment on the first payroll date after the revocation period for the Release has expired; provided, that if the time period for returning and revoking the release begins in one taxable year and ends in a second taxable year, the payments shall not commence until the first payroll date in the second taxable year.

 

In addition, if the termination is not (1) a termination for Cause, as described in Section 5(c) ; (2) a voluntary termination by the Executive without Good Reason as described in Section 5(d) ; (3) a termination as a result of the Executive’s death or Disability (as defined below); or (4) a termination due to non-renewal of the then current term as described in Section 5(e) , then, subject to compliance with the restrictive covenants in Section 9 and Section 10 , the execution and timely return by the Executive of the Release, and except as otherwise provided by Sections 12 and 18, the Executive shall be entitled to the following:

 

(i)                                      Any options, restricted shares or other awards granted to the Executive under the Plan shall become fully vested and, in the case of options, exercisable in full;

 

3



 

(ii)                                   Provided that the Executive elects continuation of coverage under the Company’s group health plan pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1986, as amended (“COBRA”), the Executive shall be provided continued coverage at the Company’s expense under any health insurance programs maintained by the Company in which the Executive participated at the time of his termination for twelve (12) months, or until, if earlier, the date the Executive obtains comparable coverage under a group health plan maintained by a new employer. To the extent the benefits provided under the immediately preceding sentence are otherwise taxable to the Executive, such benefits, for purposes of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) (and the regulations and other guidance issued thereunder) shall be provided as separate monthly in-kind payments of those benefits, and to the extent those benefits are subject to and not otherwise excepted from Section 409A of the Code, the provision of the in-kind benefits during one calendar year shall not affect the in-kind benefits to be provided in any other calendar year; and

 

(iii)                                Any Annual Bonus(es) payable under Section 3 above that would have been earned based solely on continued employment for the remainder of the then current term, and if none, then an amount equal to fifty percent (50%) of the Executive’s then current Base Salary, payable at the same time as bonuses are paid to other active employees of the Company with respect to such performance period, and forfeited if the Executive violates any of the restrictive covenants in Section 9 and Section 10 .

 

(b)                                  Disability . The Company shall be entitled to terminate the Executive’s employment if the Board determines that the Executive has been unable to attend to his duties for at least ninety (90) days because of a Disability (as defined below), and has received a written opinion from a physician acceptable to the Board that such condition prevents the Executive from resuming full performance of his duties and is likely to continue for an indefinite period. Upon such involuntary termination, the Executive shall be entitled to receive the Accrued Obligations. Such payments shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of involuntary termination). In addition, subject to compliance with the restrictive covenants in Section 9 and Section 10 and the execution and timely return by the Executive of the Release, the Company shall pay severance to the Executive in accordance with its normal payroll practices, equal to twelve (12) months of the Executive’s Base Salary as in effect at the time his employment terminates, with the first payment on the first payroll date after the revocation period for the Release has expired; provided, that (i) if the time period for returning and revoking the Release begins in one taxable year and ends in a second taxable year, the payments shall not commence until the first payroll date in the second taxable year; and (ii) all such payments shall immediately terminate at an earlier date if the Executive returns to active employment, either with the Company or otherwise. Any amounts payable under this Section 5(b)  shall be reduced on a dollar-for-dollar basis by the amount of bona fide disability pay (within the meaning of Treas. Reg. section 1.409A-1(a)(5)) received or receivable by the Executive during such twelve-month period, provided such disability payments are made pursuant to a plan sponsored by the Company that covers a substantial number of employees of the Company and was established prior to the date the Executive incurred a permanent disability, and further provided that such reduction does not otherwise affect the time of payment of amounts pursuant to this Section 5(b) . For purposes of this Agreement, “Disability” means the Executive is incapacitated due to physical or mental illness and such incapacity, with or without reasonable accommodation, prevents the Executive from satisfactorily performing the essential functions of his job for the Company on a full-time basis for at least ninety (90) days in a calendar year.

 

4



 

(c)                                   Termination for Cause . If the Executive’s employment is terminated by the Company for Cause, the amount the Executive shall be entitled to receive from the Company shall be limited to the Accrued Obligations. Such payments shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of termination).

 

For purposes of this Agreement, the term “Cause” shall be limited to the following:

 

(i)                                      the Executive engaging in any act of fraud, dishonesty, theft, misappropriation or embezzlement of funds or misrepresentation with respect to the Company;

 

(ii)                                   the Executive’s conviction or plea of no contest with respect to any felony or other crime involving moral turpitude;

 

(iii)                                the Executive’s material breach of his obligations under this Agreement, including, without limitation, breach of the covenants set forth in Section 9 and Section 10 below or the refusal of the Executive to perform his job duties as directed by the Board, which the Executive failed to cure within thirty (30) days after receiving written notice from the Board specifying the alleged breach;

 

(iv)                               violation of any material duty or obligation to the Company or of any direction or any rule or regulation reasonably established by the Board, which the Executive failed to cure within thirty (30) days after receiving written notice from the Board specifying the alleged violation; or

 

(v)                                  insubordination or misconduct in the performance of, or neglect of, the Executive’s duties which the Executive failed to cure within thirty (30) days after receiving written notice from the Board specifying the alleged insubordination, misconduct, or neglect.

 

(d)                                  Voluntary Termination by the Executive without Good Reason . If the Executive resigns or otherwise voluntarily terminates his employment before the end of the current Employment Term (other than in connection with a Change in Corporate Control, as described in Section 6), the amount the Executive shall be entitled to receive from the Company shall be limited to the Accrued Obligations. Such payment shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of resignation or voluntary termination).

 

For purposes of this Agreement, a resignation by the Executive shall not be deemed to be voluntary without Good Reason if, without the Executive’s prior consent, the Executive is (1) assigned to a position other than the CIO (other than for Cause or by reason of his Disability) or assigned duties materially inconsistent with such position if either such change in assignment constitutes a material diminution in the Executive’s authority, duties or responsibilities, or (2) directed to report to anyone other than the CEO if such change in reporting duties constitutes a material diminution in the authority, duties or responsibilities of the supervisor to whom the Executive is required to report; provided that the Executive has notified the Company within the first ninety (90) days following the initial date of such change in assignment or reporting duties that the Executive regards such change in assignment or reporting duties as grounds justifying resignation under this Section 5(d)  and the Company has failed to cure such change in assignment or reporting duties within ninety (90) days following its receipt of such notice from the

 

5



 

Executive; and provided further that the Executive resigns under this Section 5(d)  within six (6) months following the initial existence of a change in assignment or reporting duties described herein.

 

(e)                                   Non-Renewal . The Executive’s employment shall terminate in the event that the then-current Employment Term expires by reason of a party giving a notice of an election not to renew as provided in Section 2. If the Executive’s employment terminates due to non-renewal of the Agreement, the amount the Executive shall be entitled to receive from the Company shall be limited to the Accrued Obligations. Such payment shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the expiration of the then-current term).

 

6.                                       EFFECT OF CHANGE IN CORPORATE CONTROL

 

(a)                                  Accelerated Vesting of Awards . In the event of a “change in control” (as such term is defined in the Plan), the vesting of any options, restricted shares or other awards granted to the Executive under the terms of the Plan shall be accelerated (to the extent permitted by the terms of the Plan) and such awards shall become immediately vested in full and, in the case of options, exercisable in full.

 

(b)                                  Severance Payment . If, during the Employment Term at any time during the period of twelve (12) consecutive months following the occurrence of a Change in Corporate Control, the Executive is involuntarily terminated (other than for Cause) or the Executive terminates his employment for Good Reason, then subject to compliance with the restrictive covenants in Section 9 and Section 10 and the execution and timely return by the Executive of the Release, the Executive shall be entitled to receive a lump sum severance payment equal to the present value of a series of monthly payments for twenty-four (24) months, each in an amount equal to one-twelfth (1/12th) of the sum of (i) the Executive’s Base Salary, as in effect at the time of the Change in Corporate Control, and (ii) the average of the annual bonuses paid to the Executive for the prior two fiscal years of the Company ending prior to the Change in Corporate Control, if any. Such present value shall be calculated using a discount rate equal to the interest rate on 90-day Treasury bills, as reported in the Wall Street Journal (or similar publication) on the date of the Change in Corporate Control. Such lump sum payment shall be made to the Executive within sixty (60) days following the date of such involuntary termination.

 

In addition, if during the Employment Term within twelve (12) months after a Change in Corporate Control the Executive is involuntarily terminated (other than for Cause) or the Executive terminates his employment for Good Reason, he shall be entitled to continued coverage at the Company’s expense under any health insurance programs maintained by the Company in which the Executive participated at the time of his termination, which coverage shall be continued for eighteen (18) months or until, if earlier, the date the Executive obtains comparable coverage under a group health plan maintained by a new employer. To the extent the benefits provided under the immediately preceding sentence are otherwise taxable to the Executive, such benefits, for purposes of Section 409A of the Code (and the regulations and other guidance issued thereunder) shall be provided as separate monthly in-kind payments of those benefits, and to the extent those benefits are subject to and not otherwise excepted from Section 409A of the Code, the provision of the in-kind benefits during one calendar year shall not affect the in-kind benefits to be provided in any other calendar year.

 

(c)                                   Definition of Change in Corporate Control .  For purposes of this Agreement, a “Change in Corporate Control” shall include any of the following events:

 

6



 

(i)                                      The acquisition in one or more transactions of more than fifty percent (50%) of the Company’s outstanding Common Shares (or the equivalent in voting power of any class or classes of securities of the Company entitled to vote in elections of trustees) by any Company, or other person or group (within the meaning of Section 14(d)(3) of the Securities Exchange Act of 1934, as amended);

 

(ii)                                   Any transfer or sale of substantially all of the assets of the Company, or any merger or consolidation of the Company into or with another Company in which the Company is not the surviving entity;

 

Provided, however, that no event shall constitute a Change in Corporate Control unless such event is also a “change in ownership”, a “change in effective control” or a “change in the ownership of a substantial portion of the assets” of the Company, as determined in accordance with Section 409A of the Code, and the regulations and guidance issued thereunder.

 

7.                                       DEATH

 

If the Executive dies during the Employment Term, the Company shall pay to the Executive’s surviving spouse or if there is no surviving spouse, the Executive’s estate, a lump sum payment equal to the Accrued Obligations. Such payment shall be paid within the time period required by applicable law (and in all events within sixty (60) days following the date of the Executive’s death). In addition, the death benefits payable by reason of the Executive’s death under any retirement, deferred compensation, life insurance or other employee benefit plan maintained by the Company shall be paid to the beneficiary designated by the Executive, and the options, restricted shares or other awards held by the Executive under the Company’s equity incentive plans shall become fully vested, and, in the case of options, exercisable in full, in accordance with the terms of the applicable plan or plans.

 

8.                                       WITHHOLDING

 

The Company shall, to the extent permitted by law, have the right to withhold and deduct from any payment hereunder any federal, state or local taxes of any kind required by law to be withheld with respect to any such payment.

 

9.                                       PROTECTION OF CONFIDENTIAL INFORMATION

 

During the Executive’s employment with the Company, the Company shall grant the Executive otherwise prohibited access to its trade secrets and confidential information which are not known to the Company’s competitors or within the Company’s industry generally, which were developed by the Company over a long period of time and/or at its substantial expense, and which are of great competitive value to the Company, and access to the Company’s customers and clients. For purposes of this Agreement, “Confidential Information” includes all trade secrets and confidential and proprietary information of the Company, including, but not limited to, the following: financial models, financial information and data, business methods, electronic files, computer drives/disks, passwords, address and telephone lists, internal memoranda, correspondence, business strategies, business plans and/or projections, lease forms, construction contract forms, development and construction management service agreements, tenant lists, lease terms, rates, rent rolls, strategies, improvements, discoveries, plans for research or future business, infrastructure, marketing and sales plans and strategies, budgets, customer and client information, employee, customer and client nonpublic personal information, supplier lists, business records, audit processes, management methods and information, reports, recommendations and conclusions, information regarding the names, contact information, skills and compensation of employees and contractors of the Company, other information not generally known to the public, and other business

 

7



 

information disclosed to the Executive by the Company, either directly or indirectly, in writing, orally, or by drawings or observation.

 

The Executive acknowledges and agrees that Confidential Information is proprietary to and a trade secret of the Company and, as such, is a special and unique asset of the Company, and that any disclosure or unauthorized use of any Confidential Information by the Executive will cause irreparable harm and loss to the Company. The Executive understands and acknowledges that each and every component of the Confidential Information (i) has been developed by the Company at significant effort and expense and is sufficiently secret to derive economic value from not being generally known to other parties, and (ii) constitutes a protectable business interest of the Company. The Executive acknowledges and agrees that the Company owns the Confidential Information. The Executive agrees not to dispute, contest, or deny any such ownership rights either during or after the Executive’s employment with the Company. The Executive agrees to preserve and protect the confidentiality of all Confidential Information. The Executive agrees that the Executive shall not at any time (whether during or after the Executive’s employment), directly or indirectly, disclose to any unauthorized person or use for the Executive’s own account any Confidential Information without the Company’s consent. Throughout the Executive’s employment and at all times thereafter: (i) the Executive shall hold all Confidential Information in the strictest confidence, take all reasonable precautions to prevent its inadvertent disclosure to any unauthorized person, and follow all policies of the Company protecting the Confidential Information; (ii) the Executive shall not, directly or indirectly, utilize, disclose or make available to any other person or entity, any of the Confidential Information, other than in the proper performance of the Executive’s duties; (iii) the Executive shall not use the Confidential Information or trade secrets to attempt to solicit, induce, recruit, or take away clients or customers of the Company; and (iv) if the Executive learns that any person or entity is taking or threatening to take any actions which would compromise any Confidential Information, the Executive shall promptly advise the Company of all facts concerning such action or threatened action. The foregoing shall not apply to any information which is already in the public domain, or is generally disclosed by the Company or is otherwise in the public domain at the time of disclosure (other than through an unauthorized disclosure by the Executive or any other person).

 

Upon the termination of the Executive’s employment for any reason, the Executive shall immediately return and deliver to the Company any and all Confidential Information, software, devices, cell phones, personal data assistants, credit cards, data, reports, proposals, lists, correspondence, materials, equipment, computers, hard drives, papers, books, records, documents, memoranda, manuals, e-mail, electronic or magnetic recordings or data, including all copies thereof, which belong to the Company or relate to the Company’s business and which are in the Executive’s possession, custody or control, whether prepared by the Executive or others. If at any time after termination of the Executive’s employment he determines that he has any Confidential Information in his possession or control, the Executive shall immediately return to the Company all such Confidential Information in the Executive’s possession or control, including all copies and portions thereof.

 

The Executive recognizes that because his work for the Company may bring him into contact with confidential and proprietary information of the Company, the restrictions of this Section 9 are required for the reasonable protection of the Company and its investments and for the Company’s reliance on and confidence in the Executive.

 

10.                                RESTRICTIVE COVENANTS

 

In consideration for (i) the Company’s promise to provide Confidential Information to the Executive, (ii) the substantial economic investment made by the Company in the Confidential Information and goodwill of the Company, and/or the business opportunities disclosed or entrusted to the Executive,

 

8



 

(iii) access to the Company’s customers and clients, and (iv) the Company’s employment of the Executive pursuant to this Agreement and the compensation and other benefits provided by the Company to the Executive, to protect the Company’s Confidential Information and business goodwill of the Company, the Executive agrees to the following restrictive covenants.

 

(a)                                  Non-Competition . The Executive hereby agrees that during the Restricted Period (defined below), other than in connection with the Executive’s duties under this Agreement, the Executive shall not, and shall not use any Confidential Information to, without the prior consent of the Company, directly or indirectly, either individually or as an owner, principal, partner, stockholder, manager, contractor, distributor, lender, investor, consultant, agent, employee, co-venturer or as a director or officer of any corporation or association, or in any other manner or capacity whatsoever, become employed by, control, carry on, join, lend money for, engage in, establish, perform services for, invest in, solicit investors for, consult for, do business with or otherwise engage in any Competing Business (defined below) within the Restricted Territory (defined below); provided however, that nothing in this Section 10(a)  shall prevent the Executive from owning a passive investment in up to two percent (2%) of the stock of a publicly traded corporation engaged in a Competing Business and such ownership shall not be considered to be a violation of Section 10(a) .

 

(i)                                      “Restricted Period” means during the Executive’s employment with the Company and for a period equal to the later of (i) one (1) year immediately following the date of the Executive’s termination from employment for any reason or (ii) the number of months for which the Executive is receiving monthly severance payments under Section 5 or Section 6 of this Agreement.

 

(ii)                                   “Competing Business” means any business, individual, partnership, firm, corporation or other entity that provides the same or substantially similar products or services as those provided by the Company during the Executive’s employment, which includes, without limitation, the business of buying, managing, holding and selling medical office buildings.

 

(iii)                                As CIO of the Company, the Executive has responsibility for the Company’s operations throughout the United States. Because the Company does business throughout the United States, the “Restricted Territory” means the United States and any other region or state in which the Executive performed services, was assigned responsibility for the Company, or about which the Executive received Confidential Information.

 

(b)                                  Non-Solicitation . The Executive agrees that during the Restricted Period, other than in connection with the Executive’s duties under this Agreement, the Executive shall not, and shall not use any Confidential Information to, directly or indirectly, either individually or as an owner, principal, partner, stockholder, manager, contractor, distributor, lender, investor, consultant, agent, employee, co-venturer or as a director or officer of any corporation or association, or in any other manner or capacity whatsoever, and whether personally or through other persons:

 

(i)                                      Solicit business from, interfere with, attempt to solicit business with, or do business with any customer or client of the Company with whom the Company did business or who the Company solicited within the preceding two (2) years, and who or which: (1) the Executive contacted, called on, serviced, or did business with during his employment with the Company; (2) the Executive learned of as a result of his

 

9



 

employment with the Company; or (3) about whom the Executive received Confidential Information. This restriction applies only to business which is in the scope of services or products provided by the Company; or

 

(ii)                                   Solicit, induce, or attempt to solicit or induce, engage or hire, on behalf of himself or any other person or entity, any person who is an employee or full-time consultant of the Company or who was employed or retained by the Company within the preceding two (2) years.

 

(c)                                   Non-Disparagement . The Executive shall refrain, both during and after the Employment Term, from publishing any oral or written statements about the Company or any of the Company’s board of trustees, equity holders, members, shareholders, managers, officers, employees, consultants, agents or representatives that (i) are slanderous, libelous or defamatory; or (ii) place the Company or any of its trustees, managers, officers, employees, consultants, agents or representatives in a false light before the public. A violation or threatened violation of this prohibition may be enjoined by the courts. The rights afforded the Company under this provision are in addition to any and all rights and remedies otherwise afforded by law.

 

(d)                                  Tolling . If the Executive violates any of the restrictions contained in Section 10 , the Restricted Period shall be suspended and shall not run in favor of the Executive from the time of the commencement of any violation until the time when the Executive cures the violation to the satisfaction of the Company.

 

(e)                                   Reasonableness . The Executive hereby represents to the Company that he has read and understands, and agrees to be bound by, the terms of this Section 10 . The Executive acknowledges that the geographic scope and duration of the covenants contained in this Section 10 are fair and reasonable in light of (i) the nature and wide geographic scope of the operations of the Company’s business; (ii) the Executive’s level of control over and contact with the business in the Restricted Territory; and (iii) the amount of compensation, trade secrets and Confidential Information that the Executive is receiving in connection with his employment by the Company. It is the desire and intent of the parties that the provisions of Section 10 be enforced to the fullest extent permitted under applicable law, whether now or hereafter in effect and therefore, to the extent permitted by applicable law, the Executive and the Company hereby waive any provision of applicable law that would render any provision of Section 10 invalid or unenforceable.

 

11.                                INJUNCTIVE RELIEF

 

The Executive acknowledges that (a) compliance with the covenants set forth in Section 9 and Section 10 of this Agreement are necessary to protect the Company’s business and Confidential Information; (b) a breach or threatened breach of any of such covenants will irreparably harm the Company; and (c) an award of money damages will not be adequate to remedy such harm. Consequently, the Executive acknowledges and agrees that, in addition to other remedies, in the event the Executive breaches or threatens to breach any of the covenants contained in this Agreement, the Company shall be entitled to both a temporary and/or permanent injunction to prevent the continuation of such harm and enforce such provisions and money damages insofar as they can be determined, including, without limitation, all costs and reasonable attorneys’ fees incurred by or on behalf of the Company in the enforcement of the terms of this Agreement. The Company may apply to any court of competent jurisdiction for a temporary restraining order, preliminary injunction or other interim or conservatory relief, as necessary or applicable. This provision with respect to injunctive relief shall not, however, diminish the Company’s right to claim and recover damages.

 

10



 

It is expressly understood and agreed that although the parties consider the restrictions contained in this Agreement to be reasonable, if a court determines that the time or territory or any other restriction contained in this Agreement is an unenforceable restriction on the activities of the Executive, no such provision of this Agreement shall be rendered void but shall be deemed amended to apply as to such maximum time and territory and to such extent as such court may judicially determine or indicate to be reasonable. By agreeing to this contractual modification prospectively at this time, the Company and the Executive intend to make this provision enforceable under the law or laws of all applicable jurisdictions so that the entire agreement not to compete and this Agreement as prospectively modified shall remain in full force and effect and shall not be rendered void or illegal.

 

12.                                CLAWBACK

 

Any compensation paid to the Executive shall be subject to recovery by the Company, and the Executive shall be required to repay such compensation, if (i) such recovery and repayment is required by applicable law or (ii) either in the year such compensation is paid, or within the three (3) year period thereafter the Company is required to prepare an accounting restatement due to material noncompliance of the Company with any financial reporting requirement under applicable securities laws and the Executive is either (A) a named executive officer or (B) an employee who is responsible for preparation of the Company’s financial statements. The parties agree that the repayment obligations set forth in this Section 12 shall only apply to the extent repayment is required by applicable law, or to the extent the Executive’s compensation is determined to be in excess of the amount that would have been deliverable to the Executive taking into account any restatement or correction of any inaccurate financial statements or materially inaccurate performance metric criteria.

 

13.                                MANDATORY MEDIATION AND ARBITRATION

 

In the event there is an unresolved legal dispute between the Executive and the Company that involves legal rights or remedies arising from this Agreement or the employment relationship between the Executive and the Company (“Dispute”), except as otherwise provided herein, before commencing an arbitration action or other legal proceeding, the parties shall promptly submit the Dispute to mediation, using a mediator jointly selected by the parties, or if the parties are unable to agree upon a mediator then the Dispute shall be submitted to non-binding mediation with the American Arbitration Association in Waukesha County, Wisconsin in accordance with its rules. The cost of the mediation shall be borne equally between the parties. If the parties are unable to achieve a mutually agreeable resolution of the Dispute through mediation, the parties agree to submit their Dispute to binding arbitration under the authority of the Federal Arbitration Act and/or the Wisconsin Uniform Arbitration Act; provided, however, that the Company may pursue a temporary restraining order, preliminary injunction and/or other interim or conservatory relief in accordance with Section 11 above, with related expedited discovery for the parties, in a court of law, and, thereafter, require arbitration of all issues of final relief. Insured workers compensation claims (other than wrongful discharge claims), and claims for unemployment insurance are excluded from arbitration under this provision. The Arbitration will be conducted by the American Arbitration Association pursuant to the American Arbitration Association’s National Rules for the Resolution of Employment Disputes. The arbitrator(s) shall be duly licensed to practice law in the State of Wisconsin. Each party will be allowed at least one deposition. The arbitrator(s) shall be required to state in a written opinion all facts and conclusions of law relied upon to support any decision rendered. No arbitrator will have authority to render a decision that contains an outcome determinative error of state or federal law, or to fashion a cause of action or remedy not otherwise provided for under applicable state or federal law. Any dispute over whether the arbitrator(s) has failed to comply with the foregoing will be resolved by summary judgment in a court of law. In all other respects, the arbitration process will be conducted in accordance with the American Arbitration Association’s National Rules for the Resolution of Employment Disputes. The Company will pay the arbitration costs and arbitrator’s fees beyond $500,

 

11



 

subject to a final arbitration award on who should bear costs and fees. All proceedings shall be conducted in Waukesha County, Wisconsin, or another mutually agreeable site. The duty to arbitrate described above shall survive the termination of this Agreement. Except as otherwise provided above, the parties hereby waive trial in a court of law or by jury. All other rights, remedies, statutes of limitation and defenses applicable to claims asserted in a court of law will apply in the arbitration.

 

14.                                NOTICES

 

All notices or communications hereunder shall be in writing and sent certified or registered mail, return receipt requested, postage prepaid, addressed as follows (or to such other address as such party may designate in writing from time to time):

 

If to the Company:

 

Physicians Realty Trust

735 North Water Street

Suite 1000

Milwaukee, Wisconsin 53202

(414) 978.6400

Attention: Corporate Secretary

 

If to the Executive:

 

John Sweet

c/o Physicians Realty Trust

735 North Water Street

Suite 1000

Milwaukee, Wisconsin 53202

(414) 978.6400

Attention: Corporate Secretary

 

The actual date of receipt, as shown by the receipt therefor, shall determine the time at which notice was given.

 

15.                                SEPARABILITY

 

If any provision of this Agreement shall be declared to be invalid or unenforceable, in whole or in part, such invalidity or unenforceability shall not affect the remaining provisions hereof which shall remain in full force and effect.

 

16.                                ASSIGNMENT

 

This Agreement shall be binding upon and inure to the benefit of the heirs and representatives of the Executive and the assigns and successors of the Company, but neither this Agreement nor any rights hereunder shall be assignable or otherwise subject to hypothecation by the Executive.

 

17.                                ENTIRE AGREEMENT

 

This Agreement represents the entire agreement of the parties and shall supersede any and all previous contracts, arrangements or understandings (whether oral or written) between the Company and the Executive with respect to the subject matter hereof. No oral statements or prior written material not

 

12



 

specifically incorporated in this Agreement shall be of any force and effect. The Agreement may be amended at any time by mutual written agreement of the parties hereto. The Executive acknowledges and represents that in executing this Agreement, he did not rely on, has not relied on, and specifically disavows any reliance on any communications, promises, statements, inducements, or representation(s), oral or written, by the Company, except as expressly contained in this Agreement. The parties represent that they relied on their own judgment in entering into this Agreement.

 

18.                                SECTION 409A COMPLIANCE

 

This Agreement and the benefits or payments to be provided under this Agreement are intended to be exempt from with the requirements of Section 409A of the Code, and shall be interpreted and construed consistently with such intent, provided, that if the Agreement is not exempt, the Agreement is drafted in a manner to comply with the requirements of Section 409A of the Code. The payments to the Executive pursuant to this Agreement are also intended to be exempt from Section 409A of the Code to the maximum extent possible, under either the separation pay exemption pursuant to Treasury Regulation Section 1.409A-1(b)(9)(iii) or as short-term deferrals pursuant to Treasury Regulation Section 1.409A-1(b)(4). Each payment and benefit hereunder shall constitute a “separately identified” amount within the meaning of Treasury Regulation Section 1.409A-2(b)(2). In the event the terms of this Agreement would subject the Executive to taxes or penalties under Section 409A of the Code (“409A Penalties”), the Company and the Executive shall cooperate diligently to amend the terms of the Agreement to avoid such 409A Penalties, to the extent possible. To the extent any amounts under this Agreement are payable by reference to Executive’s “termination,” “termination of employment,” or similar phrases, such term shall be deemed to refer to the Executive’s “separation from service” (as defined in Treasury Regulation Section 1.409A-1(h) (without regard to any permissible alternative definition thereunder) with the Company and all entities treated as a single employer with the Company under Sections 414(b) and (c) of the Code but substituting a 50% ownership level for the 80% ownership level set forth therein). Notwithstanding any other provision in this Agreement, if the Executive is a “Specified Employee” (as defined in Treasury Regulation Section 1.409A-1(i) on December 31st of the prior calendar year), as of the date of the Executive’s separation from service, then to the extent any amount payable under this Agreement (i) constitutes the payment of nonqualified deferred compensation, within the meaning of Section 409A of the Code, (ii) is payable upon the Executive’s separation from service and (iii) under the terms of this Agreement would be payable prior to the six-month anniversary of the Executive’s separation from service, such payment shall be delayed and paid to the Executive, together with interest at an annual rate equal to the interest rate specified by Regions Bank for a six-month certificate of deposit, on the first day of the first calendar month beginning seven (7) months following the date of termination, or, if earlier, within ninety (90) days following the Executive’s death to the Executive’s surviving spouse (or such other beneficiary as the Executive may designate in writing). Any reimbursement or advancement payable to the Executive pursuant to this Agreement shall be conditioned on the submission by the Executive of all expense reports reasonably required by the Company under any applicable expense reimbursement policy, and shall be paid to the Executive within thirty (30) days following receipt of such expense reports, but in no event later than the last day of the calendar year following the calendar year in which the Executive incurred the reimbursable expense. Any amount of expenses eligible for reimbursement, or in-kind benefit provided, during a calendar year shall not affect the amount of expenses eligible for reimbursement, or in-kind benefit to be provided, during any other calendar year. The right to any reimbursement or in-kind benefit pursuant to this Agreement shall not be subject to liquidation or exchange for any other benefit.

 

19.                                GOVERNING LAW

 

This Agreement shall be construed, interpreted, and governed in accordance with the laws of the State of Wisconsin, other than the conflict of laws provisions of such laws. Subject to Section 13, venue

 

13



 

of any litigation arising from this Agreement or any disputes relating to the Executive’s employment shall be in the United States District Court for the Eastern District of Wisconsin, or a state district court of competent jurisdiction in Waukesha County, Wisconsin. The Executive consents to personal jurisdiction of the United States District Court for the Eastern District of Wisconsin, or a state district court of competent jurisdiction in Waukesha County, Wisconsin for any dispute relating to or arising out of this Agreement or the Executive’s employment, and Executive agrees that Executive shall not challenge personal or subject matter jurisdiction in such courts.

 

20.                                SURVIVAL

 

The Executive’s post-termination obligations in Section 9 and Section 10 shall continue as provided in this Agreement.

 

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

14



 

IN WITNESS WHEREOF , the Company has caused this Agreement to be duly executed, and the Executive has hereunto set his hand, as of the day and year first above written.

 

 

 

PHYSICIANS REALTY TRUST

 

 

 

 

 

By:

/s/ Tommy G. Thompson

 

Its:

Chairman, Board of Trustees, Physicians Realty Trust

 

 

 

 

 

EXECUTIVE:

 

 

 

 

 

/s/ John Sweet

 

John Sweet

 

15


Exhibit 10.3

 

AMENDED AND RESTATED

EMPLOYMENT AGREEMENT

 

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) by and between PHYSICIANS REALTY TRUST, a Maryland trust, (the “Company”) and JOHN LUCEY (the “Executive”) is entered into this 6th day of May, 2014, but effective as of the 2nd day of August, 2013 (the “Effective Date”).

 

WHEREAS , the Company and the Executive entered into an Employment Agreement (the “Original Agreement”) dated the 24th day of July, 2013 but effective as of the Effective Date, providing for the Executive’s employment and setting forth the terms and conditions for such employment; and

 

WHEREAS , the Company and the Executive desire to amend and restate the Original Agreement to provide for certain changes to the terms and conditions of the Executive’s employment by the Company, as reflected in this Agreement.

 

NOW THEREFORE , in consideration of the mutual covenants herein contained, the parties, intending to be legally bound, hereby agree as follows:

 

1.                                       EMPLOYMENT

 

The Company hereby agrees to employ the Executive as its Senior Vice President — Principal Financial and Accounting Officer (the “Senior Vice President”) upon the terms and conditions herein contained, and the Executive hereby agrees to accept such employment and to serve in such position.  As Senior Vice President, the Executive will have those duties which can reasonably be expected to be performed by a person in such position and shall undertake such other responsibilities as may be assigned to the Executive by the Company’s Chief Executive Officer from time to time.  For purposes of this Agreement, all references to the “Board” shall mean the Board of Trustees.  In such capacity, the Executive shall report to the Company’s Executive Vice President — Chief Investment Officer and Chief Financial Officer (the “CFO”) and shall have such powers and responsibilities consistent with his position as may be assigned. Throughout the Employment Term, the Executive shall devote his best efforts and all of his business time and services to the business and affairs of the Company.

 

2.                                       TERM OF AGREEMENT

 

Subject to earlier termination as herein provided, the Executive’s employment under this Agreement shall begin on the Effective Date and shall continue in effect until the third anniversary of the Effective Date (the “Initial Term”).  The Agreement will automatically renew, subject to earlier termination as herein provided, for successive one (1) year periods (the “Additional Terms”), unless either the Executive or the Company provide notice of non-renewal at least sixty (60) days prior to the expiration of the Initial Term or the then Additional Term, whichever is applicable.  The Initial Term and any Additional Term(s) shall be referred to collectively as the “Employment Term.”

 

Notwithstanding the foregoing, the Company shall be entitled to terminate this Agreement immediately, subject to a continuing obligation to make any payments required under Section 5 below, if the Executive (i) incurs a Disability as described in Section 5(b) , (ii) is terminated for Cause, as defined in Section 5(c) , or (iii) voluntarily terminates his employment without Good Reason (as defined below) during the Employment Term, as described in Section 5(d) .

 

3.                                       SALARY AND BONUS

 

The Executive shall receive a base salary during the Employment Term at a rate of $150,000 per

 



 

annum for 2013 (the “Base Salary”), payable in substantially equal semi-monthly installments.  The Compensation Committee of the Board shall consult with the Senior Vice President and review the Executive’s Base Salary at annual intervals, and may increase the Executive’s annual Base Salary from time to time as the Committee deems to be appropriate.

 

Subject to Section 12 , the Executive will have an annual cash bonus opportunity for each calendar year during the Employment Term (the “Annual Bonus”) based upon performance goals that are established by the Board or the Compensation Committee of the Board, as the case may be, in its sole discretion.  In the event an Annual Bonus is payable pursuant to this Section 3 , such bonus shall be paid to the Executive no later than March 15th of the year after the year to which the bonus relates.

 

On or as soon as administratively practicable after the date of an Initial Public Offering (as defined below) (but in no event later than sixty (60) days after the date of an Initial Public Offering), the Executive shall receive a grant of restricted shares of the Company’s common shares having a value of $75,000 based on the public offering price per share of the Company’s common shares offered for sale at the Initial Public Offering (the “Restricted Shares”).  The Restricted Shares shall be subject to the restrictions set forth in the restricted share agreement between the Company and the Executive and the terms of an equity incentive plan adopted by the Company prior to the grant of the Restricted Shares (the “Plan”).  The Restricted Shares shall vest over a three-year period, with one-third of the Restricted Shares vesting equally on the first, second, and third anniversary of the Effective Date, subject to any forfeiture or acceleration provisions set forth in the restricted share agreement and the Plan.  For purposes of this Agreement, “Initial Public Offering” means any underwritten sale of the Company’s equity securities pursuant to an effective registration statement under the Securities Act of 1933 filed with the Securities and Exchange Commission on Form S-1 or any other eligible form (or a successor form thereto adopted by the Securities and Exchange Commission).

 

4.                                       ADDITIONAL COMPENSATION AND BENEFITS

 

The Executive shall receive the following additional compensation and welfare and fringe benefits during the term of the Agreement:

 

(a)                                  Options and Other Long-Term Incentives .  During the Employment Term, any options, restricted shares or other awards granted under the Plan shall be at the discretion of the Compensation Committee of the Company’s Board.

 

(b)                                  Vacation .  The Executive shall be entitled to up to three (3) weeks of vacation during each year during the Employment Term and any extensions thereof, prorated for partial years.

 

(c)                                   Business Expenses .  The Company shall reimburse the Executive for all reasonable expenses he incurs in promoting the Company’s business, including expenses for travel and similar items, upon presentation by the Executive from time to time of an itemized account of such expenditures.  Any reimbursement of expenses made under this Agreement shall only be made for eligible expenses (including transportation and cellular service expenses as set forth above) incurred during the Employment Term, and no reimbursement of any expense shall be made by the Company after December 31st of the year following the calendar year in which the expense was incurred.  The amount eligible for reimbursement under this Agreement during a taxable year may not affect expenses eligible for reimbursement in any other taxable year, and the right to reimbursement under this Agreement is not subject to liquidation or exchange for another benefit.  The Executive will comply with the Company’s policies regarding these benefits, including all Internal Revenue Service rules and requirements.

 

2



 

(d)                                  Professional Expenses .  Each calendar year during the Employment Term, the Company agrees to reimburse the Executive for up to $10,000 of reasonable professional expenses (i.e., accounting, financial planning, estate planning expenses) incurred by the Executive during such year for personal advice rendered to the Executive.

 

(e)                                   Other Benefits and Perquisites .

 

(i)                                      The Executive shall be entitled to participate in the benefit plans provided by the Company for all employees, generally, and for the Company’s executive employees.  The Company shall be entitled to change or terminate these plans in its sole discretion at any time.

 

(ii)                                   The Company agrees to reimburse the Executive for the amount of any premiums the Executive pays for his (and his eligible dependents’) medical and dental coverage, including, without limitation COBRA continuation coverage, up to $25,000.00 for the period beginning on the Effective Date and ending on December 31, 2013 (the “Medical Coverage”).  On a monthly basis, the Executive shall provide the Company with documentation of the amount of out-of-pocket insurance premiums to be reimbursed for that month for the Medical Coverage.  The Company shall reimburse the Executive this amount within thirty (30) days of submission.  The amount eligible for reimbursement under this Section 4(e)(ii)  during a taxable year may not affect expenses eligible for reimbursement in any other taxable year, and the right to reimbursement under this Section 4(e)(ii)  is not subject to liquidation or exchange for another benefit.

 

5.                                       PAYMENTS UPON TERMINATION

 

(a)                                  Involuntary Termination .  If the Executive’s employment is involuntarily terminated by the Company during the Employment Term, the Executive shall be entitled to receive his Base Salary accrued through the date of termination, any accrued but unpaid vacation pay, plus any bonuses earned but unpaid with respect to fiscal years or other periods ending before the termination date (collectively, the “Accrued Obligations”).  Such payments shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of involuntary termination).  The Executive shall also receive any nonforfeitable benefits payable to him under the terms of any deferred compensation, incentive or other benefit plans maintained by the Company, payable in accordance with the terms of the applicable plan.

 

If the termination is not (1) a termination for Cause (as defined below), as described in Section 5(c) ; (2) a voluntary termination by the Executive without Good Reason (as defined below) as described in Section 5(d) ; (3) a termination as a result of the Executive’s death or Disability (as defined below); or (4) a termination due to non-renewal of the then current term as described in Section 5(e) , then subject to compliance with the restrictive covenants in Section 9 and Section 10 and the execution and timely return by the Executive of a release of claims in a form and substance reasonably requested by the Company (the “Release”), and except as otherwise provided by Sections 12 and 18 , the Company shall pay severance to the Executive in accordance with its normal payroll practices, equal to the Executive’s Base Salary as in effect at the time his employment terminates for a period equal to the greater of (a) the remainder of the then current term of this Agreement or (b) twenty-four (24) months, with the first payment on the first payroll date after the revocation period for the Release has expired; provided, that if the time period for returning and revoking the release begins in one taxable year and ends in a second taxable year, the payments shall not commence until the first payroll date in the second taxable year.

 

3



 

In addition, if the termination is not (1) a termination for Cause, as described in Section 5(c) ; (2) a voluntary termination by the Executive without Good Reason as described in Section 5(d) ; (3) a termination as a result of the Executive’s death or Disability (as defined below); or (4) a termination due to non-renewal of the then current term as described in Section 5(e) , then, subject to compliance with the restrictive covenants in Section 9 and Section 10 , the execution and timely return by the Executive of the Release, and except as otherwise provided by Sections 12 and 18 , the Executive shall be entitled to the following:

 

(i)                                      Any options, restricted shares or other awards granted to the Executive under the Plan shall become fully vested and, in the case of options, exercisable in full;

 

(ii)                                   Provided that the Executive elects continuation of coverage under the Company’s group health plan pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1986, as amended (“COBRA”), the Executive shall be provided continued coverage at the Company’s expense under any health insurance programs maintained by the Company in which the Executive participated at the time of his termination for twelve (12) months, or until, if earlier, the date the Executive obtains comparable coverage under a group health plan maintained by a new employer.  To the extent the benefits provided under the immediately preceding sentence are otherwise taxable to the Executive, such benefits, for purposes of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) (and the regulations and other guidance issued thereunder) shall be provided as separate monthly in-kind payments of those benefits, and to the extent those benefits are subject to and not otherwise excepted from Section 409A of the Code, the provision of the in-kind benefits during one calendar year shall not affect the in-kind benefits to be provided in any other calendar year; and

 

(iii)                                Any Annual Bonus(es) payable under Section 3 above that would have been earned based solely on continued employment for the remainder of the then current term, and if none, then an amount equal to fifty percent (50%) of the Executive’s then current Base Salary, payable at the same time as bonuses are paid to other active employees of the Company with respect to such performance period, and forfeited if the Executive violates any of the restrictive covenants in Section 9 and Section 10 .

 

(b)                                  Disability .  The Company shall be entitled to terminate the Executive’s employment if the Board determines that the Executive has been unable to attend to his duties for at least ninety (90) days because of a Disability (as defined below), and has received a written opinion from a physician acceptable to the Board that such condition prevents the Executive from resuming full performance of his duties and is likely to continue for an indefinite period.  Upon such involuntary termination, the Executive shall be entitled to receive the Accrued Obligations.  Such payments shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of involuntary termination).  In addition, subject to compliance with the restrictive covenants in Section 9 and Section 10 and the execution and timely return by the Executive of the Release, the Company shall pay severance to the Executive in accordance with its normal payroll practices, equal to twelve (12) months of the Executive’s Base Salary as in effect at the time his employment terminates, with the first payment on the first payroll date after the revocation period for the Release has expired; provided, that (i) if the time period for returning and revoking the Release begins in one taxable year and ends in a second taxable year, the payments shall not commence until the first payroll date in the second taxable year; and (ii) all such payments shall immediately terminate at an earlier date if the Executive returns to active employment, either with the Company or otherwise.  Any amounts payable under this Section 5(b)  shall be reduced on a dollar-for-dollar basis by the amount of bona fide disability pay (within the meaning of Treas. Reg. section 1.409A-1(a)(5)) received or

 

4



 

receivable by the Executive during such twelve-month period, provided such disability payments are made pursuant to a plan sponsored by the Company that covers a substantial number of employees of the Company and was established prior to the date the Executive incurred a permanent disability, and further provided that such reduction does not otherwise affect the time of payment of amounts pursuant to this Section 5(b) .  For purposes of this Agreement, “ Disability ” means the Executive is incapacitated due to physical or mental illness and such incapacity, with or without reasonable accommodation, prevents the Executive from satisfactorily performing the essential functions of his job for the Company on a full-time basis for at least ninety (90) days in a calendar year.

 

(c)                                   Termination for Cause .  If the Executive’s employment is terminated by the Company for Cause, the amount the Executive shall be entitled to receive from the Company shall be limited to the Accrued Obligations.  Such payments shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of termination).

 

For purposes of this Agreement, the term “Cause” shall be limited to the following:

 

(i)                                      the Executive engaging in any act of fraud, dishonesty, theft, misappropriation or embezzlement of funds or misrepresentation with respect to the Company;

 

(ii)                                   the Executive’s conviction or plea of no contest with respect to any felony or other crime involving moral turpitude;

 

(iii)                                the Executive’s material breach of his obligations under this Agreement, including, without limitation, breach of the covenants set forth in Section 9 and Section 10 below or the refusal of the Executive to perform his job duties as directed by the Board, which the Executive failed to cure within thirty (30) days after receiving written notice from the Board specifying the alleged breach;

 

(iv)                               violation of any material duty or obligation to the Company or of any direction or any rule or regulation reasonably established by the Board, which the Executive failed to cure within thirty (30) days after receiving written notice from the Board specifying the alleged violation; or

 

(v)                                  insubordination or misconduct in the performance of, or neglect of, the Executive’s duties which the Executive failed to cure within thirty (30) days after receiving written notice from the Board specifying the alleged insubordination, misconduct, or neglect.

 

(d)                                  Voluntary Termination by the Executive without Good Reason .  If the Executive resigns or otherwise voluntarily terminates his employment before the end of the current Employment Term (other than in connection with a Change in Corporate Control, as described in Section 6 ), the amount the Executive shall be entitled to receive from the Company shall be limited to the Accrued Obligations.  Such payment shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of resignation or voluntary termination).

 

For purposes of this Agreement, a resignation by the Executive shall not be deemed to be voluntary without Good Reason if, without the Executive’s prior consent, the Executive is (1) assigned to a position other than the Senior Vice President (other than for Cause or by reason of

 

5



 

his Disability) or assigned duties materially inconsistent with such position if either such change in assignment constitutes a material diminution in the Executive’s authority, duties or responsibilities, or (2) directed to report to anyone other than the CFO if such change in reporting duties constitutes a material diminution in the authority, duties or responsibilities of the supervisor to whom the Executive is required to report; provided that the Executive has notified the Company within the first ninety (90) days following the initial date of such change in assignment or reporting duties that the Executive regards such change in assignment or reporting duties as grounds justifying resignation under this Section 5(d)  and the Company has failed to cure such change in assignment or reporting duties within ninety (90) days following its receipt of such notice from the Executive; and provided further that the Executive resigns under this Section 5(d)  within six (6) months following the initial existence of a change in assignment or reporting duties described herein.

 

(e)                                   Non-Renewal .  The Executive’s employment shall terminate in the event that the then-current Employment Term expires by reason of a party giving a notice of an election not to renew as provided in Section 2 .  If the Executive’s employment terminates due to non-renewal of the Agreement, the amount the Executive shall be entitled to receive from the Company shall be limited to the Accrued Obligations.  Such payment shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the expiration of the then-current term).

 

6.                                       EFFECT OF CHANGE IN CORPORATE CONTROL

 

(a)                                  Accelerated Vesting of Awards .  In the event of a “change in control” (as such term is defined in the Plan), the vesting of any options, restricted shares or other awards granted to the Executive under the terms of the Plan shall be accelerated (to the extent permitted by the terms of the Plan) and such awards shall become immediately vested in full and, in the case of options, exercisable in full.

 

(b)                                  Severance Payment .  If, during the Employment Term at any time during the period of twelve (12) consecutive months following the occurrence of a Change in Corporate Control, the Executive is involuntarily terminated (other than for Cause) or the Executive terminates his employment for Good Reason, then subject to compliance with the restrictive covenants in Section 9 and Section 10 and the execution and timely return by the Executive of the Release, the Executive shall be entitled to receive a lump sum severance payment equal to the present value of a series of monthly payments for twenty-four (24) months, each in an amount equal to one-twelfth (1/12th) of the sum of (i) the Executive’s Base Salary, as in effect at the time of the Change in Corporate Control, and (ii) the average of the annual bonuses paid to the Executive for the prior two fiscal years of the Company ending prior to the Change in Corporate Control, if any.  Such present value shall be calculated using a discount rate equal to the interest rate on 90-day Treasury bills, as reported in the Wall Street Journal (or similar publication) on the date of the Change in Corporate Control.  Such lump sum payment shall be made to the Executive within sixty (60) days following the date of such involuntary termination.

 

In addition, if during the Employment Term within twelve (12) months after a Change in Corporate Control the Executive is involuntarily terminated (other than for Cause) or the Executive terminates his employment for Good Reason, he shall be entitled to continued coverage at the Company’s expense under any health insurance programs maintained by the Company in which the Executive participated at the time of his termination, which coverage shall be continued for eighteen (18) months or until, if earlier, the date the Executive obtains comparable coverage under a group health plan maintained by a new employer.  To the extent the benefits provided under the immediately preceding sentence are otherwise taxable to the Executive, such

 

6



 

benefits, for purposes of Section 409A of the Code (and the regulations and other guidance issued thereunder) shall be provided as separate monthly in-kind payments of those benefits, and to the extent those benefits are subject to and not otherwise excepted from Section 409A of the Code, the provision of the in-kind benefits during one calendar year shall not affect the in-kind benefits to be provided in any other calendar year.

 

(c)                                   Definition of Change in Corporate Control .  For purposes of this Agreement, a “Change in Corporate Control” shall include any of the following events:

 

(i)                                      The acquisition in one or more transactions of more than fifty percent (50%) of the Company’s outstanding Common Shares (or the equivalent in voting power of any class or classes of securities of the Company entitled to vote in elections of trustees) by any Company, or other person or group (within the meaning of Section 14(d)(3) of the Securities Exchange Act of 1934, as amended);

 

(ii)                                   Any transfer or sale of substantially all of the assets of the Company, or any merger or consolidation of the Company into or with another Company in which the Company is not the surviving entity;

 

Provided, however, that no event shall constitute a Change in Corporate Control unless such event is also a “change in ownership”, a “change in effective control” or a “change in the ownership of a substantial portion of the assets” of the Company, as determined in accordance with Section 409A of the Code, and the regulations and guidance issued thereunder.

 

7.                                       DEATH

 

If the Executive dies during the Employment Term, the Company shall pay to the Executive’s surviving spouse or if there is no surviving spouse, the Executive’s estate, a lump sum payment equal to the Accrued Obligations.  Such payment shall be paid within the time period required by applicable law (and in all events within sixty (60) days following the date of the Executive’s death).  In addition, the death benefits payable by reason of the Executive’s death under any retirement, deferred compensation, life insurance or other employee benefit plan maintained by the Company shall be paid to the beneficiary designated by the Executive, and the options, restricted shares or other awards held by the Executive under the Company’s equity incentive plans shall become fully vested, and, in the case of options, exercisable in full, in accordance with the terms of the applicable plan or plans.

 

8.                                       WITHHOLDING

 

The Company shall, to the extent permitted by law, have the right to withhold and deduct from any payment hereunder any federal, state or local taxes of any kind required by law to be withheld with respect to any such payment.

 

9.                                       PROTECTION OF CONFIDENTIAL INFORMATION

 

During the Executive’s employment with the Company, the Company shall grant the Executive otherwise prohibited access to its trade secrets and confidential information which are not known to the Company’s competitors or within the Company’s industry generally, which were developed by the Company over a long period of time and/or at its substantial expense, and which are of great competitive value to the Company, and access to the Company’s customers and clients.  For purposes of this Agreement, “Confidential Information” includes all trade secrets and confidential and proprietary information of the Company, including, but not limited to, the following: financial models, financial

 

7



 

information and data, business methods, electronic files, computer drives/disks, passwords, address and telephone lists, internal memoranda, correspondence, business strategies, business plans and/or projections, lease forms, construction contract forms, development and construction management service agreements, tenant lists, lease terms, rates, rent rolls, strategies, improvements, discoveries, plans for research or future business, infrastructure, marketing and sales plans and strategies, budgets, customer and client information, employee, customer and client nonpublic personal information, supplier lists, business records, audit processes, management methods and information, reports, recommendations and conclusions, information regarding the names, contact information, skills and compensation of employees and contractors of the Company, other information not generally known to the public, and other business information disclosed to the Executive by the Company, either directly or indirectly, in writing, orally, or by drawings or observation.

 

The Executive acknowledges and agrees that Confidential Information is proprietary to and a trade secret of the Company and, as such, is a special and unique asset of the Company, and that any disclosure or unauthorized use of any Confidential Information by the Executive will cause irreparable harm and loss to the Company.  The Executive understands and acknowledges that each and every component of the Confidential Information (i) has been developed by the Company at significant effort and expense and is sufficiently secret to derive economic value from not being generally known to other parties, and (ii) constitutes a protectable business interest of the Company.  The Executive acknowledges and agrees that the Company owns the Confidential Information.  The Executive agrees not to dispute, contest, or deny any such ownership rights either during or after the Executive’s employment with the Company.  The Executive agrees to preserve and protect the confidentiality of all Confidential Information.  The Executive agrees that the Executive shall not at any time (whether during or after the Executive’s employment), directly or indirectly, disclose to any unauthorized person or use for the Executive’s own account any Confidential Information without the Company’s consent.  Throughout the Executive’s employment and at all times thereafter: (i) the Executive shall hold all Confidential Information in the strictest confidence, take all reasonable precautions to prevent its inadvertent disclosure to any unauthorized person, and follow all policies of the Company protecting the Confidential Information; (ii) the Executive shall not, directly or indirectly, utilize, disclose or make available to any other person or entity, any of the Confidential Information, other than in the proper performance of the Executive’s duties; (iii) the Executive shall not use the Confidential Information or trade secrets to attempt to solicit, induce, recruit, or take away clients or customers of the Company; and (iv) if the Executive learns that any person or entity is taking or threatening to take any actions which would compromise any Confidential Information, the Executive shall promptly advise the Company of all facts concerning such action or threatened action.  The foregoing shall not apply to any information which is already in the public domain, or is generally disclosed by the Company or is otherwise in the public domain at the time of disclosure (other than through an unauthorized disclosure by the Executive or any other person).

 

Upon the termination of the Executive’s employment for any reason, the Executive shall immediately return and deliver to the Company any and all Confidential Information, software, devices, cell phones, personal data assistants, credit cards, data, reports, proposals, lists, correspondence, materials, equipment, computers, hard drives, papers, books, records, documents, memoranda, manuals, e-mail, electronic or magnetic recordings or data, including all copies thereof, which belong to the Company or relate to the Company’s business and which are in the Executive’s possession, custody or control, whether prepared by the Executive or others.  If at any time after termination of the Executive’s employment he determines that he has any Confidential Information in his possession or control, the Executive shall immediately return to the Company all such Confidential Information in the Executive’s possession or control, including all copies and portions thereof.

 

The Executive recognizes that because his work for the Company may bring him into contact with confidential and proprietary information of the Company, the restrictions of this Section 9 are

 

8



 

required for the reasonable protection of the Company and its investments and for the Company’s reliance on and confidence in the Executive.

 

10.          RESTRICTIVE COVENANTS

 

In consideration for (i) the Company’s promise to provide Confidential Information to the Executive, (ii) the substantial economic investment made by the Company in the Confidential Information and goodwill of the Company, and/or the business opportunities disclosed or entrusted to the Executive, (iii) access to the Company’s customers and clients, and (iv) the Company’s employment of the Executive pursuant to this Agreement and the compensation and other benefits provided by the Company to the Executive, to protect the Company’s Confidential Information and business goodwill of the Company, the Executive agrees to the following restrictive covenants.

 

(a)           Non-Competition .  The Executive hereby agrees that during the Restricted Period (defined below), other than in connection with the Executive’s duties under this Agreement, the Executive shall not, and shall not use any Confidential Information to, without the prior consent of the Company, directly or indirectly, either individually or as an owner, principal, partner, stockholder, manager, contractor, distributor, lender, investor, consultant, agent, employee, co-venturer or as a director or officer of any corporation or association, or in any other manner or capacity whatsoever, become employed by, control, carry on, join, lend money for, engage in, establish, perform services for, invest in, solicit investors for, consult for, do business with or otherwise engage in any Competing Business (defined below) within the Restricted Territory (defined below); provided however, that nothing in this Section 10(a)  shall prevent the Executive from owning a passive investment in up to two percent (2%) of the stock of a publicly traded corporation engaged in a Competing Business and such ownership shall not be considered to be a violation of Section 10(a) .

 

(i)            “Restricted Period” means during the Executive’s employment with the Company and for a period equal to the later of (i) one (1) year immediately following the date of the Executive’s termination from employment for any reason or (ii) the number of months for which the Executive is receiving monthly severance payments under Section 5 or Section 6 of this Agreement.

 

(ii)           “Competing Business” means any business, individual, partnership, firm, corporation or other entity that provides the same or substantially similar products or services as those provided by the Company during the Executive’s employment, which includes, without limitation, the business of buying, managing, holding and selling medical office buildings.

 

(iii)          As Senior Vice President of the Company, the Executive has responsibility for the Company’s operations throughout the United States.  Because the Company does business throughout the United States, the “Restricted Territory” means the United States and any other region or state in which the Executive performed services, was assigned responsibility for the Company, or about which the Executive received Confidential Information.

 

(b)           Non-Solicitation .  The Executive agrees that during the Restricted Period, other than in connection with the Executive’s duties under this Agreement, the Executive shall not, and shall not use any Confidential Information to, directly or indirectly, either individually or as an owner, principal, partner, stockholder, manager, contractor, distributor, lender, investor, consultant, agent, employee, co-venturer or as a director or officer of any corporation or

 

9



 

association, or in any other manner or capacity whatsoever, and whether personally or through other persons:

 

(i)            Solicit business from, interfere with, attempt to solicit business with, or do business with any customer or client of the Company with whom the Company did business or who the Company solicited within the preceding two (2) years, and who or which: (1) the Executive contacted, called on, serviced, or did business with during his employment with the Company; (2) the Executive learned of as a result of his employment with the Company; or (3) about whom the Executive received Confidential Information.  This restriction applies only to business which is in the scope of services or products provided by the Company; or

 

(ii)           Solicit, induce, or attempt to solicit or induce, engage or hire, on behalf of himself or any other person or entity, any person who is an employee or full-time consultant of the Company or who was employed or retained by the Company within the preceding two (2) years.

 

(c)           Non-Disparagement .  The Executive shall refrain, both during and after the Employment Term, from publishing any oral or written statements about the Company or any of the Company’s board of trustees, equity holders, members, shareholders, managers, officers, employees, consultants, agents or representatives that (i) are slanderous, libelous or defamatory; or (ii) place the Company or any of its trustees, managers, officers, employees, consultants, agents or representatives in a false light before the public.  A violation or threatened violation of this prohibition may be enjoined by the courts.  The rights afforded the Company under this provision are in addition to any and all rights and remedies otherwise afforded by law.

 

(d)           Tolling .  If the Executive violates any of the restrictions contained in Section 10 , the Restricted Period shall be suspended and shall not run in favor of the Executive from the time of the commencement of any violation until the time when the Executive cures the violation to the satisfaction of the Company.

 

(e)           Reasonableness .  The Executive hereby represents to the Company that he has read and understands, and agrees to be bound by, the terms of this Section 10 .  The Executive acknowledges that the geographic scope and duration of the covenants contained in this Section 10 are fair and reasonable in light of (i) the nature and wide geographic scope of the operations of the Company’s business; (ii) the Executive’s level of control over and contact with the business in the Restricted Territory; and (iii) the amount of compensation, trade secrets and Confidential Information that the Executive is receiving in connection with his employment by the Company.  It is the desire and intent of the parties that the provisions of Section 10 be enforced to the fullest extent permitted under applicable law, whether now or hereafter in effect and therefore, to the extent permitted by applicable law, the Executive and the Company hereby waive any provision of applicable law that would render any provision of Section 10 invalid or unenforceable.

 

11.          INJUNCTIVE RELIEF

 

The Executive acknowledges that (a) compliance with the covenants set forth in Section 9 and Section 10 of this Agreement are necessary to protect the Company’s business and Confidential Information; (b) a breach or threatened breach of any of such covenants will irreparably harm the Company; and (c) an award of money damages will not be adequate to remedy such harm.  Consequently, the Executive acknowledges and agrees that, in addition to other remedies, in the event the Executive breaches or threatens to breach any of the covenants contained in this Agreement, the Company shall be entitled to both a temporary and/or permanent injunction to prevent the continuation of such harm and

 

10



 

enforce such provisions and money damages insofar as they can be determined, including, without limitation, all costs and reasonable attorneys’ fees incurred by or on behalf of the Company in the enforcement of the terms of this Agreement.  The Company may apply to any court of competent jurisdiction for a temporary restraining order, preliminary injunction or other interim or conservatory relief, as necessary or applicable.  This provision with respect to injunctive relief shall not, however, diminish the Company’s right to claim and recover damages.

 

It is expressly understood and agreed that although the parties consider the restrictions contained in this Agreement to be reasonable, if a court determines that the time or territory or any other restriction contained in this Agreement is an unenforceable restriction on the activities of the Executive, no such provision of this Agreement shall be rendered void but shall be deemed amended to apply as to such maximum time and territory and to such extent as such court may judicially determine or indicate to be reasonable.  By agreeing to this contractual modification prospectively at this time, the Company and the Executive intend to make this provision enforceable under the law or laws of all applicable jurisdictions so that the entire agreement not to compete and this Agreement as prospectively modified shall remain in full force and effect and shall not be rendered void or illegal.

 

12.          CLAWBACK

 

Any compensation paid to the Executive shall be subject to recovery by the Company, and the Executive shall be required to repay such compensation, if (i) such recovery and repayment is required by applicable law or (ii) either in the year such compensation is paid, or within the three (3) year period thereafter the Company is required to prepare an accounting restatement due to material noncompliance of the Company with any financial reporting requirement under applicable securities laws and the Executive is either (A) a named executive officer or (B) an employee who is responsible for preparation of the Company’s financial statements.  The parties agree that the repayment obligations set forth in this Section 12 shall only apply to the extent repayment is required by applicable law, or to the extent the Executive’s compensation is determined to be in excess of the amount that would have been deliverable to the Executive taking into account any restatement or correction of any inaccurate financial statements or materially inaccurate performance metric criteria.

 

13.          MANDATORY MEDIATION AND ARBITRATION

 

In the event there is an unresolved legal dispute between the Executive and the Company that involves legal rights or remedies arising from this Agreement or the employment relationship between the Executive and the Company (“Dispute”), except as otherwise provided herein, before commencing an arbitration action or other legal proceeding, the parties shall promptly submit the Dispute to mediation, using a mediator jointly selected by the parties, or if the parties are unable to agree upon a mediator then the Dispute shall be submitted to non-binding mediation with the American Arbitration Association in Waukesha County, Wisconsin in accordance with its rules.  The cost of the mediation shall be borne equally between the parties.  If the parties are unable to achieve a mutually agreeable resolution of the Dispute through mediation, the parties agree to submit their Dispute to binding arbitration under the authority of the Federal Arbitration Act and/or the Wisconsin Uniform Arbitration Act; provided, however, that the Company may pursue a temporary restraining order, preliminary injunction and/or other interim or conservatory relief in accordance with Section 11 above, with related expedited discovery for the parties, in a court of law, and, thereafter, require arbitration of all issues of final relief.  Insured workers compensation claims (other than wrongful discharge claims), and claims for unemployment insurance are excluded from arbitration under this provision.  The Arbitration will be conducted by the American Arbitration Association pursuant to the American Arbitration Association’s National Rules for the Resolution of Employment Disputes.  The arbitrator(s) shall be duly licensed to practice law in the State of Wisconsin.  Each party will be allowed at least one deposition.  The arbitrator(s) shall be required to state in a written opinion all facts and conclusions of law relied upon to support any decision rendered.

 

11



 

No arbitrator will have authority to render a decision that contains an outcome determinative error of state or federal law, or to fashion a cause of action or remedy not otherwise provided for under applicable state or federal law.  Any dispute over whether the arbitrator(s) has failed to comply with the foregoing will be resolved by summary judgment in a court of law.  In all other respects, the arbitration process will be conducted in accordance with the American Arbitration Association’s National Rules for the Resolution of Employment Disputes.  The Company will pay the arbitration costs and arbitrator’s fees beyond $500, subject to a final arbitration award on who should bear costs and fees.  All proceedings shall be conducted in Waukesha County, Wisconsin, or another mutually agreeable site.  The duty to arbitrate described above shall survive the termination of this Agreement.  Except as otherwise provided above, the parties hereby waive trial in a court of law or by jury.  All other rights, remedies, statutes of limitation and defenses applicable to claims asserted in a court of law will apply in the arbitration.

 

14.          NOTICES

 

All notices or communications hereunder shall be in writing and sent certified or registered mail, return receipt requested, postage prepaid, addressed as follows (or to such other address as such party may designate in writing from time to time):

 

If to the Company:

 

Physicians Realty Trust

735 North Water Street

Suite 1000

Milwaukee, Wisconsin 53202

(414) 978.6400

Attention: Corporate Secretary

 

If to the Executive:

 

John Lucey

c/o Physicians Realty Trust

735 North Water Street

Suite 1000

Milwaukee, Wisconsin 53202

(414) 978.6400

Attention: Corporate Secretary

 

The actual date of receipt, as shown by the receipt therefor, shall determine the time at which notice was given.

 

12



 

15.          SEPARABILITY

 

If any provision of this Agreement shall be declared to be invalid or unenforceable, in whole or in part, such invalidity or unenforceability shall not affect the remaining provisions hereof which shall remain in full force and effect.

 

16.          ASSIGNMENT

 

This Agreement shall be binding upon and inure to the benefit of the heirs and representatives of the Executive and the assigns and successors of the Company, but neither this Agreement nor any rights hereunder shall be assignable or otherwise subject to hypothecation by the Executive.

 

17.          ENTIRE AGREEMENT

 

This Agreement represents the entire agreement of the parties and shall supersede any and all previous contracts, arrangements or understandings (whether oral or written) between the Company and the Executive with respect to the subject matter hereof.  No oral statements or prior written material not specifically incorporated in this Agreement shall be of any force and effect.  The Agreement may be amended at any time by mutual written agreement of the parties hereto.  The Executive acknowledges and represents that in executing this Agreement, he did not rely on, has not relied on, and specifically disavows any reliance on any communications, promises, statements, inducements, or representation(s), oral or written, by the Company, except as expressly contained in this Agreement.  The parties represent that they relied on their own judgment in entering into this Agreement.

 

18.          SECTION 409A COMPLIANCE

 

This Agreement and the benefits or payments to be provided under this Agreement are intended to be exempt from with the requirements of Section 409A of the Code, and shall be interpreted and construed consistently with such intent, provided, that if the Agreement is not exempt, the Agreement is drafted in a manner to comply with the requirements of Section 409A of the Code.  The payments to the Executive pursuant to this Agreement are also intended to be exempt from Section 409A of the Code to the maximum extent possible, under either the separation pay exemption pursuant to Treasury Regulation Section 1.409A-1(b)(9)(iii) or as short-term deferrals pursuant to Treasury Regulation Section 1.409A-1(b)(4).  Each payment and benefit hereunder shall constitute a “separately identified” amount within the meaning of Treasury Regulation Section 1.409A-2(b)(2).  In the event the terms of this Agreement would subject the Executive to taxes or penalties under Section 409A of the Code (“409A Penalties”), the Company and the Executive shall cooperate diligently to amend the terms of the Agreement to avoid such 409A Penalties, to the extent possible.  To the extent any amounts under this Agreement are payable by reference to Executive’s “termination,” “termination of employment,” or similar phrases, such term shall be deemed to refer to the Executive’s “separation from service” (as defined in Treasury Regulation Section 1.409A-1(h) (without regard to any permissible alternative definition thereunder) with the Company and all entities treated as a single employer with the Company under Sections 414(b) and (c) of the Code but substituting a 50% ownership level for the 80% ownership level set forth therein).  Notwithstanding any other provision in this Agreement, if the Executive is a “Specified Employee” (as defined in Treasury Regulation Section 1.409A-1(i) on December 31st of the prior calendar year), as of the date of the Executive’s separation from service, then to the extent any amount payable under this Agreement (i) constitutes the payment of nonqualified deferred compensation, within the meaning of Section 409A of the Code, (ii) is payable upon the Executive’s separation from service and (iii) under the terms of this Agreement would be payable prior to the six-month anniversary of the Executive’s separation from service, such payment shall be delayed and paid to the Executive, together with interest at an annual rate equal to the interest rate specified by Regions Bank for a six-month certificate of deposit, on the first day of the first calendar month beginning seven (7) months following the date of termination,

 

13



 

or, if earlier, within ninety (90) days following the Executive’s death to the Executive’s surviving spouse (or such other beneficiary as the Executive may designate in writing).  Any reimbursement or advancement payable to the Executive pursuant to this Agreement shall be conditioned on the submission by the Executive of all expense reports reasonably required by the Company under any applicable expense reimbursement policy, and shall be paid to the Executive within thirty (30) days following receipt of such expense reports, but in no event later than the last day of the calendar year following the calendar year in which the Executive incurred the reimbursable expense.  Any amount of expenses eligible for reimbursement, or in-kind benefit provided, during a calendar year shall not affect the amount of expenses eligible for reimbursement, or in-kind benefit to be provided, during any other calendar year.  The right to any reimbursement or in-kind benefit pursuant to this Agreement shall not be subject to liquidation or exchange for any other benefit.

 

19.          GOVERNING LAW

 

This Agreement shall be construed, interpreted, and governed in accordance with the laws of the State of Wisconsin, other than the conflict of laws provisions of such laws.  Subject to Section 13 , venue of any litigation arising from this Agreement or any disputes relating to the Executive’s employment shall be in the United States District Court for the Eastern District of Wisconsin, or a state district court of competent jurisdiction in Waukesha County, Wisconsin.  The Executive consents to personal jurisdiction of the United States District Court for the Eastern District of Wisconsin, or a state district court of competent jurisdiction in Waukesha County, Wisconsin for any dispute relating to or arising out of this Agreement or the Executive’s employment, and Executive agrees that Executive shall not challenge personal or subject matter jurisdiction in such courts.

 

20.          SURVIVAL

 

The Executive’s post-termination obligations in Section 9 and Section 10 shall continue as provided in this Agreement.

 

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

14



 

IN WITNESS WHEREOF , the Company has caused this Agreement to be duly executed, and the Executive has hereunto set his hand, as of the day and year first above written.

 

 

PHYSICIANS REALTY TRUST

 

 

 

By:

/s/ Tommy G. Thompson

 

Its:

Chairman, Board of Trustees, Physicians Realty Trust

 

 

 

 

 

 

 

 

EXECUTIVE:

 

 

 

 

 

 

 

 

/s/ John Lucey

 

 

John Lucey

 

15


Exhibit 10.4

 

AMENDED AND RESTATED

EMPLOYMENT AGREEMENT

 

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), by and between PHYSICIANS REALTY TRUST, a Maryland trust, (the “Company”), and MARK D. THEINE (the “Executive”) is entered into this 6th day of May, 2014, but effective as of the 24th day of July, 2013 (the “Effective Date”).

 

WHEREAS , the Company and the Executive entered into an Employment Agreement (the “Original Agreement”) dated the Effective Date, providing for the Executive’s employment and setting forth the terms and conditions for such employment; and

 

WHEREAS , the Company and the Executive desire to amend and restate the Original Agreement to provide for certain changes to the terms and conditions of the Executive’s employment by the Company, as reflected in this Agreement.

 

NOW THEREFORE , in consideration of the mutual covenants herein contained, the parties, intending to be legally bound, hereby agree as follows:

 

1.                                       EMPLOYMENT

 

The Company hereby agrees to employ the Executive as its Senior Vice President of Asset and Investment Management (the “Senior Vice President”) upon the terms and conditions herein contained, and the Executive hereby agrees to accept such employment and to serve in such position. As Senior Vice President, the Executive will have those duties which can reasonably be expected to be performed by a person in such position and shall undertake such other responsibilities as may be assigned to the Executive by the Company’s Chief Executive Officer (“CEO”) from time to time. For purposes of this Agreement, all references to the “Board” shall mean the Board of Trustees. In such capacity, the Executive shall report to the Company’s Board and shall have such powers and responsibilities consistent with his position as may be assigned. Throughout the Employment Term, the Executive shall devote his best efforts and all of his business time and services to the business and affairs of the Company.

 

2.                                       TERM OF AGREEMENT

 

Subject to earlier termination as herein provided, the Executive’s employment under this Agreement shall begin on the Effective Date and shall continue in effect until the third anniversary of the Effective Date (the “Initial Term”). The Agreement will automatically renew, subject to earlier termination as herein provided, for successive one (1) year periods (the “Additional Terms”), unless either the Executive or the Company provide notice of non-renewal at least sixty (60) days prior to the expiration of the Initial Term or the then Additional Term, whichever is applicable. The Initial Term and any Additional Term(s) shall be referred to collectively as the “Employment Term.”

 

Notwithstanding the foregoing, the Company shall be entitled to terminate this Agreement immediately, subject to a continuing obligation to make any payments required under Section 5 below, if the Executive (i) incurs a Disability as described in Section 5(b) , (ii) is terminated for Cause, as defined in Section 5(c) , or (iii) voluntarily terminates his employment without Good Reason (as defined below) during the Employment Term, as described in Section 5(d) .

 

3.                                       SALARY AND BONUS

 

The Executive shall receive a base salary during the Employment Term at a rate of $150,000 per

 



 

annum for 2013 (the “Base Salary”), payable in substantially equal semi-monthly installments. The Compensation Committee of the Board shall consult with the Senior Vice President and review the Executive’s Base Salary at annual intervals, and may increase the Executive’s annual Base Salary from time to time as the Committee deems to be appropriate.

 

Subject to Section 12 , the Executive will have an annual cash bonus opportunity for each calendar year during the Employment Term (the “Annual Bonus”) based upon performance goals that are established by the Board or the Compensation Committee of the Board, as the case may be, in its sole discretion.  In the event an Annual Bonus is payable pursuant to this Section 3 , such bonus shall be paid to the Executive no later than March 15th of the year after the year to which the bonus relates.

 

On or as soon as administratively practicable after the date of an Initial Public Offering (as defined below) (but in no event later than sixty (60) days after the date of an Initial Public Offering), the Executive shall receive a grant of restricted shares of the Company’s common shares having a value of $400,000 based on the public offering price per share of the Company’s common shares offered for sale at the Initial Public Offering (the “Restricted Shares”). The Restricted Shares shall be subject to the restrictions set forth in the restricted share agreement between the Company and the Executive and the terms of an equity incentive plan adopted by the Company prior to the grant of the Restricted Shares (the “Plan”). The Restricted Shares shall vest over a three-year period, with one-third of the Restricted Shares vesting equally on the first, second, and third anniversary of the Effective Date, subject to any forfeiture or acceleration provisions set forth in the restricted share agreement and the Plan. For purposes of this Agreement, “Initial Public Offering” means any underwritten sale of the Company’s equity securities pursuant to an effective registration statement under the Securities Act of 1933 filed with the Securities and Exchange Commission on Form S-1 or any other eligible form (or a successor form thereto adopted by the Securities and Exchange Commission).

 

4.                                       ADDITIONAL COMPENSATION AND BENEFITS

 

The Executive shall receive the following additional compensation and welfare and fringe benefits during the term of the Agreement:

 

(a)                                  Options and Other Long-Term Incentives . During the Employment Term, any options, restricted shares or other awards granted under the Plan shall be at the discretion of the Compensation Committee of the Company’s Board.

 

(b)                                  Vacation . The Executive shall be entitled to up to four (4) weeks of vacation during each year during the Employment Term and any extensions thereof, prorated for partial years.

 

(c)                                   Business Expenses . The Company shall reimburse the Executive for all reasonable expenses he incurs in promoting the Company’s business, including expenses for travel and similar items, upon presentation by the Executive from time to time of an itemized account of such expenditures. Any reimbursement of expenses made under this Agreement shall only be made for eligible expenses (including transportation and cellular service expenses as set forth above) incurred during the Employment Term, and no reimbursement of any expense shall be made by the Company after December 31st of the year following the calendar year in which the expense was incurred. The amount eligible for reimbursement under this Agreement during a taxable year may not affect expenses eligible for reimbursement in any other taxable year, and the right to reimbursement under this Agreement is not subject to liquidation or exchange for another benefit. The Executive will comply with the Company’s policies regarding these benefits, including all Internal Revenue Service rules and requirements.

 

2



 

(d)                                  Professional Expenses . Each calendar year during the Employment Term, the Company agrees to reimburse the Executive for up to $10,000 of reasonable professional expenses (i.e., accounting, financial planning, estate planning expenses) incurred by the Executive during such year for personal advice rendered to the Executive.

 

(e)                                   Other Benefits and Perquisites . The Executive shall be entitled to participate in the benefit plans provided by the Company for all employees, generally, and for the Company’s executive employees. The Company shall be entitled to change or terminate these plans in its sole discretion at any time.

 

5.                                       PAYMENTS UPON TERMINATION

 

(a)                                  Involuntary Termination . If the Executive’s employment is involuntarily terminated by the Company during the Employment Term, the Executive shall be entitled to receive his Base Salary accrued through the date of termination, any accrued but unpaid vacation pay, plus any bonuses earned but unpaid with respect to fiscal years or other periods ending before the termination date (collectively, the “Accrued Obligations”). Such payments shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of involuntary termination). The Executive shall also receive any nonforfeitable benefits payable to him under the terms of any deferred compensation, incentive or other benefit plans maintained by the Company, payable in accordance with the terms of the applicable plan.

 

If the termination is not (1) a termination for Cause (as defined below), as described in Section 5(c) ; (2) a voluntary termination by the Executive without Good Reason (as defined below) as described in Section 5(d) ; (3) a termination as a result of the Executive’s death or Disability (as defined below); or (4) a termination due to non-renewal of the then current term as described in Section 5(e) , then subject to compliance with the restrictive covenants in Section 9 and Section 10 and the execution and timely return by the Executive of a release of claims in a form and substance reasonably requested by the Company (the “Release”), and except as otherwise provided by Sections 12 and 18 , the Company shall pay severance to the Executive in accordance with its normal payroll practices, equal to the Executive’s Base Salary as in effect at the time his employment terminates for a period equal to the greater of (a) the remainder of the then current term of this Agreement or (b) twenty-four (24) months, with the first payment on the first payroll date after the revocation period for the Release has expired; provided, that if the time period for returning and revoking the release begins in one taxable year and ends in a second taxable year, the payments shall not commence until the first payroll date in the second taxable year.

 

In addition, if the termination is not (1) a termination for Cause, as described in Section 5(c) ; (2) a voluntary termination by the Executive without Good Reason as described in Section 5(d) ; (3) a termination as a result of the Executive’s death or Disability (as defined below); or (4) a termination due to non-renewal of the then current term as described in Section 5(e) , then, subject to compliance with the restrictive covenants in Section 9 and Section 10 , the execution and timely return by the Executive of the Release, and except as otherwise provided by Sections 12 and 18 , the Executive shall be entitled to the following:

 

(i)                                      Any options, restricted shares or other awards granted to the Executive under the Plan shall become fully vested and, in the case of options, exercisable in full;

 

3



 

(ii)                                   Provided that the Executive elects continuation of coverage under the Company’s group health plan pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1986, as amended (“COBRA”), the Executive shall be provided continued coverage at the Company’s expense under any health insurance programs maintained by the Company in which the Executive participated at the time of his termination for twelve (12) months, or until, if earlier, the date the Executive obtains comparable coverage under a group health plan maintained by a new employer. To the extent the benefits provided under the immediately preceding sentence are otherwise taxable to the Executive, such benefits, for purposes of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) (and the regulations and other guidance issued thereunder) shall be provided as separate monthly in-kind payments of those benefits, and to the extent those benefits are subject to and not otherwise excepted from Section 409A of the Code, the provision of the in-kind benefits during one calendar year shall not affect the in-kind benefits to be provided in any other calendar year; and

 

(iii)                                Annual Bonus(es) payable under Section 3 above that would have been earned based solely on continued employment for the remainder of the then current term, and if none, then an amount equal to fifty percent (50%) of the Executive’s then current Base Salary, payable at the same time as bonuses are paid to other active employees of the Company with respect to such performance period, and forfeited if the Executive violates any of the restrictive covenants in Section 9 and Section 10 .

 

(b)                                  Disability . The Company shall be entitled to terminate the Executive’s employment if the Board determines that the Executive has been unable to attend to his duties for at least ninety (90) days because of a Disability (as defined below), and has received a written opinion from a physician acceptable to the Board that such condition prevents the Executive from resuming full performance of his duties and is likely to continue for an indefinite period. Upon such involuntary termination, the Executive shall be entitled to receive the Accrued Obligations. Such payments shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of involuntary termination). In addition, subject to compliance with the restrictive covenants in Section 9 and Section 10 and the execution and timely return by the Executive of the Release, the Company shall pay severance to the Executive in accordance with its normal payroll practices, equal to twelve (12) months of the Executive’s Base Salary as in effect at the time his employment terminates, with the first payment on the first payroll date after the revocation period for the Release has expired; provided, that (i) if the time period for returning and revoking the Release begins in one taxable year and ends in a second taxable year, the payments shall not commence until the first payroll date in the second taxable year; and (ii) all such payments shall immediately terminate at an earlier date if the Executive returns to active employment, either with the Company or otherwise. Any amounts payable under this Section 5(b)  shall be reduced on a dollar-for-dollar basis by the amount of bona fide disability pay (within the meaning of Treas. Reg. section 1.409A-1(a)(5)) received or receivable by the Executive during such twelve-month period, provided such disability payments are made pursuant to a plan sponsored by the Company that covers a substantial number of employees of the Company and was established prior to the date the Executive incurred a permanent disability, and further provided that such reduction does not otherwise affect the time of payment of amounts pursuant to this Section 5(b) . For purposes of this Agreement, “Disability” means the Executive is incapacitated due to physical or mental illness and such incapacity, with or without reasonable accommodation, prevents the Executive from satisfactorily performing the essential functions of his job for the Company on a full-time basis for at least ninety (90) days in a calendar year.

 

4



 

(c)                                   Termination for Cause . If the Executive’s employment is terminated by the Company for Cause, the amount the Executive shall be entitled to receive from the Company shall be limited to the Accrued Obligations. Such payments shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of termination).

 

For purposes of this Agreement, the term “Cause” shall be limited to the following:

 

(i)                                      the Executive engaging in any act of fraud, dishonesty, theft, misappropriation or embezzlement of funds or misrepresentation with respect to the Company;

 

(ii)                                   the Executive’s conviction or plea of no contest with respect to any felony or other crime involving moral turpitude;

 

(iii)                                the Executive’s material breach of his obligations under this Agreement, including, without limitation, breach of the covenants set forth in Section 9 and Section 10 below or the refusal of the Executive to perform his job duties as directed by the Board, which the Executive failed to cure within thirty (30) days after receiving written notice from the Board specifying the alleged breach;

 

(iv)                               violation of any material duty or obligation to the Company or of any direction or any rule or regulation reasonably established by the Board, which the Executive failed to cure within thirty (30) days after receiving written notice from the Board specifying the alleged violation; or

 

(v)                                  insubordination or misconduct in the performance of, or neglect of, the Executive’s duties which the Executive failed to cure within thirty (30) days after receiving written notice from the Board specifying the alleged insubordination, misconduct, or neglect.

 

(d)                                  Voluntary Termination by the Executive without Good Reason . If the Executive resigns or otherwise voluntarily terminates his employment before the end of the current Employment Term (other than in connection with a Change in Corporate Control, as described in Section 6 ), the amount the Executive shall be entitled to receive from the Company shall be limited to the Accrued Obligations. Such payment shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the date of resignation or voluntary termination).

 

For purposes of this Agreement, a resignation by the Executive shall not be deemed to be voluntary without Good Reason if, without the Executive’s prior consent, the Executive is (1) assigned to a position other than the Senior Vice President (other than for Cause or by reason of his Disability) or assigned duties materially inconsistent with such position if either such change in assignment constitutes a material diminution in the Executive’s authority, duties or responsibilities, or (2) directed to report to anyone other than the CEO if such change in reporting duties constitutes a material diminution in the authority, duties or responsibilities of the supervisor to whom the Executive is required to report; provided that the Executive has notified the Company within the first ninety (90) days following the initial date of such change in assignment or reporting duties that the Executive regards such change in assignment or reporting duties as grounds justifying resignation under this Section 5(d)  and the Company has failed to cure such change in assignment or reporting duties within ninety (90) days following its receipt of

 

5



 

such notice from the Executive; and provided further that the Executive resigns under this Section 5(d)  within six (6) months following the initial existence of a change in assignment or reporting duties described herein.

 

(e)                                   Non-Renewal . The Executive’s employment shall terminate in the event that the then-current Employment Term expires by reason of a party giving a notice of an election not to renew as provided in Section 2 . If the Executive’s employment terminates due to non-renewal of the Agreement, the amount the Executive shall be entitled to receive from the Company shall be limited to the Accrued Obligations. Such payment shall be made to the Executive within the time period required by applicable law (and in all events within sixty (60) days following the expiration of the then-current term).

 

6.                                       EFFECT OF CHANGE IN CORPORATE CONTROL

 

(a)                                  Accelerated Vesting of Awards . In the event of a “change in control” (as such term is defined in the Plan), the vesting of any options, restricted shares or other awards granted to the Executive under the terms of the Plan shall be accelerated (to the extent permitted by the terms of the Plan) and such awards shall become immediately vested in full and, in the case of stock options, exercisable in full.

 

(b)                                  Severance Payment . If, during the Employment Term at any time during the period of twelve (12) consecutive months following the occurrence of a Change in Corporate Control, the Executive is involuntarily terminated (other than for Cause) or the Executive terminates his employment for Good Reason, then subject to compliance with the restrictive covenants in Section 9 and Section 10 and the execution and timely return by the Executive of the Release, the Executive shall be entitled to receive a lump sum severance payment equal to the present value of a series of monthly payments for twenty-four (24) months, each in an amount equal to one-twelfth (1/12th) of the sum of (i) the Executive’s Base Salary, as in effect at the time of the Change in Corporate Control, and (ii) the average of the annual bonuses paid to the Executive for the prior two fiscal years of the Company ending prior to the Change in Corporate Control, if any. Such present value shall be calculated using a discount rate equal to the interest rate on 90-day Treasury bills, as reported in the Wall Street Journal (or similar publication) on the date of the Change in Corporate Control. Such lump sum payment shall be made to the Executive within sixty (60) days following the date of such involuntary termination.

 

In addition, if during the Employment Term within twelve (12) months after a Change in Corporate Control the Executive is involuntarily terminated (other than for Cause) or the Executive terminates his employment for Good Reason, he shall be entitled to continued coverage at the Company’s expense under any health insurance programs maintained by the Company in which the Executive participated at the time of his termination, which coverage shall be continued for eighteen (18) months or until, if earlier, the date the Executive obtains comparable coverage under a group health plan maintained by a new employer. To the extent the benefits provided under the immediately preceding sentence are otherwise taxable to the Executive, such benefits, for purposes of Section 409A of the Code (and the regulations and other guidance issued thereunder) shall be provided as separate monthly in-kind payments of those benefits, and to the extent those benefits are subject to and not otherwise excepted from Section 409A of the Code, the provision of the in-kind benefits during one calendar year shall not affect the in-kind benefits to be provided in any other calendar year.

 

(c)                                   Definition of Change in Corporate Control . For purposes of this Agreement, a “Change in Corporate Control” shall include any of the following events:

 

6



 

(i)                                      The acquisition in one or more transactions of more than fifty percent (50%) of the Company’s outstanding Common Shares (or the equivalent in voting power of any class or classes of securities of the Company entitled to vote in elections of trustees) by any Company, or other person or group (within the meaning of Section 14(d)(3) of the Securities Exchange Act of 1934, as amended);

 

(ii)                                   Any transfer or sale of substantially all of the assets of the Company, or any merger or consolidation of the Company into or with another Company in which the Company is not the surviving entity;

 

Provided, however, that no event shall constitute a Change in Corporate Control unless such event is also a “change in ownership”, a “change in effective control” or a “change in the ownership of a substantial portion of the assets” of the Company, as determined in accordance with Section 409A of the Code, and the regulations and guidance issued thereunder.

 

7.                                       DEATH

 

If the Executive dies during the Employment Term, the Company shall pay to the Executive’s surviving spouse or if there is no surviving spouse, the Executive’s estate, a lump sum payment equal to the Accrued Obligations. Such payment shall be paid within the time period required by applicable law (and in all events within sixty (60) days following the date of the Executive’s death). In addition, the death benefits payable by reason of the Executive’s death under any retirement, deferred compensation, life insurance or other employee benefit plan maintained by the Company shall be paid to the beneficiary designated by the Executive, and the options, restricted shares or other awards held by the Executive under the Company’s equity incentive plans shall become fully vested, and, in the case of options, exercisable in full, in accordance with the terms of the applicable plan or plans.

 

8.                                       WITHHOLDING

 

The Company shall, to the extent permitted by law, have the right to withhold and deduct from any payment hereunder any federal, state or local taxes of any kind required by law to be withheld with respect to any such payment.

 

9.                                       PROTECTION OF CONFIDENTIAL INFORMATION

 

During the Executive’s employment with the Company, the Company shall grant the Executive otherwise prohibited access to its trade secrets and confidential information which are not known to the Company’s competitors or within the Company’s industry generally, which were developed by the Company over a long period of time and/or at its substantial expense, and which are of great competitive value to the Company, and access to the Company’s customers and clients. For purposes of this Agreement, “Confidential Information” includes all trade secrets and confidential and proprietary information of the Company, including, but not limited to, the following: financial models, financial information and data, business methods, electronic files, computer drives/disks, passwords, address and telephone lists, internal memoranda, correspondence, business strategies, business plans and/or projections, lease forms, construction contract forms, development and construction management service agreements, tenant lists, lease terms, rates, rent rolls, strategies, improvements, discoveries, plans for research or future business, infrastructure, marketing and sales plans and strategies, budgets, customer and client information, employee, customer and client nonpublic personal information, supplier lists, business records, audit processes, management methods and information, reports, recommendations and conclusions, information regarding the names, contact information, skills and compensation of employees and contractors of the Company, other information not generally known to the public, and other business

 

7



 

information disclosed to the Executive by the Company, either directly or indirectly, in writing, orally, or by drawings or observation.

 

The Executive acknowledges and agrees that Confidential Information is proprietary to and a trade secret of the Company and, as such, is a special and unique asset of the Company, and that any disclosure or unauthorized use of any Confidential Information by the Executive will cause irreparable harm and loss to the Company. The Executive understands and acknowledges that each and every component of the Confidential Information (i) has been developed by the Company at significant effort and expense and is sufficiently secret to derive economic value from not being generally known to other parties, and (ii) constitutes a protectable business interest of the Company. The Executive acknowledges and agrees that the Company owns the Confidential Information. The Executive agrees not to dispute, contest, or deny any such ownership rights either during or after the Executive’s employment with the Company. The Executive agrees to preserve and protect the confidentiality of all Confidential Information. The Executive agrees that the Executive shall not at any time (whether during or after the Executive’s employment), directly or indirectly, disclose to any unauthorized person or use for the Executive’s own account any Confidential Information without the Company’s consent. Throughout the Executive’s employment and at all times thereafter: (i) the Executive shall hold all Confidential Information in the strictest confidence, take all reasonable precautions to prevent its inadvertent disclosure to any unauthorized person, and follow all policies of the Company protecting the Confidential Information; (ii) the Executive shall not, directly or indirectly, utilize, disclose or make available to any other person or entity, any of the Confidential Information, other than in the proper performance of the Executive’s duties; (iii) the Executive shall not use the Confidential Information or trade secrets to attempt to solicit, induce, recruit, or take away clients or customers of the Company; and (iv) if the Executive learns that any person or entity is taking or threatening to take any actions which would compromise any Confidential Information, the Executive shall promptly advise the Company of all facts concerning such action or threatened action. The foregoing shall not apply to any information which is already in the public domain, or is generally disclosed by the Company or is otherwise in the public domain at the time of disclosure (other than through an unauthorized disclosure by the Executive or any other person).

 

Upon the termination of the Executive’s employment for any reason, the Executive shall immediately return and deliver to the Company any and all Confidential Information, software, devices, cell phones, personal data assistants, credit cards, data, reports, proposals, lists, correspondence, materials, equipment, computers, hard drives, papers, books, records, documents, memoranda, manuals, e-mail, electronic or magnetic recordings or data, including all copies thereof, which belong to the Company or relate to the Company’s business and which are in the Executive’s possession, custody or control, whether prepared by the Executive or others. If at any time after termination of the Executive’s employment he determines that he has any Confidential Information in his possession or control, the Executive shall immediately return to the Company all such Confidential Information in the Executive’s possession or control, including all copies and portions thereof.

 

The Executive recognizes that because his work for the Company may bring him into contact with confidential and proprietary information of the Company, the restrictions of this Section 9 are required for the reasonable protection of the Company and its investments and for the Company’s reliance on and confidence in the Executive.

 

10.                                RESTRICTIVE COVENANTS

 

In consideration for (i) the Company’s promise to provide Confidential Information to the Executive, (ii) the substantial economic investment made by the Company in the Confidential Information and goodwill of the Company, and/or the business opportunities disclosed or entrusted to the Executive,

 

8



 

(iii) access to the Company’s customers and clients, and (iv) the Company’s employment of the Executive pursuant to this Agreement and the compensation and other benefits provided by the Company to the Executive, to protect the Company’s Confidential Information and business goodwill of the Company, the Executive agrees to the following restrictive covenants.

 

(a)                                  Non-Competition . The Executive hereby agrees that during the Restricted Period (defined below), other than in connection with the Executive’s duties under this Agreement, the Executive shall not, and shall not use any Confidential Information to, without the prior consent of the Company, directly or indirectly, either individually or as an owner, principal, partner, stockholder, manager, contractor, distributor, lender, investor, consultant, agent, employee, co-venturer or as a director or officer of any corporation or association, or in any other manner or capacity whatsoever, become employed by, control, carry on, join, lend money for, engage in, establish, perform services for, invest in, solicit investors for, consult for, do business with or otherwise engage in any Competing Business (defined below) within the Restricted Territory (defined below); provided however, that nothing in this Section 10(a)  shall prevent the Executive from owning a passive investment in up to two percent (2%) of the stock of a publicly traded corporation engaged in a Competing Business and such ownership shall not be considered to be a violation of Section 10(a) .

 

(i)                                      “Restricted Period” means during the Executive’s employment with the Company and for a period equal to the later of (i) one (1) year immediately following the date of the Executive’s termination from employment for any reason or (ii) the number of months for which the Executive is receiving monthly severance payments under Section 5 or Section 6 of this Agreement.

 

(ii)                                   “Competing Business” means any business, individual, partnership, firm, corporation or other entity that provides the same or substantially similar products or services as those provided by the Company during the Executive’s employment, which includes, without limitation, the business of buying, managing, holding and selling medical office buildings.

 

(iii)                                As Senior Vice President of the Company, the Executive has responsibility for the Company’s operations throughout the United States. Because the Company does business throughout the United States, the “Restricted Territory” means the United States and any other region or state in which the Executive performed services, was assigned responsibility for the Company, or about which the Executive received Confidential Information.

 

(b)                                  Non-Solicitation . The Executive agrees that during the Restricted Period, other than in connection with the Executive’s duties under this Agreement, the Executive shall not, and shall not use any Confidential Information to, directly or indirectly, either individually or as an owner, principal, partner, stockholder, manager, contractor, distributor, lender, investor, consultant, agent, employee, co-venturer or as a director or officer of any corporation or association, or in any other manner or capacity whatsoever, and whether personally or through other persons:

 

(i)                                      Solicit business from, interfere with, attempt to solicit business with, or do business with any customer or client of the Company with whom the Company did business or who the Company solicited within the preceding two (2) years, and who or which: (1) the Executive contacted, called on, serviced, or did business with during his employment with the Company; (2) the Executive learned of as a result of his

 

9



 

employment with the Company; or (3) about whom the Executive received Confidential Information. This restriction applies only to business which is in the scope of services or products provided by the Company; or

 

(ii)                                   Solicit, induce, or attempt to solicit or induce, engage or hire, on behalf of himself or any other person or entity, any person who is an employee or full-time consultant of the Company or who was employed or retained by the Company within the preceding two (2) years.

 

(c)                                   Non-Disparagement . The Executive shall refrain, both during and after the Employment Term, from publishing any oral or written statements about the Company or any of the Company’s board of trustees, equity holders, members, shareholders, managers, officers, employees, consultants, agents or representatives that (i) are slanderous, libelous or defamatory; or (ii) place the Company or any of its trustees, managers, officers, employees, consultants, agents or representatives in a false light before the public. A violation or threatened violation of this prohibition may be enjoined by the courts. The rights afforded the Company under this provision are in addition to any and all rights and remedies otherwise afforded by law.

 

(d)                                  Tolling . If the Executive violates any of the restrictions contained in Section 10, the Restricted Period shall be suspended and shall not run in favor of the Executive from the time of the commencement of any violation until the time when the Executive cures the violation to the satisfaction of the Company.

 

(e)                                   Reasonableness . The Executive hereby represents to the Company that he has read and understands, and agrees to be bound by, the terms of this Section 10 . The Executive acknowledges that the geographic scope and duration of the covenants contained in this Section 10 are fair and reasonable in light of (i) the nature and wide geographic scope of the operations of the Company’s business; (ii) the Executive’s level of control over and contact with the business in the Restricted Territory; and (iii) the amount of compensation, trade secrets and Confidential Information that the Executive is receiving in connection with his employment by the Company. It is the desire and intent of the parties that the provisions of Section 10 be enforced to the fullest extent permitted under applicable law, whether now or hereafter in effect and therefore, to the extent permitted by applicable law, the Executive and the Company hereby waive any provision of applicable law that would render any provision of Section 10 invalid or unenforceable.

 

11.                                INJUNCTIVE RELIEF

 

The Executive acknowledges that (a) compliance with the covenants set forth in Section 9 and Section 10 of this Agreement are necessary to protect the Company’s business and Confidential Information; (b) a breach or threatened breach of any of such covenants will irreparably harm the Company; and (c) an award of money damages will not be adequate to remedy such harm. Consequently, the Executive acknowledges and agrees that, in addition to other remedies, in the event the Executive breaches or threatens to breach any of the covenants contained in this Agreement, the Company shall be entitled to both a temporary and/or permanent injunction to prevent the continuation of such harm and enforce such provisions and money damages insofar as they can be determined, including, without limitation, all costs and reasonable attorneys’ fees incurred by or on behalf of the Company in the enforcement of the terms of this Agreement. The Company may apply to any court of competent jurisdiction for a temporary restraining order, preliminary injunction or other interim or conservatory relief, as necessary or applicable. This provision with respect to injunctive relief shall not, however, diminish the Company’s right to claim and recover damages.

 

10



 

It is expressly understood and agreed that although the parties consider the restrictions contained in this Agreement to be reasonable, if a court determines that the time or territory or any other restriction contained in this Agreement is an unenforceable restriction on the activities of the Executive, no such provision of this Agreement shall be rendered void but shall be deemed amended to apply as to such maximum time and territory and to such extent as such court may judicially determine or indicate to be reasonable. By agreeing to this contractual modification prospectively at this time, the Company and the Executive intend to make this provision enforceable under the law or laws of all applicable jurisdictions so that the entire agreement not to compete and this Agreement as prospectively modified shall remain in full force and effect and shall not be rendered void or illegal.

 

12.                                CLAWBACK

 

Any compensation paid to the Executive shall be subject to recovery by the Company, and the Executive shall be required to repay such compensation, if (i) such recovery and repayment is required by applicable law or (ii) either in the year such compensation is paid, or within the three (3) year period thereafter the Company is required to prepare an accounting restatement due to material noncompliance of the Company with any financial reporting requirement under applicable securities laws and the Executive is either (A) a named executive officer or (B) an employee who is responsible for preparation of the Company’s financial statements. The parties agree that the repayment obligations set forth in this Section 12 shall only apply to the extent repayment is required by applicable law, or to the extent the Executive’s compensation is determined to be in excess of the amount that would have been deliverable to the Executive taking into account any restatement or correction of any inaccurate financial statements or materially inaccurate performance metric criteria.

 

13.                                MANDATORY MEDIATION AND ARBITRATION

 

In the event there is an unresolved legal dispute between the Executive and the Company that involves legal rights or remedies arising from this Agreement or the employment relationship between the Executive and the Company (“Dispute”), except as otherwise provided herein, before commencing an arbitration action or other legal proceeding, the parties shall promptly submit the Dispute to mediation, using a mediator jointly selected by the parties, or if the parties are unable to agree upon a mediator then the Dispute shall be submitted to non-binding mediation with the American Arbitration Association in Waukesha County, Wisconsin in accordance with its rules. The cost of the mediation shall be borne equally between the parties. If the parties are unable to achieve a mutually agreeable resolution of the Dispute through mediation, the parties agree to submit their Dispute to binding arbitration under the authority of the Federal Arbitration Act and/or the Wisconsin Uniform Arbitration Act; provided, however, that the Company may pursue a temporary restraining order, preliminary injunction and/or other interim or conservatory relief in accordance with Section 11 above, with related expedited discovery for the parties, in a court of law, and, thereafter, require arbitration of all issues of final relief. Insured workers compensation claims (other than wrongful discharge claims), and claims for unemployment insurance are excluded from arbitration under this provision. The Arbitration will be conducted by the American Arbitration Association pursuant to the American Arbitration Association’s National Rules for the Resolution of Employment Disputes. The arbitrator(s) shall be duly licensed to practice law in the State of Wisconsin. Each party will be allowed at least one deposition. The arbitrator(s) shall be required to state in a written opinion all facts and conclusions of law relied upon to support any decision rendered. No arbitrator will have authority to render a decision that contains an outcome determinative error of state or federal law, or to fashion a cause of action or remedy not otherwise provided for under applicable state or federal law. Any dispute over whether the arbitrator(s) has failed to comply with the foregoing will be resolved by summary judgment in a court of law. In all other respects, the arbitration process will be conducted in accordance with the American Arbitration Association’s National Rules for the Resolution of Employment Disputes. The Company will pay the arbitration costs and arbitrator’s fees beyond $500,

 

11



 

subject to a final arbitration award on who should bear costs and fees. All proceedings shall be conducted in Waukesha County, Wisconsin, or another mutually agreeable site. The duty to arbitrate described above shall survive the termination of this Agreement. Except as otherwise provided above, the parties hereby waive trial in a court of law or by jury. All other rights, remedies, statutes of limitation and defenses applicable to claims asserted in a court of law will apply in the arbitration.

 

14.                                NOTICES

 

All notices or communications hereunder shall be in writing and sent certified or registered mail, return receipt requested, postage prepaid, addressed as follows (or to such other address as such party may designate in writing from time to time):

 

If to the Company:

 

Physicians Realty Trust

735 North Water Street

Suite 1000

Milwaukee, Wisconsin 53202

(414) 978.6400

Attention: Corporate Secretary

 

If to the Executive:

 

Mark D. Theine

c/o Physicians Realty Trust

735 North Water Street

Suite 1000

Milwaukee, Wisconsin 53202

(414) 978.6400

Attention: Corporate Secretary

 

The actual date of receipt, as shown by the receipt therefor, shall determine the time at which notice was given.

 

15.                                SEPARABILITY

 

If any provision of this Agreement shall be declared to be invalid or unenforceable, in whole or in part, such invalidity or unenforceability shall not affect the remaining provisions hereof which shall remain in full force and effect.

 

16.                                ASSIGNMENT

 

This Agreement shall be binding upon and inure to the benefit of the heirs and representatives of the Executive and the assigns and successors of the Company, but neither this Agreement nor any rights hereunder shall be assignable or otherwise subject to hypothecation by the Executive.

 

17.                                ENTIRE AGREEMENT

 

This Agreement represents the entire agreement of the parties and shall supersede any and all previous contracts, arrangements or understandings (whether oral or written) between the Company and the Executive with respect to the subject matter hereof. No oral statements or prior written material not

 

12



 

specifically incorporated in this Agreement shall be of any force and effect. The Agreement may be amended at any time by mutual written agreement of the parties hereto. The Executive acknowledges and represents that in executing this Agreement, he did not rely on, has not relied on, and specifically disavows any reliance on any communications, promises, statements, inducements, or representation(s), oral or written, by the Company, except as expressly contained in this Agreement. The parties represent that they relied on their own judgment in entering into this Agreement.

 

18.                                SECTION 409A COMPLIANCE

 

This Agreement and the benefits or payments to be provided under this Agreement are intended to be exempt from with the requirements of Section 409A of the Code, and shall be interpreted and construed consistently with such intent, provided, that if the Agreement is not exempt, the Agreement is drafted in a manner to comply with the requirements of Section 409A of the Code. The payments to the Executive pursuant to this Agreement are also intended to be exempt from Section 409A of the Code to the maximum extent possible, under either the separation pay exemption pursuant to Treasury Regulation Section 1.409A-1(b)(9)(iii) or as short-term deferrals pursuant to Treasury Regulation Section 1.409A-1(b)(4). Each payment and benefit hereunder shall constitute a “separately identified” amount within the meaning of Treasury Regulation Section 1.409A-2(b)(2). In the event the terms of this Agreement would subject the Executive to taxes or penalties under Section 409A of the Code (“409A Penalties”), the Company and the Executive shall cooperate diligently to amend the terms of the Agreement to avoid such 409A Penalties, to the extent possible. To the extent any amounts under this Agreement are payable by reference to Executive’s “termination,” “termination of employment,” or similar phrases, such term shall be deemed to refer to the Executive’s “separation from service” (as defined in Treasury Regulation Section 1.409A-1(h) (without regard to any permissible alternative definition thereunder) with the Company and all entities treated as a single employer with the Company under Sections 414(b) and (c) of the Code but substituting a 50% ownership level for the 80% ownership level set forth therein). Notwithstanding any other provision in this Agreement, if the Executive is a “Specified Employee” (as defined in Treasury Regulation Section 1.409A-1(i) on December 31st of the prior calendar year), as of the date of the Executive’s separation from service, then to the extent any amount payable under this Agreement (i) constitutes the payment of nonqualified deferred compensation, within the meaning of Section 409A of the Code, (ii) is payable upon the Executive’s separation from service and (iii) under the terms of this Agreement would be payable prior to the six-month anniversary of the Executive’s separation from service, such payment shall be delayed and paid to the Executive, together with interest at an annual rate equal to the interest rate specified by Regions Bank for a six-month certificate of deposit, on the first day of the first calendar month beginning seven (7) months following the date of termination, or, if earlier, within ninety (90) days following the Executive’s death to the Executive’s surviving spouse (or such other beneficiary as the Executive may designate in writing). Any reimbursement or advancement payable to the Executive pursuant to this Agreement shall be conditioned on the submission by the Executive of all expense reports reasonably required by the Company under any applicable expense reimbursement policy, and shall be paid to the Executive within thirty (30) days following receipt of such expense reports, but in no event later than the last day of the calendar year following the calendar year in which the Executive incurred the reimbursable expense. Any amount of expenses eligible for reimbursement, or in-kind benefit provided, during a calendar year shall not affect the amount of expenses eligible for reimbursement, or in-kind benefit to be provided, during any other calendar year. The right to any reimbursement or in-kind benefit pursuant to this Agreement shall not be subject to liquidation or exchange for any other benefit.

 

19.                                GOVERNING LAW

 

This Agreement shall be construed, interpreted, and governed in accordance with the laws of the State of Wisconsin, other than the conflict of laws provisions of such laws. Subject to Section 13 , venue

 

13



 

of any litigation arising from this Agreement or any disputes relating to the Executive’s employment shall be in the United States District Court for the Eastern District of Wisconsin, or a state district court of competent jurisdiction in Waukesha County, Wisconsin. The Executive consents to personal jurisdiction of the United States District Court for the Eastern District of Wisconsin, or a state district court of competent jurisdiction in Waukesha County, Wisconsin for any dispute relating to or arising out of this Agreement or the Executive’s employment, and Executive agrees that Executive shall not challenge personal or subject matter jurisdiction in such courts.

 

20.                                SURVIVAL

 

The Executive’s post-termination obligations in Section 9 and Section 10 shall continue as provided in this Agreement.

 

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

14



 

IN WITNESS WHEREOF , the Company has caused this Agreement to be duly executed, and the Executive has hereunto set his hand, as of the day and year first above written.

 

 

PHYSICIANS REALTY TRUST

 

 

 

 

 

By:

/s/ Tommy G. Thompson

 

Its: Chairman, Board of Trustees, Physicians Realty Trust

 

 

 

 

 

EXECUTIVE:

 

 

 

 

 

/s/ Mark D. Theine

 

Mark D. Theine

 

15


Exhibit 10.5

 

PHYSICIANS REALTY TRUST

 

INCENTIVE BONUS PLAN

 

SECTION 1
ESTABLISHMENT AND PURPOSE

 

The Physicians Realty Trust Incentive Bonus Plan (the “Plan”) has been established by the Company, effective as of January 1, 2014, to promote the success of the Company and its Subsidiaries by providing to selected Executives of the Company and its Subsidiaries the opportunity to earn or receive bonus incentives .

 

SECTION 2
DEFINITIONS AND TERMS

 

Except as otherwise expressly provided or the context otherwise requires, financial and accounting terms are used as defined for purposes of, and shall be determined in accordance with, generally accepted accounting principles used and applied in the United States.  The following words and phrases as used herein shall have the following meanings:

 

(a)           “ Base Salary ” with respect to any Performance Period shall mean the gross base salary an Executive is entitled to receive from the Company or any of its Subsidiaries for that Performance Period, prior to any reductions for salary deferred pursuant to any deferred compensation plan or for contributions to a plan qualifying under Code Section 401(k) or to a cafeteria plan under Code Section 125.

 

(b)           “ Board ” shall mean the board of trustees of the Company, as duly elected from time to time.

 

(c)           “ Code ” shall mean the Internal Revenue Code of 1986, as amended, and as interpreted by the regulations thereunder.

 

(d)           “ Committee ” shall mean the Compensation Committee of the Board, or such other committee as may be appointed by the Board from time to time, or if no such committee is appointed, the entire Board.

 

(e)           “ Company ” shall mean Physicians Realty Trust, a Maryland real estate investment trust.

 

(f)            “ Executive ” shall mean a key employee (including any officer) performing Services for the Company or its Subsidiaries.

 

(g)           “ Effective Date ” shall mean January 1, 2014.

 

(h)           “ Fiscal Year ” shall mean the fiscal year of the Company.

 

(i)            “ Incentive Bonus ” shall mean a cash payment or payment opportunity under the Plan, as the context requires.

 



 

(j)            “ Participant ” shall mean an Executive selected by the Committee to participate in the Plan for any given Performance Period.

 

(k)           “ Performance Goals ” shall mean the specific performance measure or measures that are approved for each Participant for the Performance Period.  Such performance measures may include any one or any combination of financial, operational, sales or other goals, which may be Company-wide, on a business unit or individual basis or otherwise, and may be expressed, for example, in terms of return on invested capital, revenue, net income or loss, real estate investments, funds from operations, or the attainment of various growth objectives.

 

(l)            “ Performance Period ” means the Fiscal Year or other period with respect to which Performance Goals are approved.

 

(m)          “ Plan ” shall mean the Physicians Realty Trust Incentive Bonus Plan, as amended from time to time.

 

(n)           “ Services ” shall mean services rendered to the Company or any of its Subsidiaries as an Executive.

 

(o)           “ Subsidiary ” shall mean any corporation, partnership, limited liability company or other entity as to which 50% of the outstanding voting stock, shares or equity interests shall now or hereafter be owned or controlled directly by a person, any Subsidiary of such person, or any Subsidiary of such Subsidiary.

 

(p)           “ Total and Permanent Disability ” means a Participant is qualified for long-term disability benefits under the Company’s or a Subsidiary’s disability plan or insurance policy; or, if no such plan or policy is then in existence or if the Participant is not eligible to participate in such plan or policy, that the Participant, because of a physical or mental condition resulting from bodily injury, disease, or mental disorder, is unable to perform his or her duties of employment for a period of six (6) continuous months, as determined in good faith by the Committee, based upon medical reports or other evidence satisfactory to the Committee.

 

SECTION 3
ADMINISTRATION OF THE PLAN

 

(a)           Powers of the Committee .  The Plan shall be administered by the Committee.  The Committee shall have the authority, in its sole discretion, to interpret the Plan and to make all determinations specified in or permitted by the Plan or deemed necessary or desirable for its administration or for the conduct of the Committee’s business, including, without limitation, the authority to take the following actions:

 

(i)            to establish Performance Goals for a Performance Period;

 

(ii)           to approve achievement of such Performance Goals;

 

(iii)          to construe, interpret and administer the Plan;

 

(iv)          to amend or terminate the Plan;

 

(v)           to select Executives to become Participants and to determine their Incentive Bonus potential;

 



 

(vi)          to adopt such rules and procedures for the Plan’s administration as the Committee may from time to time deem necessary; and

 

(vii)         to take any other actions deemed necessary or advisable for the interpretation and administration of the Plan.

 

Notwithstanding the foregoing, the Chief Executive Officer may establish individual/business unit Performance Goals for a Performance Period for an Executive (other than the Chief Executive Officer).  Notwithstanding any other provision of the Plan, the Board may elect, in its sole discretion, to determine the amount of any Incentive Bonus for a Performance Period and to approve or disapprove any proposed Performance Goal or Performance Period established by the Committee with respect to any Participant.  Absent any modification or disapproval by the Board, the Committee’s determination of any Incentive Bonus or establishment of any Performance Goal or Performance Period shall be final, conclusive and binding.

 

(b)           Requisite Action .  A majority (but not fewer than two) of the members of the Committee shall constitute a quorum.  The vote of a majority of those present at a meeting at which a quorum is present or the unanimous written consent of the Committee shall constitute action by the Committee.

 

SECTION 4
SELECTION OF PARTICIPANTS

 

(a)           Selection of Participants .  For each Performance Period, the Committee shall determine, at the time the Performance Goals are set, those Executives who will be Participants in the Plan.  No Executive shall have any right to participate in the Plan.  Any Executive selected by the Committee for participation during any one Performance Period will not by virtue of such participation have the right to be selected as a Participant for any other Performance Period.

 

(b)           Effect of Mid-Year Commencement of Services .  If Services as an Executive commence after the Performance Goals are established for a Performance Period, the Committee may select such Executive for participation during the remainder of the Performance Period and may grant an Incentive Bonus to such Executive that is proportionately adjusted based on the period of actual Services during such Performance Period.

 

SECTION 5
PERFORMANCE GOALS

 

(a)           Performance Goals .  The Committee shall establish the Performance Goals for each Performance Period; provided the Chief Executive Officer may establish individual/business unit Performance Goals for the Performance Period for an Executive (other than the Chief Executive Officer).  At the time the Performance Goals are selected, the Committee (or the Chief Executive Officer with respect to individual/business unit Performance Goals) shall provide, in terms of a formula or standard for each Participant, and for any Executive who may become a Participant after the Performance Goals are set, the method of computing the specific amount of Incentive Bonus payable to such Participant if the Performance Goal is attained, subject to Section 6(a) below.  Notwithstanding the preceding sentence, the Committee or the Board may at any time modify or waive any Performance Goal or the terms and conditions of payment of any Incentive Bonus as it may deem desirable in carrying out the purposes of the Plan or take into account such other factors as it deems appropriate in administering any aspect of the Plan.

 



 

(b)           Approval of Performance Goal Attainment .  As soon as practicable following the end of the Performance Period, but no later than March 15 of the calendar year next following the end of the Performance Period, the Committee shall approve the extent to which the Performance Goals were achieved in respect of such Performance Period.

 

SECTION 6
DETERMINATION AND PAYMENT OF INCENTIVE BONUS

 

(a)           Provision for Incentive Bonus .  A Participant may receive an Incentive Bonus for a Performance Period if and only if an applicable Performance Goal established by the Committee (or the Chief Executive Officer with respect to individual/business unit Performance Goals) is attained.

 

(b)           Determination of Incentive Bonus .  As soon as practicable following approval by the Committee of the extent of the achievement of each Performance Goal for the applicable Performance Period, the Committee shall compute the Participant’s Incentive Bonus for the Performance Period.

 

(c)           Termination of Employment During Performance Period . Unless otherwise determined by the Committee or if required by applicable law or pursuant to any written agreement between the Company or any of its Subsidiaries and the Participant:

 

(i)            no Incentive Bonus shall be payable to a Participant (and a Participant shall not be entitled to receive any Incentive Bonus) if the Participant is not employed by the Company or any Subsidiary of the Company on the last day of the Performance Period for which the Incentive Bonus is otherwise payable, unless the Executive’s employment with the Company and its Subsidiaries terminates during the Performance Period by reason of the Executive’s death or Total and Permanent Disability, and

 

(ii)           in the event of the Executive’s death or Total and Permanent Disability during the Performance Period, the Executive (or the Executive’s legal representative or beneficiary) shall receive an Incentive Bonus equal to the product of (A) the Incentive Bonus he or she would have received for the entire Performance Period, multiplied by (B) a fraction, the numerator of which is the number of days during the Performance Period that the Executive was an employee of the Company or any of its Subsidiaries, and the denominator of which is the number of days in the Performance Period.

 

Payment of such Incentive Bonus shall be made in accordance with Section 6(d) below.  In the event of any conflict between the terms of any written agreement between the Company or any of its Subsidiaries and the Participant and the Plan regarding the payment of the Incentive Bonus upon termination of employment with the Company or any of its Subsidiaries, the terms of the written agreement shall control.

 

(d)           Form and Time of Payment .  An Incentive Bonus shall be paid to the Participant in a lump sum cash payment by March 15 of the calendar year following the end of the Performance Period to which such Incentive Bonus relates.  The Committee may, in its discretion, make partial payment of the anticipated amount of any Incentive Bonus before determination of the final amount.

 

SECTION 7
MISCELLANEOUS

 

(a)           No Right to Incentive Bonus or Continued Employment .  Neither the establishment of the Plan nor selection as a Participant nor any action of the Company, any of its Subsidiaries, the Board or the Committee in respect of the Plan shall be held or construed to confer upon

 



 

any person any legal right to receive, or any interest in, an Incentive Bonus, or any legal right to be continued in the employ of the Company or any of its Subsidiaries or to remain an Executive, unless the Executive has a written agreement with the Company or any of its Subsidiaries that expressly provides otherwise.  The Company and its Subsidiaries expressly reserve any and all rights to discharge a Participant in its or their sole discretion, with or without notice, with or without cause and without liability of any person or entity under the Plan or otherwise, except to the extent otherwise expressly provided in any written agreement between the Company or any of its Subsidiaries and the Participant.

 

(b)           Discretion of the Company, Board and Committee .  Any decisions made or action taken by the Company, the Board, the Committee or the Chief Executive Officer in the exercise of its or their authority under the Plan shall be within the absolute discretion of such entity and shall be conclusive and binding for all purposes and upon all persons.

 

(c)           Absence of Liability . No member of the Board or the Committee, nor any officer or employee of the Company or any of its Subsidiaries acting on behalf of the Board or the Committee, shall be personally liable for any act of commission or omission except for his or her willful and intentional wrongdoing, and all members of the Board and the Committee and each and every officer or employee of the Company or any of its Subsidiaries acting on their behalf shall, to the extent permitted by law, be fully indemnified and protected by the Company in respect of any such act.

 

(d)           No Funding of Plan .  Incentive Bonuses shall be paid from the general assets of the Company and its Subsidiaries, and no fund or trust shall be deemed to have been established under the Plan.  Any rights of a Participant or former Participant under the Plan shall be limited to those of a general unsecured creditor.

 

(e)           Non-Transferability of Benefits and Interests .  Except as expressly provided in writing by the Committee, no benefit payable under the Plan shall be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance or charge, and any such attempted action shall be void and no such benefit shall be in any manner liable for or subject to debts, contracts, liabilities, engagements or torts of any Participant or former Participant.  The preceding sentence shall not apply to an assignment of a contingency or a payment due after the death of the Executive to the deceased Executive’s legal representative or beneficiary.  No Executive or other person shall have any claim or right to receive benefits under the Plan except as provided in the Plan.

 

(f)            Governing Law .  The Plan shall be governed by and construed in accordance with the laws of the State of Wisconsin, without regard to its conflicts of laws provisions.

 

(g)           Amendment, Suspension or Termination of Plan .  The Board or the Committee may from time to time amend, suspend or terminate the Plan, in whole or in part, and if suspended or terminated, the Board or the Committee may reinstate any or all of the provisions of the Plan.  No additional Incentive Bonuses may be payable after termination of the Plan.  Termination of the Plan shall not affect any Incentive Bonuses due and payable on the date of termination, and such Incentive Bonuses shall continue to be subject to the terms of the Plan notwithstanding its termination.

 

(h)           No Fiduciary Relationship . The officers and trustees of the Company and its Subsidiaries shall have no duty to manage or operate the Company and its Subsidiaries in order to maximize the benefits granted to Participants hereunder but rather shall have full discretionary power to make all management and operational decisions based on their determination of the respective best interests of the Company, its Subsidiaries and its and their shareholders.  The Plan shall not be construed to create any fiduciary relationship.

 



 

(i)            Headings .  The headings in the Plan are inserted for convenience of reference only and in no way define, describe or limit the scope or intent of the Plan or any of the provisions hereof.

 

(j)            Severability .  If any provision of the Plan or the application thereof to any person or circumstance is held to be illegal, invalid or unenforceable to any extent or for any reason, such provision shall be severed from the Plan and shall not invalidate the remaining provisions of the Plan, and the remaining provisions of the Plan and the application thereof shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance from the Plan.  A provision which is legal, valid and enforceable shall be substituted for the severed provision.

 

(k)           Taxes .  The Company and its Subsidiaries shall be entitled to deduct from amounts payable hereunder any sums required by federal, state or local tax law to be withheld with respect to such payments.

 

(l)            Construction .  Except where the context requires otherwise, words in the singular shall include the plural and vice versa, and the masculine gender shall include the feminine and neuter genders and vice versa.  The failure to capitalize or the erroneous capitalization of any word or term shall not affect the definition of such word or term.

 

(m)          Successors .  The Plan is binding on and will inure to the benefit of any successor to the Company, whether by way of merger, consolidation, purchase or otherwise.

 

(n)           Clawback.   Any Incentive Bonus paid to the Executive shall be subject to recovery by the Company, and the Executive shall be required to repay such Incentive Bonus, if (i) such recovery and repayment is required by applicable law or (ii) either in the year such compensation is paid, or within the three (3) year period thereafter the Company is required to prepare an accounting restatement due to material noncompliance of the Company with any financial reporting requirement under applicable securities laws and the Executive is either (A) a named executive officer or (B) an employee who is responsible for preparation of the Company’s financial statements.  The repayment obligations set forth in this Section 7(n) shall only apply to the extent repayment is required by applicable law, or to the extent the Executive’s compensation is determined to be in excess of the amount that would have been deliverable to the Executive taking into account any restatement or correction of any inaccurate financial statements or materially inaccurate performance metric criteria.

 

(o)           Code Section 409A .  This Plan and the Incentive Bonuses to be provided under this Plan are intended to be exempt from with the requirements of Section 409A of the Code, and shall be interpreted and construed consistently with such intent, provided, that if the Plan or an Incentive Bonus is not exempt, the Plan is drafted in a manner to comply with the requirements of Section 409A of the Code.  The payments to the Executive pursuant to this Plan are also intended to be exempt from Section 409A of the Code to the maximum extent possible as short-term deferrals pursuant to Treasury Regulation Section 1.409A-1(b)(4).  Notwithstanding any other provision in this Agreement, if the Executive is a “Specified Employee” (as defined in Treasury Regulation Section 1.409A-1(i) on December 31st of the prior calendar year), as of the date of the Executive’s “separation from service” (as defined in Treasury Regulation Section 1.409A-1(h)), then to the extent any amount payable under this Agreement (i) constitutes the payment of nonqualified deferred compensation, within the meaning of Section 409A of the Code, (ii) is payable upon the Executive’s separation from service and (iii) under the terms of this Agreement would be payable prior to the six-month anniversary of the Executive’s separation from service, such payment shall be delayed and paid to the Executive, together with interest at an annual rate equal to the interest rate specified by Regions Bank for a six-month certificate of deposit, on the first day of the first calendar month beginning seven months following the date of separation from service, or, if

 



 

earlier, within ninety (90) days following the Executive’s death to the Executive’s surviving spouse (or such other beneficiary as the Executive may designate in writing).

 


Exhibit 10.6

 

FIRST AMENDMENT OF

PHYSICIANS REALTY TRUST 2013 EQUITY INCENTIVE PLAN

 

Physicians Realty Trust, a Maryland real estate investment trust (the “Company”), has previously established the Physicians Realty Trust 2013 Equity Incentive Plan (the “2013 Equity Plan”).  The 2013 Equity Plan provides that the Board of Trustees (the “Board”) of the Company may at any time amend the 2013 Equity Plan, provided that no amendment for which shareholder approval is required shall be effective unless such amendment shall be approved by the requisite vote of the shareholders of the Company.  The Board has previously delegated its power to amend the 2013 Equity Plan to the Compensation Committee (the “Committee”) of the Board.  The Committee has determined that it is advisable to amend the 2013 Equity Plan and that such amendment does not require shareholder approval.

 

Therefore, effective July 22, 2013, the 2013 Equity Plan is amended as follows:

 

1.               By substituting the following sentence for the third sentence of Section 6.6(a) of the 2013 Equity Plan:

 

“If the Performance Award is to be in Common Shares, the Performance Award may provide for the issuance of the Common Shares at the time of the grant of the Performance Award or at the time of the certification by the Committee that the Performance Goals for the performance period have been met.”

 

2.               By substituting for the reference to the “Board” in the first sentence of Article 9 of the 2013 Equity Plan a reference to the “Committee.”

 

3.               By deleting and not replacing Article 16 thereof.

 

In all other respects, the 2013 Equity Plan remains unchanged.

 

The foregoing amendment was approved and adopted by the Compensation Committee of the Board of Trustees of the Company on May 6, 2014.

 

 

PHYSICIANS REALTY TRUST

 

 

 

By:

/s/ John T. Thomas

 

 

 

 

Name:

John T. Thomas

 

 

 

 

Title:

Chief Executive Officer

 


Exhibit 10.7

 

RESTRICTED SHARE AWARD AGREEMENT

 

PHYSICIANS REALTY TRUST

2013 EQUITY INCENTIVE PLAN

 

1.             Grant of Award .  Pursuant to the Physicians Realty Trust 2013 Equity Incentive Plan (the “Plan”) for Employees, Consultants, and Outside Trustees of Physicians Realty Trust, a Maryland real estate investment trust (the “Company”), the Company grants to

 

(the “Participant”)

 

an Award of Restricted Shares in accordance with Section 6.3 of the Plan.  The number of Common Shares awarded under this Restricted Share Award Agreement (the “Agreement”) is                                            (                    ) shares (the “Awarded Shares”).  The “Date of Grant” of this Award is March 3, 2014.

 

2.             Subject to Plan .  This Agreement is subject to the terms and conditions of the Plan, and the terms of the Plan shall control.  The capitalized terms used herein that are defined in the Plan shall have the same meanings assigned to them in the Plan.  This Agreement is subject to any rules promulgated pursuant to the Plan by the Board or the Committee and communicated to the Participant in writing.

 

3.             Vesting .  Except as specifically provided in this Agreement and subject to certain restrictions and conditions set forth in the Plan, the Awarded Shares shall vest on the first anniversary of the Date of Grant, provided that the Participant is employed by (or if the Participant is a Consultant or an Outside Trustee, is providing services to) the Company or a Subsidiary on that date.

 

All Awarded Shares not previously vested shall immediately become fully vested upon (i) the Participant’s death; (ii) the Participant’s Termination of Service as a result of his Total and Permanent Disability; or (iii) the occurrence of a Change in Control.

 

4.             Forfeiture of Awarded Shares .  Awarded Shares that are not vested in accordance with Section 3 shall be forfeited on the date of the Participant’s Termination of Service.  Upon forfeiture, all of the Participant’s rights with respect to the forfeited Awarded Shares shall cease and terminate, without any further obligations on the part of the Company.

 

5.             Restrictions on Awarded Shares .  Subject to the provisions of the Plan and the terms of this Agreement, from the Date of Grant until the date the Awarded Shares are vested in accordance with Section 3 and are no longer subject to forfeiture in accordance with Section 4 (the “Restriction Period”), the Participant shall not be permitted to sell, transfer, pledge, hypothecate, margin, assign or otherwise encumber any of the Awarded Shares.  Except for these limitations, the Committee may, in its sole discretion, remove any or all of the restrictions on such Awarded Shares whenever it may determine that, by reason of changes in applicable laws or changes in circumstances after the date of this Agreement, such action is appropriate.

 

6.             Legend .  Awarded Shares electronically registered in a Participant’s name shall note that such shares are Restricted Shares.  If certificates for Awarded Shares are issued, the following legend shall be placed on all such certificates:

 



 

On the face of the certificate:

 

“Transfer of these Common Shares is restricted in accordance with conditions printed on the reverse of this certificate.”

 

On the reverse:

 

“The Common Shares are subject to and transferable only in accordance with that certain Physicians Realty Trust 2013 Equity Incentive Plan, a copy of which is on file at the principal office of the Company in Milwaukee, Wisconsin.  No transfer or pledge of the shares evidenced hereby may be made except in accordance with and subject to the provisions of said Plan and Award Agreement.  By acceptance of these Common Shares, any holder, transferee or pledgee hereof agrees to be bound by all of the provisions of said Plan and Award Agreement.”

 

The following legend shall be inserted on a certificate, if issued, evidencing Common Shares issued under the Plan if the shares were not issued in a transaction registered under the applicable federal and state securities laws:

 

“Common Shares represented by this certificate have been acquired by the holder for investment and not for resale, transfer or distribution, have been issued pursuant to exemptions from the registration requirements of applicable state and federal securities laws, and may not be offered for sale, sold or transferred other than pursuant to effective registration under such laws, or in transactions otherwise in compliance with such laws, and upon evidence satisfactory to the Company of compliance with such laws, as to which the Company may rely upon an opinion of counsel satisfactory to the Company.”

 

All Awarded Shares owned by the Participant shall be subject to the terms of this Agreement and shall be represented by a certificate or certificates bearing the foregoing legend, as applicable.

 

7.             Delivery of Certificates; Registration of Shares .  The Company shall deliver certificates for the Awarded Shares to the Participant (if requested by the Participant in accordance with Section 6.3(a) of the Plan and the Company has elected, in its sole discretion, to issue certificates (as opposed to electronic book entry form with respect to its Common Shares)) or shall register the Awarded Shares in the Participant’s name, free of restriction under this Agreement, promptly after, and only after, the Restriction Period has expired without forfeiture pursuant to Section 4.

 

8.             Rights of a Shareholder .  Except as provided in Section 4 and Section 5 above, the Participant shall have, with respect to his Awarded Shares, all of the rights of a shareholder of the Company, including the right to vote the shares, and the right to receive any dividends thereon.  Any share dividends paid with respect to Awarded Shares shall at all times be treated as Awarded Shares and shall be subject to all restrictions placed on Awarded Shares; any such share dividends paid with respect to Awarded Shares shall vest as the Awarded Shares become vested.

 

9.             Voting .  The Participant, as record holder of the Awarded Shares, has the exclusive right

 

2



 

to vote, or consent with respect to, such Awarded Shares until such time as the Awarded Shares are transferred in accordance with this Agreement or are forfeited pursuant to Section 4; provided, however, that this Section 9 shall not create any voting right where the holders of such Awarded Shares otherwise have no such right.

 

10.          Adjustment to Number of Awarded Shares .  The number of Awarded Shares shall be subject to adjustment in accordance with Articles 11-13 of the Plan.

 

11.          Specific Performance .  The parties acknowledge that remedies at law will be inadequate remedies for breach of this Agreement and consequently agree that this Agreement shall be enforceable by specific performance.  The remedy of specific performance shall be cumulative of all of the rights and remedies at law or in equity of the parties under this Agreement.

 

12.          Participant’s Representations .  Notwithstanding any of the provisions hereof, the Participant hereby agrees that he or she will not acquire any Awarded Shares, and that the Company will not be obligated to issue any Awarded Shares to the Participant hereunder, if the issuance or holding of such shares shall constitute a violation by the Participant or the Company of any provision of any law or regulation of any governmental authority.  In such case, any determination by the Company shall be final, binding, and conclusive.  The rights and obligations of the Company and the rights and obligations of the Participant are subject to all Applicable Laws, rules, and regulations.

 

13.          Investment Representation .  Unless the Awarded Shares are issued in a transaction registered under applicable federal and state securities laws, by his or her execution hereof, the Participant represents and warrants to the Company that all Common Shares which may be purchased and or received hereunder will be acquired by the Participant for investment purposes for his or her own account and not with any intent for resale or distribution in violation of federal or state securities laws.  Unless the Common Shares are issued to him or her in a transaction registered under the applicable federal and state securities laws, all certificates issued with respect to the Common Shares shall bear an appropriate restrictive investment legend and shall be held indefinitely, unless they are subsequently registered under the applicable federal and state securities laws or the Participant obtains an opinion of counsel, in form and substance satisfactory to the Company and its counsel, that such registration is not required.

 

14.          Participant’s Acknowledgments .  The Participant acknowledges that a copy of the Plan has been made available for his review by the Company, and represents that he is familiar with the terms and provisions thereof, and hereby accepts this Award subject to all the terms and provisions thereof.  The Participant hereby agrees to accept as binding, conclusive, and final all decisions or interpretations of the Committee or the Board, as appropriate, upon any questions arising under the Plan or this Agreement.  The Participant acknowledges and agrees that (i) sales of Common Shares will be subject to the Company’s policies regulating trading by Employees, Consultants and Outside Trustees, including any applicable “blackout” or other designated periods in which sales of Common Shares are not permitted, and (ii) Common Shares received hereunder will be subject to any recoupment or “clawback” policy applied with prospective or retroactive effect.

 

15.          Law Governing .  This Agreement shall be governed by, construed, and enforced in accordance with the laws of the State of Maryland (excluding any conflict of laws rule or principle of Maryland law that might refer the governance, construction, or interpretation of this agreement to the laws of another state).

 

16.          No Right to Continue Service or Employment .  Nothing herein shall be construed to confer upon the Participant the right to continue in the employ or to provide services to the Company or any Subsidiary, whether as an Employee or as a Consultant or as an Outside Trustee, or interfere with or

 

3



 

restrict in any way the right of the Company or any Subsidiary to discharge the Participant as an Employee, Consultant, or Outside Trustee at any time.

 

17.          Legal Construction .  In the event that any one or more of the terms, provisions, or agreements that are contained in this Agreement shall be held by a court of competent jurisdiction to be invalid, illegal, or unenforceable in any respect for any reason, the invalid, illegal, or unenforceable term, provision, or agreement shall not affect any other term, provision, or agreement that is contained in this Agreement and this Agreement shall be construed in all respects as if the invalid, illegal, or unenforceable term, provision, or agreement had never been contained herein.

 

18.          Covenants and Agreements as Independent Agreements .  Each covenant and agreement that is set forth in this Agreement shall be construed as a covenant and agreement independent of any other provision of this Agreement.  The existence of any claim or cause of action of the Participant against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by the Company of the covenants and agreements that are set forth in this Agreement.

 

19.          Entire Agreement .  This Agreement together with the Plan supersede any and all other prior understandings and agreements, either oral or in writing, between the parties with respect to the subject matter hereof and constitute the sole and only agreements between the parties with respect to the said subject matter.  All prior negotiations and agreements between the parties with respect to the subject matter hereof are merged into this Agreement.  Each party to this Agreement acknowledges that no representations, inducements, promises, or agreements, orally or otherwise, have been made by any party or by anyone acting on behalf of any party, which are not embodied in this Agreement or the Plan and that any agreement, statement or promise that is not contained in this Agreement or the Plan shall not be valid or binding or of any force or effect.

 

20.          Parties Bound .  The terms, provisions, and agreements that are contained in this Agreement shall apply to, be binding upon, and inure to the benefit of the parties and their respective heirs, executors, administrators, legal representatives, and permitted successors and assigns, subject to the limitation on assignment expressly set forth herein.  No person shall be permitted to acquire any Awarded Shares without first executing and delivering an agreement in the form satisfactory to the Company making such person or entity subject to the restrictions on transfer contained herein.

 

21.          Modification .  No change or modification of this Agreement shall be valid or binding upon the parties unless the change or modification is in writing and signed by the parties.  Notwithstanding the preceding sentence, the Company may amend the Plan or this Agreement to the extent permitted by the Plan.

 

22.          Headings .  The headings that are used in this Agreement are used for reference and convenience purposes only and do not constitute substantive matters to be considered in construing the terms and provisions of this Agreement.

 

23.          Gender and Number .  Words of any gender used in this Agreement shall be held and construed to include any other gender, and words in the singular number shall be held to include the plural, and vice versa, unless the context requires otherwise.

 

24.          Notice .  Any notice required or permitted to be delivered hereunder shall be deemed to be delivered only when actually received by the Company or by the Participant, as the case may be, at the addresses set forth below, or at such other addresses as they have theretofore specified by written notice delivered in accordance herewith:

 

4



 

a.                                       Notice to the Company shall be addressed and delivered as follows:

 

Physicians Realty Trust

735 North Water Street, Suite 1000

Milwaukee, Wisconsin  53202

Attn: Corporate Secretary

Fax: (414) 978-6550

 

Notice to the Participant shall be addressed and delivered as set forth on the signature page.

 

25.          Tax Requirements The Participant is hereby advised to consult immediately with his or her own tax advisor regarding the tax consequences of this Agreement, the method and timing for filing an election to include this Agreement in income under Section 83(b) of the Code, and the tax consequences of such election.  By execution of this Agreement, the Participant agrees that if the Participant makes such an election, the Participant shall provide the Company with written notice of such election in accordance with the regulations promulgated under Section 83(b) of the Code.  The Company or, if applicable, any Subsidiary (for purposes of this Section 25, the term Company” shall be deemed to include any applicable Subsidiary), shall have the right to deduct from all amounts paid in cash or other form in connection with the Plan, any Federal, state, local, or other taxes required by law to be withheld in connection with this Award.  The Company may, in its sole discretion, also require the Participant receiving Common Shares issued under the Plan to pay the Company the amount of any taxes that the Company is required to withhold in connection with the Participant’s income arising with respect to this Award.  Such payments shall be required to be made when requested by the Company and may be required to be made prior to the delivery of any certificate representing Common Shares, if such certificate is requested by the Participant in accordance with Section 6.3(a) of the Plan.  Such payment may be made (i) by the delivery of cash to the Company in an amount that equals or exceeds (to avoid the issuance of fractional shares under (iii) below) the required tax withholding obligations of the Company; (ii) if the Company, in its sole discretion, so consents in writing, the actual delivery by the Participant to the Company of Common Shares, other than (A) Restricted Shares, or (B) Common Shares that the Participant has acquired from the Company within six (6) months  prior thereto, which shares so delivered have an aggregate Fair Market Value that equals or exceeds (to avoid the issuance of fractional shares under (iii) below) the required tax withholding payment; (iii) if the Company, in its sole discretion, so consents in writing, the Company’s withholding of a number of shares to be delivered upon the vesting of this Award, which shares so withheld have an aggregate Fair Market Value that equals (but does not exceed) the required tax withholding payment; or (iv) any combination of (i), (ii), or (iii).  The Company may, in its sole discretion, withhold any such taxes from any other cash remuneration otherwise paid by the Company to the Participant.

 

26.          REIT Status .  This Agreement shall be interpreted and construed in a manner consistent with the Company’s status as a real estate investment trust.

 

5



 

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer, and the Participant, to evidence his or her consent and approval of all the terms hereof, has duly executed this Agreement, as of the date specified in Section 1 hereof.

 

 

 

 

COMPANY:

 

 

 

 

 

PHYSICIANS REALTY TRUST

 

 

 

 

 

 

 

By:

 

 

Name:

 

 

Title:

 

 

 

 

 

 

 

 

 

PARTICIPANT:

 

 

 

 

 

 

 

 

 

 

Signature

 

 

 

 

 

 

 

Name:

 

 

Address:

 

 

 

 

 

6


Exhibit 10.8

 

RESTRICTED SHARE AWARD AGREEMENT

 

PHYSICIANS REALTY TRUST

2013 EQUITY INCENTIVE PLAN

 

1.             Grant of Award .  Pursuant to the Physicians Realty Trust 2013 Equity Incentive Plan (the “Plan”) for Employees, Consultants, and Outside Trustees of Physicians Realty Trust, a Maryland real estate investment trust (the “Company”), the Company grants to

 

(the “Participant”)

 

an Award of Restricted Shares in accordance with Section 6.3 of the Plan.  The number of Common Shares awarded under this Restricted Share Award Agreement (the “Agreement”) is                                            (                    ) shares (the “Awarded Shares”).  The “Date of Grant” of this Award is March 3, 2014.

 

2.             Subject to Plan .  This Agreement is subject to the terms and conditions of the Plan, and the terms of the Plan shall control.  The capitalized terms used herein that are defined in the Plan shall have the same meanings assigned to them in the Plan.  This Agreement is subject to any rules promulgated pursuant to the Plan by the Board or the Committee and communicated to the Participant in writing.

 

3.             Vesting .  Except as specifically provided in this Agreement and subject to certain restrictions and conditions set forth in the Plan, the Awarded Shares shall vest on the first anniversary of the Date of Grant, provided that the Participant is providing services to the Company or a Subsidiary on that date.

 

All Awarded Shares not previously vested shall immediately become fully vested upon (i) the Participant’s death; (ii) the Participant’s Termination of Service due to Disability (as defined below); or (iii) the occurrence of a Change in Control.  “Disability” means that a Participant, because of a physical or mental condition resulting from bodily injury, disease, or mental disorder, is unable to perform his or her duties as an Outside Trustee for a period of six (6) continuous months, as determined in good faith by the Board or the Committee, based upon medical reports or other evidence satisfactory to the Board or the Committee.

 

4.             Forfeiture of Awarded Shares .  Awarded Shares that are not vested in accordance with Section 3 shall be forfeited on the date of the Participant’s Termination of Service.  Upon forfeiture, all of the Participant’s rights with respect to the forfeited Awarded Shares shall cease and terminate, without any further obligations on the part of the Company.

 

5.             Restrictions on Awarded Shares .  Subject to the provisions of the Plan and the terms of this Agreement, from the Date of Grant until the date the Awarded Shares are vested in accordance with Section 3 and are no longer subject to forfeiture in accordance with Section 4 (the “Restriction Period”), the Participant shall not be permitted to sell, transfer, pledge, hypothecate, margin, assign or otherwise encumber any of the Awarded Shares.  Except for these limitations, the Committee or the Board may, in its sole discretion, remove any or all of the restrictions on such Awarded Shares whenever it may determine that, by reason of changes in applicable laws or changes in circumstances after the date of this Agreement, such action is appropriate.

 



 

6.             Legend .  Awarded Shares electronically registered in a Participant’s name shall note that such shares are Restricted Shares.  If certificates for Awarded Shares are issued, the following legend shall be placed on all such certificates:

 

On the face of the certificate:

 

“Transfer of these Common Shares is restricted in accordance with conditions printed on the reverse of this certificate.”

 

On the reverse:

 

“The Common Shares are subject to and transferable only in accordance with that certain Physicians Realty Trust 2013 Equity Incentive Plan, a copy of which is on file at the principal office of the Company in Milwaukee, Wisconsin.  No transfer or pledge of the shares evidenced hereby may be made except in accordance with and subject to the provisions of said Plan and Award Agreement.  By acceptance of these Common Shares, any holder, transferee or pledgee hereof agrees to be bound by all of the provisions of said Plan and Award Agreement.”

 

The following legend shall be inserted on a certificate, if issued, evidencing Common Shares issued under the Plan if the shares were not issued in a transaction registered under the applicable federal and state securities laws:

 

“Common Shares represented by this certificate have been acquired by the holder for investment and not for resale, transfer or distribution, have been issued pursuant to exemptions from the registration requirements of applicable state and federal securities laws, and may not be offered for sale, sold or transferred other than pursuant to effective registration under such laws, or in transactions otherwise in compliance with such laws, and upon evidence satisfactory to the Company of compliance with such laws, as to which the Company may rely upon an opinion of counsel satisfactory to the Company.”

 

All Awarded Shares owned by the Participant shall be subject to the terms of this Agreement and shall be represented by a certificate or certificates bearing the foregoing legend, as applicable.

 

7.             Delivery of Certificates; Registration of Shares .  The Company shall deliver certificates for the Awarded Shares to the Participant (if requested by the Participant in accordance with Section 6.3(a) of the Plan and the Company has elected, in its sole discretion, to issue certificates (as opposed to electronic book entry form with respect to its Common Shares)) or shall register the Awarded Shares in the Participant’s name, free of restriction under this Agreement, promptly after, and only after, the Restriction Period has expired without forfeiture pursuant to Section 4.

 

8.             Rights of a Shareholder .  Except as provided in Section 4 and Section 5 above, the Participant shall have, with respect to his Awarded Shares, all of the rights of a shareholder of the Company, including the right to vote the shares, and the right to receive any dividends thereon.  Any share dividends paid with respect to Awarded Shares shall at all times be treated as Awarded Shares and

 

2



 

shall be subject to all restrictions placed on Awarded Shares; any such share dividends paid with respect to Awarded Shares shall vest as the Awarded Shares become vested.

 

9.             Voting .  The Participant, as record holder of the Awarded Shares, has the exclusive right to vote, or consent with respect to, such Awarded Shares until such time as the Awarded Shares are transferred in accordance with this Agreement or are forfeited pursuant to Section 4; provided, however, that this Section 9 shall not create any voting right where the holders of such Awarded Shares otherwise have no such right.

 

10.          Adjustment to Number of Awarded Shares .  The number of Awarded Shares shall be subject to adjustment in accordance with Articles 11-13 of the Plan.

 

11.          Specific Performance .  The parties acknowledge that remedies at law will be inadequate remedies for breach of this Agreement and consequently agree that this Agreement shall be enforceable by specific performance.  The remedy of specific performance shall be cumulative of all of the rights and remedies at law or in equity of the parties under this Agreement.

 

12.          Participant’s Representations .  Notwithstanding any of the provisions hereof, the Participant hereby agrees that he or she will not acquire any Awarded Shares, and that the Company will not be obligated to issue any Awarded Shares to the Participant hereunder, if the issuance or holding of such shares shall constitute a violation by the Participant or the Company of any provision of any law or regulation of any governmental authority.  In such case, any determination by the Company shall be final, binding, and conclusive.  The rights and obligations of the Company and the rights and obligations of the Participant are subject to all Applicable Laws, rules, and regulations.

 

13.          Investment Representation .  Unless the Awarded Shares are issued in a transaction registered under applicable federal and state securities laws, by his or her execution hereof, the Participant represents and warrants to the Company that all Common Shares which may be purchased and or received hereunder will be acquired by the Participant for investment purposes for his or her own account and not with any intent for resale or distribution in violation of federal or state securities laws.  Unless the Common Shares are issued to him or her in a transaction registered under the applicable federal and state securities laws, all certificates issued with respect to the Common Shares shall bear an appropriate restrictive investment legend and shall be held indefinitely, unless they are subsequently registered under the applicable federal and state securities laws or the Participant obtains an opinion of counsel, in form and substance satisfactory to the Company and its counsel, that such registration is not required.

 

14.          Participant’s Acknowledgments .  The Participant acknowledges that a copy of the Plan has been made available for his review by the Company, and represents that he is familiar with the terms and provisions thereof, and hereby accepts this Award subject to all the terms and provisions thereof.  The Participant hereby agrees to accept as binding, conclusive, and final all decisions or interpretations of the Committee or the Board, as appropriate, upon any questions arising under the Plan or this Agreement.  The Participant acknowledges and agrees that (i) sales of Common Shares will be subject to the Company’s policies regulating trading by Outside Trustees, including any applicable “blackout” or other designated periods in which sales of Common Shares are not permitted, and (ii) Common Shares received hereunder will be subject to any recoupment or “clawback” policy applied with prospective or retroactive effect.

 

15.          Law Governing .  This Agreement shall be governed by, construed, and enforced in accordance with the laws of the State of Maryland (excluding any conflict of laws rule or principle of Maryland law that might refer the governance, construction, or interpretation of this agreement to the laws of another state).

 

3



 

16.          No Right to Continue Service .  Nothing herein shall be construed to confer upon the Participant the right to continue to provide services to the Company or any Subsidiary as an Outside Trustee, or interfere with or restrict in any way the right of the Company to remove the Participant as an Outside Trustee at any time.

 

17.          Legal Construction .  In the event that any one or more of the terms, provisions, or agreements that are contained in this Agreement shall be held by a court of competent jurisdiction to be invalid, illegal, or unenforceable in any respect for any reason, the invalid, illegal, or unenforceable term, provision, or agreement shall not affect any other term, provision, or agreement that is contained in this Agreement and this Agreement shall be construed in all respects as if the invalid, illegal, or unenforceable term, provision, or agreement had never been contained herein.

 

18.          Covenants and Agreements as Independent Agreements .  Each covenant and agreement that is set forth in this Agreement shall be construed as a covenant and agreement independent of any other provision of this Agreement.  The existence of any claim or cause of action of the Participant against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by the Company of the covenants and agreements that are set forth in this Agreement.

 

19.          Entire Agreement .  This Agreement together with the Plan supersede any and all other prior understandings and agreements, either oral or in writing, between the parties with respect to the subject matter hereof and constitute the sole and only agreements between the parties with respect to the said subject matter.  All prior negotiations and agreements between the parties with respect to the subject matter hereof are merged into this Agreement.  Each party to this Agreement acknowledges that no representations, inducements, promises, or agreements, orally or otherwise, have been made by any party or by anyone acting on behalf of any party, which are not embodied in this Agreement or the Plan and that any agreement, statement or promise that is not contained in this Agreement or the Plan shall not be valid or binding or of any force or effect.

 

20.          Parties Bound .  The terms, provisions, and agreements that are contained in this Agreement shall apply to, be binding upon, and inure to the benefit of the parties and their respective heirs, executors, administrators, legal representatives, and permitted successors and assigns, subject to the limitation on assignment expressly set forth herein.  No person shall be permitted to acquire any Awarded Shares without first executing and delivering an agreement in the form satisfactory to the Company making such person or entity subject to the restrictions on transfer contained herein.

 

21.          Modification .  No change or modification of this Agreement shall be valid or binding upon the parties unless the change or modification is in writing and signed by the parties.  Notwithstanding the preceding sentence, the Company may amend the Plan or this Agreement to the extent permitted by the Plan.

 

22.          Headings .  The headings that are used in this Agreement are used for reference and convenience purposes only and do not constitute substantive matters to be considered in construing the terms and provisions of this Agreement.

 

23.          Gender and Number .  Words of any gender used in this Agreement shall be held and construed to include any other gender, and words in the singular number shall be held to include the plural, and vice versa, unless the context requires otherwise.

 

24.          Notice .  Any notice required or permitted to be delivered hereunder shall be deemed to be delivered only when actually received by the Company or by the Participant, as the case may be, at the addresses set forth below, or at such other addresses as they have theretofore specified by written notice

 

4



 

delivered in accordance herewith:

 

a.                                       Notice to the Company shall be addressed and delivered as follows:

 

Physicians Realty Trust

735 North Water Street, Suite 1000

Milwaukee, Wisconsin  53202

Attn: Corporate Secretary

Fax: (414) 978-6550

 

b.                                       Notice to the Participant shall be addressed and delivered as set forth on the signature page.

 

25.          Tax Requirements The Participant is hereby advised to consult immediately with his or her own tax advisor regarding the tax consequences of this Agreement, the method and timing for filing an election to include this Agreement in income under Section 83(b) of the Code, and the tax consequences of such election.  By execution of this Agreement, the Participant agrees that if the Participant makes such an election, the Participant shall provide the Company with written notice of such election in accordance with the regulations promulgated under Section 83(b) of the Code.  The Company or, if applicable, any Subsidiary (for purposes of this Section 25, the term “Company” shall be deemed to include any applicable Subsidiary), shall have the right to deduct from all amounts paid in cash or other form in connection with the Plan, any Federal, state, local, or other taxes required by law to be withheld in connection with this Award.  The Company may, in its sole discretion, also require the Participant receiving Common Shares issued under the Plan to pay the Company the amount of any taxes that the Company is required to withhold in connection with the Participant’s income arising with respect to this Award.  Such payments shall be required to be made when requested by the Company and may be required to be made prior to the delivery of any certificate representing Common Shares, if such certificate is requested by the Participant in accordance with Section 6.3(a) of the Plan.  Such payment may be made (i) by the delivery of cash to the Company in an amount that equals or exceeds (to avoid the issuance of fractional shares under (iii) below) the required tax withholding obligations of the Company; (ii) if the Company, in its sole discretion, so consents in writing, the actual delivery by the Participant to the Company of Common Shares, other than (A) Restricted Shares, or (B) Common Shares that the Participant has acquired from the Company within six (6) months  prior thereto, which shares so delivered have an aggregate Fair Market Value that equals or exceeds (to avoid the issuance of fractional shares under (iii) below) the required tax withholding payment; (iii) if the Company, in its sole discretion, so consents in writing, the Company’s withholding of a number of shares to be delivered upon the vesting of this Award, which shares so withheld have an aggregate Fair Market Value that equals (but does not exceed) the required tax withholding payment; or (iv) any combination of (i), (ii), or (iii).  The Company may, in its sole discretion, withhold any such taxes from any other cash remuneration otherwise paid by the Company to the Participant.

 

26.          REIT Status .  This Agreement shall be interpreted and construed in a manner consistent with the Company’s status as a real estate investment trust.

 

5



 

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer, and the Participant, to evidence his or her consent and approval of all the terms hereof, has duly executed this Agreement, as of the date specified in Section 1 hereof.

 

 

 

 

COMPANY:

 

 

 

 

 

PHYSICIANS REALTY TRUST

 

 

 

 

 

 

 

By:

 

 

Name:

 

 

Title:

 

 

 

 

 

 

 

 

 

PARTICIPANT:

 

 

 

 

 

 

 

 

 

 

Signature

 

 

 

 

 

 

 

Name:

 

 

Address:

 

 

 

 

 

6


Exhibit 10.9

 

RESTRICTED SHARE UNIT AWARD AGREEMENT

 

PHYSICIANS REALTY TRUST

2013 EQUITY INCENTIVE PLAN

 

1.             Grant of Award .  Pursuant to the Physicians Realty Trust 2013 Equity Incentive Plan (the “Plan”) for Employees, Consultants, and Outside Trustees of Physicians Realty Trust, a Maryland real estate investment trust (the “Company”), the Company grants to

 

(the “Participant”)

 

an Award of Restricted Share Units in accordance with Section 6.5 of the Plan.  The number of Restricted Share Units awarded under this Restricted Share Unit Award Agreement (the “Agreement”) is                                            (                    ) units (the “Awarded Units”).  Each Restricted Share Unit represents the right to receive one Common Share if the Restricted Share Unit becomes vested and nonforfeitable in accordance with Sections 3 and 4 of this Agreement.  The “Date of Grant” of this Award is March 3, 2014.  The Participant shall have no rights as a shareholder of the Company, no dividend rights and no voting rights with respect to the Restricted Share Units or the Common Shares underlying the Restricted Share Units unless and until the Restricted Share Units become vested and nonforfeitable and such Common Shares are delivered to the Participant in accordance with Section 6 of this Agreement.  The Participant is not required to pay any cash consideration for the grant of the Restricted Share Units.

 

2.             Subject to Plan .  This Agreement is subject to the terms and conditions of the Plan, and the terms of the Plan shall control.  The capitalized terms used herein that are defined in the Plan shall have the same meanings assigned to them in the Plan.  This Agreement is subject to any rules promulgated pursuant to the Plan by the Board or the Committee and communicated to the Participant in writing.

 

3.             Vesting .  Except as specifically provided in this Agreement and subject to certain restrictions and conditions set forth in the Plan, the Participant’s rights and interest in the Awarded Units shall vest as follows:

 

a.             The extent to which the Participant’s rights and interest in one-half (1/2) of the Awarded Units becomes vested and non-forfeitable and ceases to be restricted shall be based upon the satisfaction of the performance goal specified in this Section 3(a) (the “TSR Performance Goal”).  The TSR Performance Goal shall be based upon a comparison of the total shareholder return (“TSR”) of the Company to the TSRs of the companies (other than the Company) that comprise the NAREIT Healthcare Index during the 3-year period commencing on January 1, 2014 and ending on December 31, 2016 (the “Performance Period”), provided that only those companies that comprise the NAREIT Healthcare Index for the entire Performance Period shall be considered.  “TSR” means the percentage rate of return, which can be positive or negative, from the first day of the Performance Period to the last day of the Performance Period, of an investment of $100 in the Common Shares of the Company, or the common shares of beneficial interest issued by the relevant company in the NAREIT Healthcare Index, on the first day of the Performance Period, assuming reinvestment of all dividends paid during the Performance Period.  The portion of the Participant’s rights and interest in the one-half of the Awarded Units subject to this Section 3(a), if any, that becomes vested and nonforfeitable and

 



 

ceases to be restricted in the Performance Period shall be determined in accordance with the following schedule, using linear interpolation, as certified by the Committee:

 

Company TSR Relative to the TSR of the
Companies in the NAREIT Healthcare
Index

 

Percentage of One-Half of Awarded
Units Vested

 

Below 33rd percentile

 

0

 

33rd percentile

 

50

%

50th percentile

 

100

%

75th percentile or above

 

300

%

 

Notwithstanding the preceding schedule, if the Company TSR is a negative number, then the percentage of one-half of the Awarded Units determined in accordance with the preceding schedule shall be reduced to 80% of such percentage.

 

For the Performance Period, the applicable portion of the Participant’s interest in the Awarded Units subject to this Section 3(a) shall become vested and nonforfeitable and shall cease being restricted upon written certification by the Committee that the corresponding TSR Performance Goal for the Performance Period has been satisfied; provided, the Participant is employed by (or if the Participant is a Consultant or an Outside Trustee, is providing services to) the Company or a Subsidiary on the date of the Committee’s certification.  The Committee shall make this determination within ninety (90) days after the last day of the Performance Period.  Any determination as to whether or not and to what extent the TSR Performance Goal has been satisfied shall be made by the Committee in its sole and absolute discretion and shall be final, binding and conclusive on all persons, including, but not limited to, the Company and the Participant.  The Participant shall not be entitled to any claim or recourse if any action or inaction by the Company, or any other circumstance or event, including any circumstance or event outside the control of the Participant, adversely affects the ability of the Participant to satisfy the TSR Performance Goal or in any way prevents the satisfaction of the TSR Performance Goal.  Any portion of the one-half of the Awarded Units (and related dividend equivalents) subject to this Section 3(a) that exceeds the portion of the Awarded Units that becomes vested and nonforfeitable upon the written certification by the Committee shall be forfeited.

 

b.             The extent to which the Participant’s rights and interest in one-fifth of the Awarded Units becomes vested and non-forfeitable and ceases to be restricted shall be based upon the satisfaction of the performance goal specified in this Section 3(b) (the “Dividend Growth Performance Goal”).  The Dividend Growth Performance Goal shall be based upon the average annual growth in dividends paid per Common Share over the Performance Period, expressed as a percentage (rounded to the nearest tenth of a percent (0.1%)), determined by (i) adding the change in dividends paid per Common Share in each calendar year during the Performance Period over the dividends paid per Common Share in the preceding calendar year, with any negative change considered a zero, and (ii) dividing such sum by the dividends paid per Common Share in 2013 (that is, $.90), and further (iii) dividing the resulting amount by three.  The portion of the Participant’s rights and interest in the one-fifth of the Awarded Units subject to this Section 3(b), if any, that becomes vested and nonforfeitable and ceases to be restricted in the Performance Period shall be determined in accordance with the following schedule, using linear interpolation, as certified by the Committee:

 

2



 

Company Dividend Growth

 

Percentage of One-Fifth of Awarded Units Vested

 

Less than 2%

 

0

%

2%

 

50

%

3%

 

100

%

4% or more

 

300

%

 

For the Performance Period, the applicable portion of the Participant’s interest in the Awarded Units subject to this Section 3(b) shall become vested and nonforfeitable and shall cease being restricted upon written certification by the Committee that the corresponding Dividend Growth Performance Goal for the Performance Period has been satisfied; provided, the Participant is employed by (or if the Participant is a Consultant or an Outside Trustee, is providing services to) the Company or a Subsidiary on the date of the Committee’s certification.  The Committee shall make this determination within ninety (90) days of the last day of the Performance Period.  Any determination as to whether or not and to what extent the Dividend Growth Performance Goal has been satisfied shall be made by the Committee in its sole and absolute discretion and shall be final, binding and conclusive on all persons, including, but not limited to, the Company and the Participant.  The Participant shall not be entitled to any claim or recourse if any action or inaction by the Company, or any other circumstance or event, including any circumstance or event outside the control of the Participant, adversely affects the ability of the Participant to satisfy the Dividend Growth Performance Goal or in any way prevents the satisfaction of the Dividend Growth Performance Goal.  Any portion of the one-fifth of the Awarded Units (and related dividend equivalents) subject to this Section 3(b) that exceeds the portion of the Awarded Units that becomes vested and nonforfeitable upon the written certification by the Committee shall be forfeited.

 

c.             The extent to which the Participant’s rights and interest in one-tenth of the Awarded Units becomes vested and non-forfeitable and ceases to be restricted shall be based upon the satisfaction of the performance goal specified in this Section 3(c) (the “Absolute TSR Performance Goal”).  The Absolute TSR Performance Goal shall be based upon the “Absolute TSR Percentage,” as defined below, achieved during the Performance Period.  “Absolute TSR Percentage” means the compounded annual growth rate, expressed as a percentage (rounded to the nearest tenth of a percent (0.1%)), in the value per share of Common Shares during the Performance Period due to the appreciation in the price per share of Common Shares and dividends paid during the Performance Period, assuming reinvestment of all dividends paid during the Performance Period.  The Absolute TSR Percentage is calculated as follows:

 

 

where:

 

·                   “D” means the amount of dividends paid to a shareholder of record with respect to one share of Common Shares during the Performance Period;

·                   “N” means the number of full calendar years completed during the Performance Period;

·                   “Ending Share Price” means the 20-day simple moving average for the Common Shares on December 31, 2016;

 

3



 

·                   “Beginning Share Price” means the 20-day simple moving average for the Common Shares on December 31, 2013.

 

The portion of the Participant’s rights and interest in the one-tenth of the Awarded Units subject to this Section 3(c), if any, that becomes vested and nonforfeitable and ceases to be restricted in the Performance Period shall be determined in accordance with the following schedule, using linear interpolation, as certified by the Committee:

 

Company Absolute TSR

 

Percentage of One-Tenth of Awarded Units Vested

 

Less than 7%

 

0

%

7%

 

50

%

10%

 

100

%

14% or more

 

300

%

 

For the Performance Period, the applicable portion of the Participant’s interest in the Awarded Units subject to this Section 3(c) shall become vested and nonforfeitable and shall cease being restricted upon written certification by the Committee that the corresponding Absolute TSR Performance Goal for the Performance Period has been satisfied; provided, the Participant is employed by (or if the Participant is a Consultant or an Outside Trustee, is providing services to) the Company or a Subsidiary on the date of the Committee’s certification.  The Committee shall make this determination within ninety (90) days of the last day of the Performance Period.  Any determination as to whether or not and to what extent the Absolute TSR Performance Goal has been satisfied shall be made by the Committee in its sole and absolute discretion and shall be final, binding and conclusive on all persons, including, but not limited to, the Company and the Participant.  The Participant shall not be entitled to any claim or recourse if any action or inaction by the Company, or any other circumstance or event, including any circumstance or event outside the control of the Participant, adversely affects the ability of the Participant to satisfy the Absolute TSR Performance Goal or in any way prevents the satisfaction of the Absolute TSR Performance Goal.  Any portion of the one-tenth of the Awarded Units (and related dividend equivalents) subject to this Section 3(c) that exceeds the portion of the Awarded Units that becomes vested and nonforfeitable upon the written certification by the Committee shall be forfeited.

 

d.             The extent to which the Participant’s rights and interest in one-fifth of the Awarded Units becomes vested and non-forfeitable and ceases to be restricted shall be based upon the satisfaction of the performance goal specified in this Section 3(d) (the “Investment Grade Performance Goal”).  The Investment Grade Performance Goal shall be based upon the investment grade achieved by the last day of the Performance Period.  The portion of the Participant’s rights and interest in the one-fifth of the Awarded Units subject to this Section 3(d), if any, that becomes vested and nonforfeitable and ceases to be restricted in the Performance Period shall be determined in accordance with the following schedule, using linear interpolation, as certified by the Committee:

 

4



 

Company’s Investment Grade

 

Percentage of One-Fifth of Awarded Units 
Vested

 

Below investment grade rated

 

0

%

Investment grade rated

 

100

%

Investment grade plus one or more notches

 

300

%

 

For the Performance Period, the applicable portion of the Participant’s interest in the Awarded Units subject to this Section 3(d) shall become vested and nonforfeitable and shall cease being restricted upon written certification by the Committee that the corresponding Investment Grade Performance Goal for the Performance Period has been satisfied; provided, the Participant is employed by (or if the Participant is a Consultant or an Outside Trustee, is providing services to) the Company or a Subsidiary on the date of the Committee’s certification.  The Committee shall make this determination within ninety (90) days of the last day of the Performance Period.  Any determination as to whether or not and to what extent the Investment Grade Performance Goal has been satisfied shall be made by the Committee in its sole and absolute discretion and shall be final, binding and conclusive on all persons, including, but not limited to, the Company and the Participant.  The Participant shall not be entitled to any claim or recourse if any action or inaction by the Company, or any other circumstance or event, including any circumstance or event outside the control of the Participant, adversely affects the ability of the Participant to satisfy the Investment Grade Performance Goal or in any way prevents the satisfaction of the Investment Grade Performance Goal.  Any portion of the one-fifth of the Awarded Units (and related dividend equivalents) subject to this Section 3(d) that exceeds the portion of the Awarded Units that becomes vested and nonforfeitable upon the written certification by the Committee shall be forfeited.

 

e.             Notwithstanding the foregoing schedules, no fractional Common Shares shall be issued, and subject to the preceding limitations on the number of related Common Shares available under this Agreement (that is, 300% of the related Common Shares), any fractional Common Share that would have resulted from the foregoing calculations shall be rounded up to the next whole Common Share.

 

f.             Notwithstanding anything to the contrary in this Agreement, the Committee may, in its discretion, adjust (upwards or downwards) the number of related Common Shares that would otherwise be delivered in settlement of the Awarded Units that vest and become nonforfeitable based on achievement of the corresponding performance goal, notwithstanding the level of achievement of such performance goal.  Notwithstanding anything to the contrary in this Agreement, the Committee may, in its sole discretion, accelerate the Performance Period and determine the actual level achieved of the TSR Performance Goal under Section 3(a), the Dividend Growth Performance Goal under Section 3(b), and the Absolute TSR Performance Goal under Section 3(c) (which determination may be by means of a good faith estimate) at any time after the first year of the Performance Period and determine the number of Common Shares that may be delivered in settlement of the Awarded Units; provided, the settlement of 409A Awarded Units (as defined in Section 25) may not be accelerated by the Company except to the extent permitted under Code Section 409A (as defined in Section 25).

 

g.             In the event of a Change in Control at a time that the Participant’s Awarded Units have not yet vested, a portion of the Participant’s Awarded Units shall vest and become

 

5



 

nonforfeitable based on the actual level of the performance goal achieved.  For purposes of Sections 3(a), (b), (c), and (d), the Company shall determine the actual level of the performance goal achieved (such determination may be by means of a good faith estimate) immediately prior to the Change in Control and shall calculate the resulting number of Awarded Units that would have become vested and nonforfeitable (based on such calculation) assuming the determination date was the end of the Performance Period and the Committee had certified such level of achievement.  No fractional Common Shares shall be issued, and subject to the preceding limitations on the number of related Common Shares available under this Agreement (that is, 300% of the related Common Shares), any fractional Common Share that would have resulted from the foregoing calculations shall be rounded up to the next whole Common Share.  Any Awarded Units (and related dividend equivalents) that were unvested immediately prior to the Change in Control and that exceed the portion of the Awarded Units that become vested and nonforfeitable under this Section 3(g) shall be forfeited.

 

4.             Forfeiture of Awarded Units .

 

a.             In General.   Except as otherwise provided in this Section 4, Awarded Units (and related dividend equivalents) that are not vested in accordance with Section 3 shall be forfeited on the date of the Participant’s Termination of Service.  Upon forfeiture, all of the Participant’s rights and interest with respect to the forfeited Awarded Units (and related dividend equivalents) shall cease and terminate, without any further obligations on the part of the Company.

 

b.             Death or Total and Permanent Disability .  In the event that the Participant’s Termination of Service is due to death or Total and Permanent Disability at a time that the Participant’s Awarded Units have not yet vested, a pro rata portion of the Participant’s Awarded Units shall vest and become nonforfeitable as follows:  First, the Company shall determine the actual level of the performance goal achieved (such determination may be by means of a good faith estimate) as of the Company’s fiscal quarter-end coincident with or next preceding the Participant’s Termination of Service (or, if the Participant’s Termination of Service occurs in the first fiscal quarter of the Performance Period, then the Company’s fiscal quarter-end coincident with or next following the Participant’s Termination of Service) and calculating, on a preliminary basis, the resulting number of Awarded Units that would have become vested and nonforfeitable (based on such calculation) assuming the determination date was the end of the Performance Period and the Committee had certified such level of achievement.  Second, a pro rata portion of that number of Awarded Units will be calculated by multiplying that number by a fraction, the numerator of which is the number of months from the Date of Grant through the date of Termination of Service (rounding any partial month to the next whole month) and the denominator of which is 36.  No fractional Common Shares shall be issued, and subject to the preceding limitations on the number of related Common Shares available under this Agreement (that is, 300% of the related Common Shares), any fractional Common Share that would have resulted from the foregoing calculations shall be rounded up to the next whole Common Share.  Any Awarded Units (and related dividend equivalents) that were unvested at the date of Termination of Service and that exceed the pro rata portion of the Awarded Units that become vested and nonforfeitable under this Section 4(b) shall be forfeited.

 

c.             Retirement .  In the event that the Participant’s Termination of Service is due to Retirement at a time that the Participant’s Awarded Units have not yet vested,  the greater of: (i) 100% of the Participant’s Awarded Units or (ii) the portion of the Participant’s Awarded Units that would otherwise vest and become nonforfeitable based on the actual level of the performance goal achieved, shall vest and become nonforfeitable.  The Company shall determine the actual level of the performance goal achieved (such determination may be by means of a good faith

 

6



 

estimate) immediately prior to the Participant’s Termination of Service and shall calculate the resulting number of Awarded Units that would have become vested and nonforfeitable (based on such calculation) assuming the determination date was the date of the Participant’s Termination of Service and the Committee had certified such level of achievement.  No fractional Common Shares shall be issued, and subject to the preceding limitations on the number of related Common Shares available under this Agreement (that is, 300% of the related Common Shares), any fractional Common Share that would have resulted from the foregoing calculations shall be rounded up to the next whole Common Share.

 

5.             Restrictions on Transfer of Awarded Units .  Subject to the provisions of the Plan and the terms of this Agreement, the Participant shall not be permitted to sell, transfer, pledge, hypothecate, margin, assign or otherwise encumber any of the Awarded Units, related rights to dividend equivalents or any other rights relating thereto, and the Awarded Units, related rights to dividend equivalents and other rights relating thereto, shall not be subject to execution, attachment, lien, or similar process; provided, however, the Participant will be entitled to designate a beneficiary or beneficiaries to receive any settlement in respect of the Awarded Units upon the death of the Participant, in the manner and to the extent permitted by the Committee.  Any purported transfer or other transaction not permitted under this Section 5 shall be deemed null and void.

 

6.             Timing and Manner of Settlement of Awarded Units .

 

a.             Settlement Timing.   Unless and until the Awarded Units become vested and nonforfeitable in accordance with Sections 3 and 4 of this Agreement, the Participant will have no right to settlement of any such Awarded Units.  Awarded Units will be settled under this Section 6 by the Company delivering to the Participant (or his beneficiary in the event of death) a number of Common Shares equal to the number of Awarded Units that have become vested and nonforfeitable in accordance with Section 3 or 4 of this Agreement and are to be settled at the applicable settlement date.  In the case of Awarded Units that become vested and nonforfeitable upon the Committee’s certification in accordance with Sections 3(a), (b), (c) and (d) of this Agreement, such Awarded Units will be settled at a date that is as prompt as practicable after the date of the Committee’s certification but in no event later than two and one-half (2 1/2) months after the date of the Company’s certification.  The settlement of Awarded Units that become vested and nonforfeitable in accordance with Section 3(g) will be made on or before the Change in Control.  The settlement of Awarded Units that become vested and nonforfeitable in accordance with Section 4(b) will be made at a date that is as prompt as practicable after the Participant’s Termination of Service but in no event later than two and one-half (2 1/2) months after the end of the calendar year in which Termination of Service occurred.  The settlement of Awarded Units that become vested and nonforfeitable in accordance with Section 4(c) will be made within ninety (90) days of the  Participant’s Termination of Service, provided, however, that if such ninety-day period spans two calendar years, then such settlement shall be made in the portion of such period that falls within the later calendar year.

 

b.             Manner of Settlement .  The Company may make delivery of Common Shares in settlement of Awarded Units by either delivering certificates representing such Common Shares to the Participant (if requested by the Participant in accordance with Section 6.3(a) of the Plan and the Company has elected, in its sole discretion, to issue certificates (as opposed to electronic book entry form with respect to its Common Shares)) or by registering the Common Shares in the Participant’s name.  In no event will the Company issue fractional Common Shares.

 

c.             Effect of Settlement .  Neither the Participant nor any of the Participant’s successors, heirs, assigns or personal representatives shall have any further rights or interests in

 

7



 

any Awarded Units that have been paid and settled.  Although a settlement date or range of dates for settlement are specified above, the Company retains discretion to determine the settlement date, and no Participant or beneficiary of a Participant shall have any claim for damages or loss by virtue of the fact that the market price of Common Shares was higher on a given date upon which settlement could have been made as compared to the market price on or after the actual settlement date (any claim relating to settlement will be limited to a claim for delivery of Common Shares and related dividend equivalents).

 

7.             Legend .  The following legend shall be inserted on a certificate, if issued, evidencing Common Shares issued under the Plan if the Common Shares were not issued in a transaction registered under the applicable federal and state securities laws:

 

“Common Shares represented by this certificate have been acquired by the holder for investment and not for resale, transfer or distribution, have been issued pursuant to exemptions from the registration requirements of applicable state and federal securities laws, and may not be offered for sale, sold or transferred other than pursuant to effective registration under such laws, or in transactions otherwise in compliance with such laws, and upon evidence satisfactory to the Company of compliance with such laws, as to which the Company may rely upon an opinion of counsel satisfactory to the Company.”

 

8.             Dividend Equivalents .  During the period beginning on the Date of Grant and ending on the date that Common Shares are issued in settlement of Awarded Units, the Participant will accrue dividend equivalents equal to the cash dividend or distribution that would have been paid had the Awarded Unit been an issued and outstanding Common Share on the record date for the dividend or distribution.  Such accrued dividend equivalents (i) will vest and become payable upon the same terms and at the same time of settlement as the Awarded Units to which they relate; (ii) will be payable with respect to the total number of Awarded Units that become vested and nonforfeitable; and (ii) will be denominated and payable solely in cash.  Dividend equivalent payments, at settlement, will be net of applicable federal, state, local and social insurance withholding taxes (subject to Section 22 of this Agreement).

 

9.             Adjustment to Number of Awarded Units .  The number of Awarded Units shall be subject to adjustment in accordance with Articles 11 through 13 of the Plan.  Any such adjustment shall be made taking into account any crediting of cash dividend equivalents to the Participant under Section 8 in connection with such transaction or event.  Restricted Share Units credited to the Participant as a result of an adjustment shall be subject to the same forfeiture and settlement terms as applied to the related Awarded Units prior to the adjustment.

 

10.          Specific Performance .  The parties acknowledge that remedies at law will be inadequate remedies for breach of this Agreement and consequently agree that this Agreement shall be enforceable by specific performance.  The remedy of specific performance shall be cumulative of all of the rights and remedies at law or in equity of the parties under this Agreement.

 

11.          Participant’s Acknowledgments .  The Participant acknowledges that a copy of the Plan has been made available for his review by the Company, and represents that he is familiar with the terms and provisions thereof, and hereby accepts this Award subject to all the terms and provisions thereof.  The Participant hereby agrees to accept as binding, conclusive, and final all decisions or interpretations of the Committee or the Board, as appropriate, upon any questions arising under the Plan or this Agreement.  The Participant acknowledges and agrees that (i) sales of Common Shares delivered in settlement of the

 

8



 

Awarded Units will be subject to the Company’s policies regulating trading by Employees, Consultants and Outside Trustees, including any applicable “blackout” or other designated periods in which sales of Common Shares are not permitted, and (ii) Common Shares delivered in settlement will be subject to any recoupment or “clawback” policy applied with prospective or retroactive effect.

 

12.          Law Governing .  This Agreement shall be governed by, construed, and enforced in accordance with the laws of the State of Maryland (excluding any conflict of laws rule or principle of Maryland law that might refer the governance, construction, or interpretation of this agreement to the laws of another state).

 

13.          No Right to Continue Service or Employment .  Nothing herein shall be construed to confer upon the Participant the right to continue in the employ or to provide services to the Company or any Subsidiary, whether as an Employee or as a Consultant or as an Outside Trustee, or interfere with or restrict in any way the right of the Company or any Subsidiary to discharge the Participant as an Employee, Consultant, or Outside Trustee at any time.

 

14.          Legal Construction .  In the event that any one or more of the terms, provisions, or agreements that are contained in this Agreement shall be held by a court of competent jurisdiction to be invalid, illegal, or unenforceable in any respect for any reason, the invalid, illegal, or unenforceable term, provision, or agreement shall not affect any other term, provision, or agreement that is contained in this Agreement and this Agreement shall be construed in all respects as if the invalid, illegal, or unenforceable term, provision, or agreement had never been contained herein.

 

15.          Covenants and Agreements as Independent Agreements .  Each covenant and agreement that is set forth in this Agreement shall be construed as a covenant and agreement independent of any other provision of this Agreement.  The existence of any claim or cause of action of the Participant against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by the Company of the covenants and agreements that are set forth in this Agreement.

 

16.          Entire Agreement .  This Agreement together with the Plan supersede any and all other prior understandings and agreements, either oral or in writing, between the parties with respect to the subject matter hereof and constitute the sole and only agreements between the parties with respect to the said subject matter.  All prior negotiations and agreements between the parties with respect to the subject matter hereof are merged into this Agreement.  Each party to this Agreement acknowledges that no representations, inducements, promises, or agreements, orally or otherwise, have been made by any party or by anyone acting on behalf of any party, which are not embodied in this Agreement or the Plan and that any agreement, statement or promise that is not contained in this Agreement or the Plan shall not be valid or binding or of any force or effect.

 

17.          Parties Bound .  The terms, provisions, and agreements that are contained in this Agreement shall apply to, be binding upon, and inure to the benefit of the parties and their respective heirs, executors, administrators, legal representatives, and permitted successors and assigns, subject to the limitation on assignment expressly set forth herein.

 

18.          Modification .  No change or modification of this Agreement shall be valid or binding upon the parties unless the change or modification is in writing and signed by the parties.  Notwithstanding the preceding sentence, the Company may amend the Plan or this Agreement to the extent permitted by the Plan.

 

9



 

19.          Headings .  The headings that are used in this Agreement are used for reference and convenience purposes only and do not constitute substantive matters to be considered in construing the terms and provisions of this Agreement.

 

20.          Gender and Number .  Words of any gender used in this Agreement shall be held and construed to include any other gender, and words in the singular number shall be held to include the plural, and vice versa, unless the context requires otherwise.

 

21.          Notice .  Any notice required or permitted to be delivered hereunder shall be deemed to be delivered only when actually received by the Company or by the Participant, as the case may be, at the addresses set forth below, or at such other addresses as they have theretofore specified by written notice delivered in accordance herewith:

 

a.             Notice to the Company shall be addressed and delivered as follows:

 

Physicians Realty Trust

735 North Water Street, Suite 1000

Milwaukee, Wisconsin  53202

Attn: Corporate Secretary

Fax: (414) 978-6550

 

Notice to the Participant shall be addressed and delivered as set forth on the signature page.

 

22.          Tax Requirements The Participant is hereby advised to consult immediately with his or her own tax advisor regarding the tax consequences of this Agreement.  The Company or, if applicable, any Subsidiary (for purposes of this Section 22, the term “Company” shall be deemed to include any applicable Subsidiary) shall have the right to deduct from all amounts paid in cash or other form in connection with the Plan, any federal, state, local, or other taxes required by law to be withheld in connection with this Award.  The Company may, in its sole discretion, also require the Participant receiving Common Shares in settlement of Awarded Units pay the Company the amount of any taxes that the Company is required to withhold in connection with the Participant’s income arising with respect to this Award.  Such payments shall be required to be made when requested by the Company and may be required to be made prior to the delivery of any certificate representing Common Shares, if such certificate is requested by the Participant in accordance with Section 6.3(a) of the Plan.  Such payment may be made (i) by the delivery of cash to the Company in an amount that equals or exceeds (to avoid the issuance of fractional shares under (iii) below) the required tax withholding obligations of the Company; (ii) if the Company, in its sole discretion, so consents in writing, the actual delivery by the Participant to the Company of Common Shares, other than (A) Restricted Shares, or (B) Common Shares that the Participant has acquired from the Company within six (6) months prior thereto, which shares so delivered have an aggregate Fair Market Value that equals or exceeds (to avoid the issuance of fractional shares under (iii) below) the required tax withholding payment; (iii) if the Company, in its sole discretion, so consents in writing, the Company’s withholding of a number of shares to be delivered upon the vesting of this Award, which shares so withheld have an aggregate Fair Market Value that equals (but does not exceed) the required tax withholding payment; or (iv) any combination of (i), (ii), or (iii).  The Company may, in its sole discretion, withhold any such taxes from any other cash remuneration otherwise paid by the Company to the Participant.

 

23.          REIT Status .  This Agreement shall be interpreted and construed in a manner consistent with the Company’s status as a real estate investment trust.

 

10



 

24.          Unfunded Plan .  The Participant acknowledges and agrees that any rights of the Participant to the Participant’s Awarded Units and related dividend equivalents and any other related rights shall constitute bookkeeping entries on the books of the Company and shall not create in the Participant any right to or claim against any specific assets of the Company or any Subsidiary, nor result in the creation of any trust or escrow account for the Participant.  With respect to the Participant’s entitlement to any payment hereunder, the Participant shall be a general creditor of the Company.

 

25.          Code Section 409A.   Payments made pursuant to this Agreement are intended to be exempt from, or to otherwise comply with, Section 409A of the Code and the Treasury regulations and guidance issued thereunder (collectively, “Code Section 409A”).  Accordingly, other provisions of the Plan or this Agreement notwithstanding, the provisions of this Section 25 will apply in order that the Awarded Units, and related dividend equivalents and any other related rights, will be exempt from or otherwise comply with Code Section 409A.  In addition, the Company and the Committee reserve the right, to the extent the Company or the Committee deems necessary or advisable in its sole discretion, to unilaterally amend or modify the Plan and/or this Agreement to ensure that all Awarded Units, and related dividend equivalents and any other related rights, are exempt from or otherwise comply, and in operation comply, with Code Section 409A (including, without limitation, the avoidance of penalties thereunder).  Other provisions of the Plan and this Agreement notwithstanding, the Company makes no representations that the Awarded Units, and related dividend equivalents and any other related rights, will be exempt from or avoid any penalties that may apply under Code Section 409A, makes no undertaking to preclude Code Section 409A from applying to the Awarded Units and related dividend equivalents and any other related rights, and will not indemnify or provide a gross up payment to a Participant (or his beneficiary) for any taxes, interest or penalties imposed under Code Section 409A.  The settlement of Awarded Units that constitute nonqualified deferred compensation within the meaning of Code Section 409A (“409A Awarded Units”) may not be accelerated by the Company except to the extent permitted under Code Section 409A.  The Company may, however, accelerate the vesting of 409A Awarded Units, without changing the settlement terms of such 409A Awarded Units.  In the case of any settlement of 409A Awarded Units during a specified period following any date triggering a right to settlement, the Participant shall have no influence on any determination as to the tax year in which the settlement will be made.  Notwithstanding any other provision in this Agreement, if the Participant is a “specified employee” for purposes of Code Section 409A as of the date of the Participant’s Termination of Service, then to the extent any amount payable under this Agreement (i) constitutes the payment of nonqualified deferred compensation, within the meaning of Code Section 409A, (ii) is payable upon the Participant’s Termination of Service for a reason other than death, and (iii) under the terms of this Agreement would be payable prior to the six-month anniversary of the Participant’s Termination of Service, such payment shall be delayed and paid to the Participant on the day that is six months and one day following the Participant’s Termination of Service or, if earlier, within ninety (90) days following the Participant’s death.

 

11



 

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer, and the Participant, to evidence his or her consent and approval of all the terms hereof, has duly executed this Agreement, as of the date specified in Section 1 hereof.

 

 

COMPANY:

 

 

 

 

PHYSICIANS REALTY TRUST

 

 

 

 

 

 

 

By:

 

 

Name:

 

 

Title:

 

 

 

 

 

 

 

 

PARTICIPANT:

 

 

 

 

 

 

Signature

 

 

 

 

 

 

 

Name:

 

 

Address:

 

 

 

 

 

12


Exhibit 99.1

 

GRAPHIC

 

PRESS RELEASE

 

Contact:

Physicians Realty Trust
John T. Thomas

President and CEO

(214) 549-6611

jtt@docreit.com

John W. Sweet

(414) 978-6611

jws@docreit.com

Investors:
The Ruth Group
Stephanie Carrington/David Burke
646 536-7017/7009
scarrington@theruthgroup.com

dburke@theruthgroup.com

 

Physicians Realty Trust Reports First Quarter 2014 Financial Results Including First Quarter Acquisitions Totaling $147.4 million and Also Announces

$31 Million in Real Estate Acquisitions

Completed in April 2014

 

First Quarter Highlights:

 

·                   Reported first quarter 2014 total revenue of $8.0 million(1), up 141.0% year-over-year

·                   Recorded first quarter 2014 rental revenue of $6.8 million(1), a 172.6% year-over-year increase

·                   Generated quarterly normalized funds from operations (FFO) of $0.12(1) on a fully diluted basis

·                   Closed seven acquisitions comprised of 13 buildings totaling 550,670 square feet for approximately $147.4 million in the aggregate

·                   Declared quarterly dividend of $0.225 per share for the first quarter 2014, paid April 25 th , 2014

·                   Surpassed 93.5% portfolio wide occupancy based on square footage as of March 31, 2014

·                   Increased gross leasable square footage by 61.1% to 1,452,013 square feet as of March 31, 2014, from 901,343 as of December 31, 2013

 

Milwaukee, WI —May 7, 2014 — Physicians Realty Trust (NYSE: DOC) (the “Company,” the “Trust,” “we,” “our” and “us”), a self-managed healthcare real estate company, today announced results for the first quarter ended March 31, 2014.

 



 

John Thomas, President and Chief Executive Officer of the Trust, commented, “During the first quarter of 2014, we continued to successfully execute on our acquisition strategy, utilizing proceeds from the December 2013 equity capital raise and our increased credit line capacity. In total, we deployed over $147 million in capital during the first quarter in acquiring high quality medical office buildings, highlighted by the purchase of Peachtree Dunwoody Medical Center.  Peachtree Dunwoody is a showcase investment, located in the heart of Atlanta’s “Pill Hill” hospital market, anchored by Northside Hospital, Peachtree Orthopedics and several other high quality medical practice tenants.  In the aggregate, we increased leasable square footage of our portfolio by over 61% and increased our overall occupancy to close to 94% during the quarter.  Other medical office acquisitions included high quality oncology facilities, leased to practices owned and managed by 21 st  Century Oncology along the southwest Florida coast and family practice clinics developed, owned, and operated by Eagles Landing Family Practice, in suburban Atlanta.   We also expanded our existing relationships with Foundation Surgical Hospitals and LifeCare Healthcare, with new long term sale-leaseback transactions.  All of these investments present the long term opportunity to collect reliable rising rental revenues.”

 

“A unique benefit of our focus on investment with physician groups and hospital operators, with whom we have long term relationships, is the opportunity to build our investment pipeline with opportunities referred to us by our existing physician and hospital partners.  Hospital CEOs and physicians alike are calling us to explore opportunities, and we continue to develop a strong pipeline for future growth,” Mr. Thomas added. “With the implementation of changes to the healthcare system in the U.S., the needs of physicians, in particular those in private practice, are evolving. This provides Physicians Realty Trust with numerous opportunities in the current market to develop and build relationships in which we can support the needs of our tenant partners, as well as create value for our shareholders through portfolio expansion, which will enable us to provide a reliable, rising dividend.”

 

First Quarter Financial Results (1)

 

Total revenues for the first quarter of 2014 were $8.0 million, an increase of 141.0% compared to the three months ended March 31, 2013 for our Predecessor.

 

Rental revenues for the three months ended March 31, 2014 were $6.8 million, an increase of 172.6% from the same period in 2013 for our Predecessor, owing to the expansion of the Company’s portfolio to 40 properties totaling 1,452,013 square feet, of which 93.5% were leased as of March 31, 2014. On a pro forma basis as if all the 2014 first quarter acquisitions occurred on the first day of the first quarter of 2014, rental

 


(1)   Comparative financial results for the three-month period ended March 31, 2013 reflect the operations of the Company’s predecessor. The predecessor was not a legal entity but rather a combination of real estate entities under common control by The Ziegler Companies, Inc. and represents results prior to completion of our IPO and our ownership of the properties in our initial portfolio.

 



 

revenues would have increased by an additional $2.8 million, to a pro forma total of $9.6 million.

 

Total expenses for the first quarter 2014 were $11.6 million, an increase of 214.5% or $7.9 million, compared to our Predecessor’s first quarter of 2013.  General and administrative expenses increased by $1.9 million from the build out of the public company infrastructure ($0.7 million in payroll/benefits, which includes $0.3 million of non-cash stock compensation costs, $0.7 million in professional fees, $0.3 million in other administrative costs and $0.2 million in Board of Trustee expenses), $4.3 million from acquisition related expenses, and $1.4 million from increased depreciation and amortization. On a pro forma basis as if all the 2014 first quarter acquisitions occurred on the first day of the first quarter 2014, depreciation and amortization and interest expense would have increased by an additional $1.1 million and $0.4 million, respectively.

 

Net loss for the first quarter of 2014 was $3.6 million, compared to a net loss of $0.3 million for the first quarter of 2013 for our Predecessor.

 

Net loss attributable to common shareholders for the first quarter of 2014 was $3.1 million, or $0.15 per diluted share based on 21.3 million weighted average shares outstanding.

 

Funds from operations (FFO) for the first quarter 2014, comprised of net loss plus depreciation and amortization, were negative at $1.1 million, or $(0.05) per diluted share. Normalized FFO, which adds back acquisition expenses, were $3.1 million, or $0.12 per diluted share.

 

Normalized Funds available for distribution (FAD) for the first quarter 2014, which consists of normalized FFO adjusted for non-cash share compensation, straight-line rent adjustments, amortization of acquired above-market leases, amortization of lease inducements and amortization of deferred financing fees, was $3.0 million, or $0.12 per diluted share for the first quarter 2014.

 

As previously announced, the Company declared a dividend of $0.225 per share for the first quarter. The dividend was payable on April 25, 2014 to shareholders of record on April 11, 2014.

 

Recent Events

 

On April 22, 2014, through a subsidiary of its operating partnership, the Company closed on the acquisition of the Pinnacle Health Cardiology Portfolio, consisting of two medical office buildings located in Wormleysburg and Carlisle, Pennsylvania from Front Carlisle Investors, LLC.  The buildings total approximately 38,118 square feet, are 100% occupied as of April 30, 2014 and were acquired for approximately $9.3 million in cash.

 

On April 30, 2014, through a subsidiary of its operating partnership, the Company closed on the acquisition of an approximately 45,200 square foot medical official building

 



 

known as the South Bend Orthopaedics Medical Office Building, located in Mishawaka, Indiana for $14.9 million. The building is 100% occupied as of April 30, 2014 and was acquired for approximately $14.9 million in cash.

 

Trent Miller, Chief Executive Officer of South Bend Orthopaedics commented, “We have been very impressed with Physicians Realty Trust as we worked through some very complicated aspects of our sale transaction. Based on how well they handled those issues, we are confident our long term relationship going forward will be mutually beneficial.”

 

On April 30, 2014, through a subsidiary of its operating partnership, the Company closed on the acquisition of an approximately 52,818 square foot medical office building located in Grenada, Mississippi.  The medical office building is 94.7% occupied as of April 30, 2014 and was acquired for approximately $7.1 million in cash.

 

Commenting on the acquisitions, Mr. Thomas stated, “We are pleased to have closed these acquisitions in such a short period of time, which was possible as a result of our robust pipeline and financial flexibility. This is representative of our strategy to aggressively build a large portfolio of high quality medical office buildings through small transactions in which we face less competition and have the advantage of close relationships. Since the beginning of 2014, we have closed $186.8 million in real estate investments, and a total of $323.2 million since our initial public offering in July of last year. More importantly, our average cap rate for the acquisitions since our IPO is 8.24%, providing a significant return on our investment.”

 

Conference Call Information

 

The Company has scheduled a conference call on Wednesday, May 7, 2014 at 10:00 a.m. ET to discuss its financial performance and operating results for the first quarter ended March 31, 2014. The conference call can be accessed by dialing (877) 407-0784 from within the U.S. or (201) 689-8560 for international callers. Participants can reference the Physicians Realty Trust First Quarter 2014 Earnings Call or passcode 13579307. The conference call will also be available via a live listen-only webcast and can be accessed through the Investor Relations section of the Company’s website, www.docreit.com. A replay of the conference call will be available beginning May 7, 2014 at 1:00 p.m. ET until May 14, 2014 at 11:59 p.m. ET, by dialing (877) 870-5176 (U.S.) or (858) 384-5517 (International); passcode: 13579307. A replay of the webcast will also be accessible on the Investor Relations website for one year following the event. The Company’s supplemental information package for the first quarter 2014 also will be accessible through the Investor Relations section of the Company’s website under the “Supplemental Information” tab.

 

About Physicians Realty Trust

 

Physicians Realty Trust (NYSE: DOC) is a self-managed healthcare real estate company was organized in 2013 to acquire, selectively develop, own and manage healthcare properties that are leased to physicians, hospitals and healthcare delivery systems. The Company invests in real estate that is integral to providing high quality healthcare. The Company is a Maryland real estate investment trust and plans to make an election to be taxed as a real estate investment trust (REIT) for U.S. federal income tax purposes. The Company conducts its business through an UPREIT structure in which its properties are owned by Physicians Realty L.P., a Delaware limited partnership (the “operating partnership”), directly or through limited partnerships, limited liability companies or other subsidiaries. The Company is the sole general partner of the operating partnership

 



 

and as of March 31, 2014, owns approximately 85.4% of the partnership interests in the operating partnership.

 

The Company had no business operations prior to completion of its initial public offering (the “IPO”) on July 24, 2013. The Company’s predecessor, which is not a legal entity, is comprised of the four healthcare real estate funds managed by B.C. Ziegler & Company (“Ziegler”), which are referred to as the Ziegler Funds, that owned directly or indirectly interests in entities that owned the initial properties the Company acquired through the operating partnership on July 24, 2013 in connection with completion of the IPO and related formation transactions.

 

Forward-Looking Statements

 

Certain matters within this press release are discussed using forward-looking language as specified in the Private Securities Litigation Reform Act of 1995, and, as such, may involve known and unknown risks, uncertainties and other factors that may cause the actual results or performance to differ from those projected in the forward looking statement.  These forward-looking statements may include statements related to the Company’s ability to generate internal and external growth, the 2014 outlook, anticipated cash returns, cap rates or yields on properties, anticipated closing of property acquisitions, and ability to execute its business plan.  While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this press release. We disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. For a description of factors that may cause the Company’s actual results or performance to differ from its forward-looking statements, please review the information under the heading “Risk Factors” included in the Company’s Annual Report on form 10-K filed by the Company with the Securities and Exchange Commission (the “SEC”) on March 21, 2014. Additional information will also be set forth in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 to be filed with the SEC.

 



 

Physicians Realty Trust and Predecessor

Consolidated and Combined Statements of Operations

(In thousands, except share and per share data)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2014

 

Predecessor
2013

 

Revenues:

 

 

 

 

 

Rental revenues

 

$

6,808

 

$

2,497

 

Expense recoveries

 

1,070

 

814

 

Interest income from real estate note receivable and other

 

113

 

5

 

Total revenues

 

7,991

 

3,316

 

Expenses:

 

 

 

 

 

Interest expense, net

 

1,281

 

1,166

 

General and administrative

 

2,014

 

120

 

Operating expenses

 

1,609

 

1,188

 

Depreciation and amortization

 

2,416

 

979

 

Acquisition expenses

 

4,287

 

 

Management fees

 

 

238

 

Total expenses

 

11,607

 

3,691

 

Other income :

 

 

 

 

 

Change in fair value of derivative

 

41

 

74

 

Equity in income of unconsolidated subsidiary

 

17

 

 

Net loss

 

(3,558

)

$

(301

)

Less: Net loss attributable to noncontrolling interests — operating partnership

 

531

 

 

 

Less: Net loss attributable to noncontrolling interests — partially owned properties

 

(66

)

 

 

Net loss attributable to common shareholders

 

(3,093

)

 

 

Net loss per share:

 

 

 

 

 

Basic and diluted

 

$

(0.15

)

 

 

Weighted average common shares:

 

 

 

 

 

Basic and diluted

 

21,298,597

 

 

 

 

 

 

 

 

 

Dividends and distributions declared per common share and unit

 

$

0.225

 

 

 

 

Comparative financial results for the three-month period ended March 31, 2013 reflect the operations of the predecessor. The predecessor was not a legal entity but rather a combination of real estate entities under common control by The Ziegler Companies, Inc. and represents results for the properties in our initial portfolio prior to completion of our IPO.

 



 

Physicians Realty Trust Consolidated Balance Sheets

(In thousands, except share and per share data)

 

 

 

March 31,

 

December 31,

 

 

 

2014

 

2013

 

ASSETS

 

 

 

 

 

Investment properties:

 

 

 

 

 

Land and improvements

 

$

44,419

 

$

26,088

 

Buildings and improvements

 

313,985

 

192,959

 

Tenant improvements

 

5,498

 

5,458

 

Acquired lease intangibles

 

39,712

 

31,236

 

Property under development

 

225

 

225

 

 

 

403,839

 

255,966

 

Accumulated depreciation and amortization

 

(30,858

)

(28,427

)

Net real estate property

 

372,981

 

227,539

 

Real estate loan receivable

 

6,855

 

 

Investment in unconsolidated entity

 

1,317

 

 

Net real estate investments

 

381,153

 

227,539

 

Cash and cash equivalents

 

10,092

 

56,478

 

Tenant receivables, net

 

1,403

 

837

 

Deferred costs, net

 

2,690

 

2,105

 

Other assets

 

6,513

 

5,901

 

Total assets

 

$

401,851

 

$

292,860

 

LIABILITIES AND EQUITY

 

 

 

 

 

Liabilities:

 

 

 

 

 

Debt

 

$

159,382

 

$

42,821

 

Accounts payable

 

722

 

836

 

Dividends payable

 

5,699

 

5,681

 

Accrued expenses and other liabilities

 

3,889

 

2,288

 

Derivative liability

 

356

 

397

 

Total liabilities

 

170,048

 

52,023

 

Equity:

 

 

 

 

 

Common shares, $0.01 par value, 500,000,000 shares authorized, 21,632,863 and 21,548,597 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively

 

216

 

215

 

Additional paid-in capital

 

213,833

 

213,359

 

Accumulated deficit

 

(16,630

)

(8,670

)

Total shareholders’ equity

 

197,419

 

204,904

 

Noncontrolling interests:

 

 

 

 

 

Operating partnership

 

33,749

 

35,310

 

Partially owned properties

 

635

 

623

 

Total noncontrolling interests

 

34,384

 

35,933

 

Total equity

 

231,803

 

240,837

 

Total liabilities and equity

 

$

401,851

 

$

292,860

 

 



 

Physicians Realty Trust

Reconciliation of Non-GAAP Measures

(In thousands, except share and per share data)

 

 

 

Three Months Ended
March 31, 2014

 

Net loss

 

$

(3,558

)

Depreciation and amortization

 

2,416

 

FFO

 

$

(1,142

)

FFO per share

 

$

(0.05

)

Acquisition - related expenses

 

4,287

 

Change in fair value of derivative financial instrument

 

(41

)

Normalized FFO

 

$

3,104

 

Normalized FFO per share

 

$

0.12

 

 

 

 

 

Normalized FFO

 

$

3,104

 

Non-cash share compensation

 

273

 

Straight-line rent adjustments

 

(652

)

Amortization of acquired above market leases

 

46

 

Amortization of lease inducements

 

34

 

Amortization of deferred financing costs

 

148

 

Normalized FAD

 

$

2,953

 

Normalized FAD per share

 

$

0.12

 

 

 

 

 

Weighted average number of shares and units outstanding

 

25,274,626

 

 

This press release includes Funds From Operations, or FFO, and Normalized Funds Available For Distribution, or FAD, which are non-GAAP financial measures. For purposes of the SEC’s Regulation G, a non-GAAP financial measure is a numerical measure of a company’s historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable financial measure calculated and presented in accordance with GAAP in the statement of operations, balance sheet or statement of cash flows (or equivalent statements) of the company, or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable financial measure so calculated and presented. As used in this press release, GAAP refers to generally accepted accounting principles in the United States of America. Pursuant to the requirements of Regulation G, the Company has provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

 

The Company calculates and reports FFO in accordance with the definition and interpretive guidelines issued by the National Association of Real Estate Investment Trusts (“NAREIT”), and consequently, FFO is defined as net income available to common share and unit holders, adjusted for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairments on real estate assets. The Company believes that FFO is an important supplemental measure of its operating performance. Because the historical cost accounting convention used for real estate assets requires depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time, while real estate values instead have historically risen or fallen with market conditions. The term FFO was designed by the real estate industry to address this issue. FFO described herein is not necessarily comparable to FFO of other real estate investment trusts, or REITs, that do not use the same definition or implementation guidelines or interpret the standards differently from the Company.

 

The Company uses FFO as one of several criteria to measure the operating performance of its business. The Company further believes that by excluding the effect of depreciation, amortization, impairments on real estate assets and gains

 



 

or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, FFO can facilitate comparisons of operating performance between periods and between other REITs. The Company offers this measure to assist the users of its financial statements in analyzing its performance; however, this is not a measure of financial performance under GAAP and should not be considered a measure of liquidity, an alternative to net income or an indicator of any other performance measure determined in accordance with GAAP. Investors and potential investors in the Company’s securities should not rely on this measure as a substitute for any GAAP measure, including net income.

 

Normalized FFO is calculated as FFO available to common share and unit holders excluding the impact of non-cash stock-based compensation and certain revenue and expense items identified in the table above. The Company believes that Normalized FFO provides an enhanced measure of the operating performance of the Company’s core portfolio as a REIT. The Company’s computation of Normalized FFO is not comparable to the NAREIT definition of FFO or to similar measures reported by other REITs, but the Company believes it is an appropriate measure for the Company.

 

The Company defines Normalized FAD, a non-GAAP measure, which excludes from Normalized FFO, non-cash compensation expense, straight-line rent adjustments, amortization of acquired above market leases, amortization of deferred financing costs and amortization of lease inducements. The Company believes Normalized FAD provides a meaningful supplemental measure of its ability to fund its ongoing distributions. In order to understand and analyze the Company’s liquidity, Normalized FAD should be compared with cash flow (computed in accordance with GAAP). Normalized FAD should not be considered as an alternative to net income or loss attributable to controlling interest (computed in accordance with GAAP) as an indicator of the Company’s financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of the Company’s liquidity. Normalized FAD should be reviewed in connection with other GAAP measurements.

 


 

Exhibit 99.2

 

March 2014

 

 



 

 

TABLE OF CONTENTS

 

COMPANY OVERVIEW

 

 

 

COMPANY INFORMATION

5

 

 

FIRST QUARTER HIGHLIGHTS

7

 

 

FINANCIAL HIGHLIGHTS

8

 

 

FINANCIAL INFORMATION

 

 

 

FUNDS FROM OPERATIONS (FFO), NORMALIZED FUNDS FROM OPERATIONS (NORMALIZED FFO), AND NORMALIZED FUNDS AVAILABLE FOR DISTRIBUTION (NORMALIZED FAD)

9

 

 

NET OPERATING INCOME AND ADJUSTED EBITDA

10

 

 

MARKET CAPITALIZATION AND DEBT SUMMARY

11

 

 

FINANCIAL STATISTICS

12

 

 

FIRST QUARTER ACQUISITION ACTIVITY AND TENANT OCCUPANCY

13

 

 

PORTFOLIO INFORMATION

 

 

 

PORTFOLIO LEASE EXPIRATIONS AND HISTORICAL OCCUPANCY

14

 

 

PORTFOLIO DISTRIBUTION BY STATE

15

 

 

PORTFOLIO DIVERSIFICATION BY TYPE

16

 

 

TOP 10 HEALTH SYSTEM RELATIONSHIPS

17

 

 

CONSOLIDATED BALANCE SHEETS

18

 

 

CONSOLIDATED AND COMBINED STATEMENTS OF OPERATIONS

19

 

 

REPORTING DEFINITIONS

20

 

 

 

FORWARD LOOKING STATEMENTS:

 

Certain statements made in this supplemental information package constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (set forth in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). In particular, statements pertaining to our capital resources, portfolio performance and results of operations contain forward-looking statements.  Likewise, our pro forma financial statements and our statements regarding anticipated market conditions are forward-looking statements. You can identify forward-looking statements by the use of forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans,” “pro forma,” “estimates” or “anticipates” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans or intentions.

 

2



 

 

Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:

 

·                   general economic conditions;

 

·                   adverse economic or real estate developments, either nationally or in the markets in which our properties are located;

 

·                   our failure to generate sufficient cash flows to service our outstanding indebtedness;

 

·                   fluctuations in interest rates and increased operating costs;

 

·                   the availability, terms and deployment of debt and equity capital, including our senior secured revolving credit facility;

 

·                   our ability to make distributions on our shares of beneficial interest;

 

·                   general volatility of the market price of our common shares;

 

·                   our limited operating history;

 

·                   our increased vulnerability economically due to the concentration of our investments in healthcare properties;

 

·                   a substantial portion of our revenue is derived from our five largest tenants and thus, the bankruptcy, insolvency or weakened financial position of any one of them could seriously harm our operating results and financial condition;

 

·                   our geographic concentrations in Texas and greater Atlanta, Georgia metropolitan area causes us to be particularly exposed to downturns in these economies or other changes in real estate market conditions;

 

·                   changes in our business or strategy;

 

·                   our dependence upon key personnel whose continued service is not guaranteed;

 

·                   our ability to identify, hire and retain highly qualified personnel in the future;

 

·                   the degree and nature of our competition;

 

·                   changes in governmental regulations, tax rates and similar matters;

 

·                   defaults on or non-renewal of leases by tenants;

 

·                   decreased rental rates or increased vacancy rates;

 

·                   difficulties in identifying healthcare properties to acquire and complete acquisitions;

 

·                   competition for investment opportunities;

 

3



 

 

·                   our failure to successfully develop, integrate and operate acquired properties and operations;

 

·                   the impact of our investment in joint ventures;

 

·                   the financial condition and liquidity of, or disputes with, joint venture and development partners;

 

·                   our ability to operate as a public company;

 

·                   changes in accounting principles generally accepted in the United States (or GAAP);

 

·                   lack of or insufficient amounts of insurance;

 

·                   other factors affecting the real estate industry generally;

 

·                   our failure to qualify and maintain our qualification as a REIT for U.S. federal income tax purposes;

 

·                   limitations imposed on our business and our ability to satisfy complex rules in order for us to qualify as a REIT for U.S. federal income tax purposes; and

 

·                   changes in governmental regulations or interpretations thereof, such as real estate and zoning laws and increases in real property tax rates and taxation of REITs.

 

While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this report. We disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes after the date of this prospectus, except as required by applicable law. For a further discussion of these and other factors that could impact our future results, performance or transactions, see Part I, Item 1A (Risk Factors) of our Annual Report on Form 10-K for the fiscal year December 31, 2013 and Part II, Item1A (Risk Factors) of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2014.

 

 

ADDITIONAL INFORMATION

 

The information in this supplemental information package should be read in conjunction with the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, earnings press release dated May 7, 2014 and other information filed with, or furnished to, the SEC. You can access the Company’s SEC reports and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act in the “Investor Relations” section on the Company’s website (www.docreit.com) under the tab “SEC Filings” as soon as reasonably practicable after they are filed with, or furnished to, the SEC. The information on or connected to the Company’s website is not, and shall not be deemed to be, a part of, or incorporated into this supplemental information package. You also can review these SEC filings and other information by accessing the SEC’s website at http://www.sec.gov.

 

4



 

 

ABOUT PHYSICIANS REALTY TRUST

 

Physicians Realty Trust (NYSE:DOC) (the “Trust,” the “Company,” “DOC,” “we,” “our” and “us”) is a self-managed healthcare real estate company organized in 2013 to acquire, selectively develop, own and manage healthcare properties that are leased to physicians, hospitals and healthcare delivery systems.

 

We invest in real estate that is integral to providing high quality healthcare services. Our properties typically are on a campus with a hospital or other healthcare facilities or strategically located and affiliated with a hospital or other healthcare facilities.

 

Our management team has significant public healthcare REIT experience and long established relationships with physicians, hospitals and healthcare delivery system decision makers that we believe will provide quality investment opportunities to generate attractive risk-adjusted returns to our shareholders.

 

We are a Maryland real estate investment trust and will elect to be taxed as a real estate investment trust (REIT) for U.S. federal income tax purposes beginning with our short taxable year ending December 31, 2013 upon the filing of our federal income tax return for such year. We conduct our business through an UPREIT structure in which our properties are owned by Physicians Realty L.P., a Delaware limited partnership (the “operating partnership”), directly or through limited partnerships, limited liability companies or other subsidiaries. We are the sole general partner of the operating partnership and as of March 31, 2014, own approximately 85.4% of the partnership interests in the operating partnership.

 

We had no business operations prior to completion of our initial public offering (the “IPO”) on July 24, 2013. Our predecessor, which is not a legal entity, is comprised of the four healthcare real estate funds managed by B.C. Ziegler & Company (“Ziegler”), which are referred to as the Predecessor Ziegler Funds, that owned directly or indirectly interests in entities that owned the initial properties we acquired through the operating partnership on July 24, 2013 in connection with completion of the IPO and related formation transactions.

 

COMPANY SNAPSHOT

 

 

 

As of
March 31, 2014

 

Gross real estate investments (thousands)

 

$

412,011

 

Total buildings

 

40

 

Occupancy

 

93.5

%

Total portfolio gross leasable area

 

1,452,013

 

 

 

 

 

% of MOB GLA on-campus / affiliated

 

75

%

Average remaining lease term for all buildings (years)

 

10.1

 

 

 

 

 

Cash and cash equivalents (thousands)

 

$

10,092

 

Total debt to total capitalization

 

34.6

%

Weighted average interest rate per annum on portfolio debt

 

3.97

%

Equity market cap (thousands)

 

$

301,129

 

Quarterly dividend

 

$

0.225

 

Quarter end stock price

 

$

13.92

 

Dividend yield

 

6.5

%

Shares and units outstanding (1) 

 

25,331,740

 

Total enterprise value (thousands) (2) 

 

$

512,000

 

 

(1)          In conjunction with our IPO, we issued 2,744,000 common units in our operating partnerships in connection with our acquisition of our initial portfolio of 19 medical office buildings and assumed the debt related to such properties. In connection with our purchase of the Crescent City Surgical Centre, we issued 954,877 common units in our operating partnership as well as additional cash consideration to the physician sellers.

(2)          Represents the value of outstanding shares and units based on the closing stock price on March 31, 2014 plus the amount of outstanding debt at March 31, 2014.

 

5



 

 

ABOUT PHYSICIANS REALTY TRUST CONTINUED

 

Board of Trustees

 

Tommy G. Thompson

Chairman

William A. Ebinger, M.D.

Richard A. Weiss

 

 

 

Albert C. Black

Mark A. Baumgartner

Stanton D. Anderson

Compensation, Nominating and Governance Committee Chair

Finance and Investment Committee Chair

Audit Committee Chair

 

 

 

John T. Thomas

 

 

Chief Executive Officer, President

 

 

 

 

 

Management Team

 

 

 

John T. Thomas

John W. Sweet

Chief Executive Officer, President

Executive Vice President - Chief Investment Officer

 

 

John W. Lucey

Mark D. Theine

Senior Vice President — Principal Accounting and Reporting Officer

Senior Vice President — Asset & Investment Management

 

 

Location & Contact Information

 

 

 

Corporate Headquarters

Transfer Agent

735 N. Water Street, Suite 1000

Registrar and Transfer Company

Milwaukee, WI 53202

10 Commerce Drive

(414) 978-6494

Cranford, NJ 07010

 

(908) 497-2300

 

 

Corporate & REIT Tax Counsel

Investor Relations

Baker & McKenzie

The Ruth Group

Richard Lipton

Stephanie Carrington

Partner

Senior Vice President

300 E Randolph Street

757 Third Avenue, 22 nd  Floor

Chicago, IL 60601

New York, NY 10017

(312) 861-8000

(646) 536-7017

 

 

 

 

External Auditor

 

Ernst & Young

 

155 N. Upper Wacker Drive

 

Chicago, IL 60606

 

(312) 879-2000

 

 

6


 


 

 

FIRST QUARTER HIGHLIGHTS

 

Operating

 

·                   First quarter 2014 total revenue of $8.0 million, up 141.0% over the prior year period

·                   First quarter 2014 rental revenue of $6.8 million, an increase of 172.6% over the prior year period

·                   Generated quarterly funds from operations (Normalized FFO) of $0.12 on a fully diluted basis

·                   Closed on seven acquisitions comprising 13 buildings totaling 550,670 square feet for approximately $147.4 million in the aggregate

·                   Declared quarterly dividend of $0.225 per share for the first quarter

·                   Surpassed 93.5% portfolio wide occupancy based on square footage as of March 31, 2014

·                   Increased gross leasable square footage by 61.1% to 1,452,013 square feet, as of March 31, 2014, from 901,343 at end of fourth quarter 2013

 

First Quarter Acquisitions

 

·                   Foundations San Antonio Surgical Hospital and MOB, San Antonio, TX

·                   Eagles Landing Family Practice, GA

·                   21 st  Century Oncology, Sarasota, FL

·                   Peachtree Dunwoody MOB, Atlanta, GA

·                   LifeCare, Pittsburgh, PA and Fort Worth, TX

 

Company Announcements

 

·                   January 2, 2014: Announced that it closed its previously announced mezzanine loan of approximately $6.9 million to affiliates controlled by MedProperties Holdings, LLC a leading Dallas-based private investor in healthcare real estate (Global Rehab-Rehabilitation Hospital, Scottsdale, AZ, featured on the cover)

·                   January 27, 2014: Announced tax reporting information for dividends paid to its shareholders during the year ended December 31, 2013

·                   February 3, 2014: Entered into an Agreement of Sale and Purchase to purchase an approximately 45,200 square foot medical office building known as South Bend Orthopaedics Medical Office Building

·                   February 11, 2014: Entered into an Agreement of Sale and Purchase to purchase four medical office buildings located in Sarasota, Venice, Engelwood and Port Charlotte, Florida

·                   February 19, 2014: Announced that it closed on the purchase and leaseback of the Eagles Landing Family Practice medical office buildings. The four medical facilities located in Jackson, Conyers and McDonough (2), Georgia total approximately 68,711 square feet and are 100% leased

·                   February 20, 2014: Entered into and closed an Agreement of Sale and Purchase to purchase a surgical hospital located in San Antonio, Texas

·                   February 27, 2014: Announced financial results for the fourth quarter and year ended December 31, 2013

·                   March 3, 2014: Announced the execution and closing of a contract to purchase the Peachtree Dunwoody Medical Center, a premier multi-tenant medical office building located in the heart of Atlanta’s “Pill Hill” hospital market

·                   March 31, 2014: Announced the execution and closing of an Agreement of Sale and Purchase to purchase and leaseback two long-term acute care hospitals located in Pittsburgh, Pennsylvania and Fort Worth, Texas

 

7



 

 

FINANCIAL HIGHLIGHTS

 

(Unaudited and in thousands, except per share data)

See Glossary for definition of terms.

 

 

 

Three Months Ended
March 31, 2014

 

 

 

 

 

INCOME ITEMS

 

 

 

Revenues

 

$

7,991

 

NOI

 

6,399

 

Annualized Adjusted EBITDA

 

18,632

 

Normalized FFO

 

3,104

 

Normalized FAD

 

2,953

 

Net loss Available to Common Shareholders per common share

 

$

(0.15

)

Normalized FAD per common share and unit

 

$

0.12

 

Fixed Charge Coverage Ratio (EBITDA/Int Exp, net)

 

0.08

x

 

 

 

As of

 

 

 

March 31, 2014(1)

 

ASSETS

 

 

 

Gross Real Estate Investments (including gross lease intangibles)

 

$

412,011

 

Total Assets

 

401,851

 

CAPITALIZATION

 

 

 

Total Debt

 

$

159,382

 

Total Shareholder’s Equity

 

231,803

 

Total Market Capitalization (1)

 

352,618

 

Total Debt / Total Market Capitalization

 

45

%

 

(1)          Represents outstanding shares and units at quarter end multiplied by the share price at quarter end.

 

8



 

 

RECONCILIATION OF NON-GAAP MEASURES

See Glossary for definition of terms.

FUNDS FROM OPERATIONS (FFO),

NORMALIZED FUNDS FROM OPERATIONS (NORMALIZED FFO)

AND NORMALIZED FUNDS AVAILABLE FOR DISTRIBUTION (NORMALIZED FAD)

(Unaudited and in thousands, except share and per share data)

 

 

 

Three Months Ended
March 31, 2014

 

Net loss

 

$

(3,558

)

Depreciation and amortization expense

 

2,416

 

FFO

 

$

(1,142

)

FFO per share and unit

 

$

(0.05

)

Acquisition related expenses

 

4,287

 

Net change in fair value of derivative financial instrument

 

(41

)

Normalized FFO

 

$

3,104

 

Normalized FFO per share and unit

 

$

0.12

 

 

 

 

 

Normalized FFO

 

$

3,104

 

Non-cash share compensation expense

 

273

 

Straight-line rent adjustments

 

(652

)

Amortization of acquired above market leases

 

46

 

Amortization of lease inducements

 

34

 

Amortization of deferred financing costs

 

148

 

Normalized FAD

 

$

2,953

 

Normalized FAD per share and unit

 

$

0.12

 

 

 

 

 

Weighted average number of shares and units outstanding

 

25,274,626

 

 

9



 

 

NET OPERATING INCOME AND ADJUSTED EBITDA

(Unaudited and in thousands)

See Glossary for definition of terms.

 

Net Operating Income (NOI)

 

 

 

Three Months Ended
March 31, 2014 
(1)

 

Net loss

 

$

(3,558

)

General and administrative

 

2,014

 

Acquisition related expenses

 

4,287

 

Depreciation and amortization

 

2,416

 

Interest expense, net

 

1,281

 

Change in fair value of derivative liability

 

(41

)

NOI

 

$

6,399

 

 

 

 

 

NOI

 

$

6,399

 

Straight-line rent adjustments

 

(652

)

Amortization of acquired above market leases

 

46

 

Amortization of lease inducement

 

34

 

Cash NOI

 

$

5,827

 

Cash NOI percentage growth over 4 th  quarter 2013

 

20.6

%

 

Adjusted EBITDA

 

 

 

Three Months Ended
March 31, 2014

 

Net loss

 

$

(3,558

)

 

 

 

 

Depreciation and amortization

 

2,416

 

Interest expense, net

 

1,281

 

Change in fair value of derivative liability

 

(41

)

EBITDA

 

98

 

Acquisition related expenses

 

4,287

 

Non-cash share compensation

 

273

 

Adjusted EBITDA

 

$

4,658

 

 

 

 

 

Adjusted EBITDA Annualized (1)

 

$

18,632

 

 

(1)          We have been operating as a public REIT for less than a full year and can make no assurances that our actual EBITDA or Adjusted EBITDA in future periods will be consistent with the annualized amount shown above and may differ significantly.

 

10



 

 

MARKET CAPITALIZATION AND DEBT SUMMARY

(In thousands, except share and per share data)

 

Market Capitalization

 

Revolving Credit Facility Debt

 

$

80,000

 

Senior Notes and Term Loans

 

79,382

 

Total Debt

 

$

159,382

 

 

 

 

 

Stock price (closing price as of March 31, 2014)

 

$

13.92

 

Total Common Shares Outstanding

 

21,632,863

 

Equity Market Capitalization

 

$

301,129

 

 

 

 

 

Total Capitalization (Debt + Equity)

 

$

460,511

 

 

 

 

 

Total Debt / Total Capitalization

 

34.6

%

Total Debt / Total Assets

 

39.7

%

Total Debt / Total Enterprise Value

 

31.1

%

 

Debt Summary

 

 

 

Balance as of
March 31, 2014

 

Stated Interest
Rate:

 

Interest
Rate (1):

 

Maturity Date:

 

 

 

 

 

 

 

 

 

 

 

Revolving Credit Facility

 

$

80,000

 

LIBOR + 2.65

%

 

 

8/29/2016

 

Senior Notes and Term Loans:

 

 

 

 

 

 

 

 

 

Canton MOB

 

6,282

 

5.94

%

5.94

%

06/06/17

 

Firehouse Square

 

2,812

 

6.58

%

6.58

%

09/06/17

 

Hackley Medical Center

 

5,486

 

5.93

%

5.93

%

01/06/17

 

MeadowView Professional Center

 

10,538

 

5.81

%

5.81

%

6/06/17

 

Mid Coast Hospital MOB

 

8,023

 

LIBOR + 2.25

%

4.82

%

05/16/16

 

Remington Medical Commons

 

4,499

 

LIBOR + 2.75

%

2.93

%

09/28/17

 

Valley West Hospital MOB

 

4,957

 

4.83

%

4.83

%

11/10/20

 

Oklahoma City, OK MOB

 

7,771

 

4.71

%

4.71

%

01/01/20

 

Crescent City Surgical Center

 

18,750

 

5.00

%

5.00

%

02/01/19

 

San Antonio Hospital

 

10,264

 

5.00

%

5.00

%

06/01/22

 

Total:

 

$

159,382

 

 

 

 

 

 

 

 

(1) Weighted average interest rate per annum on portfolio debt: 5.26%

(2) Weighted average interest rate per annum on portfolio debt: 3.97%

 

 

11



 

 

FINANCIAL STATISTICS

(Unaudited and in thousands, except share and per share data)

 

 

 

March 31, 2014

 

Weighted Average Shares and Units Outstanding

 

 

 

Weighted average common shares

 

21,298,597

 

Weighted average unvested restricted shares

 

334,266

 

Weighted average units

 

3,698,877

 

Weighted Average Shares and Units - Diluted

 

25,331,740

 

 

 

 

 

Outstanding Common Shares and OP Units at Quarter End

 

25,331,740

 

 

 

 

 

Common Dividend Yield

 

 

 

Annualized dividend rate (1)

 

$

0.90

 

Price per share (2)

 

$

13.92

 

Annualized dividend yield

 

6.47

%

 

 

 

 

Net Debt / Adjusted EBITDA Ratio

 

 

 

Total debt

 

$

159,382

 

Net debt (less cash)

 

$

149,290

 

Adjusted EBITDA (annualized)*

 

$

18,632

 

Net Debt / Adjusted EBITDA Ratio

 

8.01x

 

 

 

 

 

Interest Coverage Ratio

 

 

 

Adjusted EBITDA (annualized)*

 

$

18,632

 

Cash interest expense (annualized)*

 

$

4,532

 

Interest Coverage Ratio

 

4.11x

 

 

 

 

 

Quarterly Fixed Charge Coverage Ratio

 

 

 

Total interest

 

$

1,281

 

Secured debt principal amortization

 

384

 

Total fixed charges

 

$

1,665

 

Adjusted EBITDA

 

$

4,658

 

Adjusted fixed charge coverage ratio

 

2.80x

 

 

 

 

 

Enterprise Value

 

 

 

Outstanding shares and units multiplied by stock price (3/31/14)

 

$

352,618

 

Total debt

 

159,382

 

Total Enterprise Value

 

$

512,000

 

 

 

 

 

Leverage

 

 

 

Total debt

 

$

159,382

 

Total assets

 

$

401,851

 

Total Debt / Total Assets

 

39.7

%

Total Debt / Total Enterprise Value

 

31.1

%

 

(1)          Annualized rate based on $0.225 quarterly dividend for the quarter ending March 31, 2014. Actual dividend amounts will be determined by the Trust’s board of trustees based on a variety of factors.

(2)          Closing share price of $13.92 as of March 31, 2014

   *              Amounts are annualized and actual amounts may differ significantly from the annualized amounts shown.

 

12



 

 

FIRST QUARTER ACQUISITION ACTIVITY AND TENANT OCCUPANCY

 

Acquisition Activity

 

Property

 

Property Location

 

Date Acquired

 

Percent Leased
at Acquisition

 

Purchase
Price

 

GLA

 

Foundations San Antonio Hospital

 

San Antonio, TX

 

2/19/2014

 

100

%

$

25,555,555

 

45,954

 

Eagles Landing Family Practice

 

GA

 

2/19/2014

 

100

%

$

20,800,000

 

68,711

 

21 st  Century Oncology

 

Sarasota, FL

 

2/26/2014

 

100

%

$

17,486,000

 

46,895

 

Foundations San Antonio MOB

 

San Antonio, TX

 

2/28/2014

 

100

%

$

6,800,000

 

22,832

 

Peachtree Dunwoody MOB

 

Atlanta, GA

 

2/28/2014

 

96

%

$

36,726,000

 

131,368

 

LifeCare Ft. Worth

 

Fort Worth, TX

 

3/31/2014

 

100

%

$

27,160,493

 

80,000

 

LifeCare Pittsburgh

 

Pittsburgh, PA

 

3/31/2014

 

100

%

$

12,839,507

 

154,910

 

Total

 

 

 

 

 

 

 

$

147,367,555

 

550,670

 

 

Tenant Occupancy

 

Total Portfolio

 

 

 

Total GLA at beginning of quarter

 

901,343

 

Occupied GLA beginning of quarter

 

820,895

 

Occupancy percentage beginning of quarter

 

91.1

%

 

 

 

 

Occupied GLA from leasing

 

 

 

Expirations:

 

 

 

Expiring GLA

 

(47,643

)

Leasing:

 

 

 

Renewal leases in Q1

 

38,098

 

New leases commencing in Q1

 

0

 

Lease terminations in Q1

 

0

 

Total leasing activity

 

38,098

 

 

 

 

 

GLA change from acquisitions/dispositions

 

 

 

Occupied acquisitions square feet added

 

545,491

 

Vacant square feet acquired

 

5,179

 

Total acquisitions square feet added

 

550,670

 

 

 

 

 

Occupied disposition square feet

 

0

 

 

 

 

 

Total square feet end of quarter

 

1,452,013

 

Occupied square feet end of quarter

 

1,356,841

 

Occupancy percentage end of quarter

 

93.5

%

 

13



 

 

PORTFOLIO LEASE EXPIRATIONS AND HISTORICAL OCCUPANCY

as of March 31, 2014

 

Portfolio Lease Expirations

 

Expiration

 

Number
of Leases
Expiring

 

Total
GLA of
Expiring
Leases

 

Percent of
Area
Represented
by Expiring
Leases

 

Annualized
Base Rent
Under
Expiring
Leases (1)

 

Percent of
Total
Annualized
Base Rent
of
Expiring
Leases

 

Annualized
Rent
Leased by
GLA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2014

 

9

 

21,336

 

1.5

%

$

552,983

 

1.6

%

25.92

 

2015

 

8

 

24,770

 

1.7

%

482,320

 

1.4

%

19.47

 

2016

 

11

 

68,254

 

4.7

%

1,586,613

 

4.7

%

23.25

 

2017

 

6

 

30,301

 

2.1

%

881,951

 

2.6

%

29.11

 

2018

 

16

 

146,019

 

10.1

%

3,152,757

 

9.3

%

21.59

 

2019

 

8

 

99,329

 

6.8

%

2,234,756

 

6.6

%

22.50

 

2020

 

6

 

17,957

 

1.2

%

433,500

 

1.3

%

24.14

 

2021

 

6

 

44,814

 

3.1

%

1,090,090

 

3.2

%

24.32

 

2022

 

3

 

13,517

 

0.9

%

288,034

 

0.8

%

21.31

 

2023

 

1

 

52,000

 

3.6

%

1,248,000

 

3.7

%

24.00

 

Thereafter:

 

36

 

836,944

 

57.6

%

21,948,686

 

64.7

%

26.22

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

MTM

 

1

 

1,600

 

0.1

%

9,000

 

0.0

%

5.63

 

Vacant

 

26

 

95,172

 

6.6

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total/Average:

 

137

 

1,452,013

 

100.0

%

$

33,908,690

 

100.0

%

$

24.99

 

 

(1)Calculated by multiplying (a) base rent payments for the month ended March 31, 2014, by (b) 12.

 

Historical Occupancy

 

 

 

As of

 

 

 

3/31/2014

 

12/31/2013

 

9/30/2013

 

6/30/2013

 

3/31/2013

 

Total Portfolio Occupancy, end of period

 

93.5

%

91.1

%

90.3

%

84.6

%

82.5

%

 

 

14



 

 

PORTFOLIO DISTRIBUTION BY STATE

as of March 31, 2014

 

Market

 

GLA

 

% of Portfolio

 

Texas

 

364,012

 

25.07

%

Georgia

 

347,632

 

23.94

%

Pennsylvania

 

154,910

 

10.67

%

Michigan

 

92,210

 

6.35

%

Ohio

 

76,433

 

5.26

%

Illinois

 

74,912

 

5.16

%

Florida

 

69,214

 

4.77

%

Tennessee

 

64,200

 

4.42

%

Louisiana

 

60,000

 

4.13

%

Oklahoma

 

52,000

 

3.58

%

Maine

 

44,677

 

3.08

%

Wisconsin

 

26,377

 

1.82

%

Arizona

 

12,800

 

0.88

%

Montana

 

12,636

 

0.87

%

Total

 

1,452,013

 

100

%

 

 

15



 

 

PORTFOLIO DIVERSIFICATION BY TYPE

as of  March 31, 2014

 

Portfolio Diversification by Type

 

 

 

Number
of
Buildings

 

GLA

 

% of
Total
GLA

 

Occupancy

 

Number
of States

 

Medical office buildings:

 

 

 

 

 

 

 

 

 

 

 

Single-tenant

 

17

 

354,830

 

24.4

%

91.9

%

8

 

Multi-tenant

 

17

 

603,877

 

41.6

 

89.0

 

9

 

Other facilities that serve healthcare industry:

 

 

 

 

 

 

 

 

 

 

 

Hospitals

 

3

 

182,954

 

12.6

 

100.0

 

2

 

Post-acute

 

3

 

310,352

 

21.4

 

100.0

 

2

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

40

 

1,452,013

 

100.0

%

 

 

 

 

 

Campus Proximity and Asset Type

 

 

 

Hospital and Post-Acute Care Coverage Ratio (EBITDAR / Rent) for March 31, 2014 is 3.21x.

 

16



 

 

TOP 10 HEALTH SYSTEM RELATIONSHIPS (TENANTS)

as of March 31, 2014

 

Tenant

 

Weighted
Average
Remaining
Lease Term

 

Total Leased
GLA

 

Percent of
Leased GLA

 

Annualized Base
Rent

 

Percent of
Annualized
Base Rent

 

LifeCare

 

13.76

 

310,352

 

21.37

%

4,697,063

 

13.85

%

East El Paso Physicians Medical Center

 

14.43

 

77,000

 

5.30

%

3,282,377

 

9.68

%

Crescent City Surgical Centre

 

14.51

 

60,000

 

4.13

%

3,000,000

 

8.85

%

Foundation Bariatric Hospital

 

11.23

 

68,786

 

4.74

%

2,884,873

 

8.51

%

Northside Hospital

 

8.81

 

72,102

 

4.97

%

1,817,889

 

6.60

%

Eagles Landing Family Practice

 

14.93

 

68,711

 

4.73

%

1,560,000

 

4.60

%

21 st  Century

 

11.92

 

44,295

 

3.05

%

1,454,839

 

4.29

%

Foundation Surgical Affiliates, LLC

 

9.51

 

52,000

 

3.58

%

1,248,000

 

3.68

%

Holston Medical Group

 

5.16

 

42,220

 

2.91

%

895,498

 

2.64

%

Peachtree Orthopaedics

 

9.34

 

27,573

 

1.90

%

810,066

 

2.39

%

 

 

17



 

 

CONSOLIDATED BALANCE SHEETS

(In thousands, except for share and per share data)

 

 

 

March 31,

 

December 31,

 

 

 

2014

 

2013

 

 

 

(Unaudited)

 

(Audited)

 

ASSETS

 

 

 

 

 

Investment properties:

 

 

 

 

 

Land and improvements

 

$

44,419

 

$

26,088

 

Building and improvements

 

313,985

 

192,959

 

Tenant improvements

 

5,498

 

5,458

 

Acquired lease intangibles

 

39,712

 

31,236

 

Property under development

 

225

 

225

 

 

 

403,839

 

255,966

 

Accumulated depreciation

 

(30,858

)

(28,427

)

Net real estate property

 

372,981

 

227,539

 

Real estate loan receivable

 

6,855

 

 

Investment in unconsolidated entity

 

1,317

 

 

Net real estate investments

 

381,153

 

227,539

 

Cash and cash equivalents

 

10,092

 

56,478

 

Tenant receivables, net

 

1,403

 

837

 

Deferred costs, net

 

2,690

 

2,105

 

Other assets

 

6,513

 

5,901

 

Total assets

 

$

401,851

 

$

292,860

 

LIABILITIES AND EQUITY

 

 

 

 

 

Liabilities:

 

 

 

 

 

Debt

 

$

159,382

 

$

42,821

 

Accounts payable

 

722

 

836

 

Dividend payable

 

5,699

 

5,681

 

Accrued expenses and other liabilities

 

3,889

 

2,288

 

Derivative liability

 

356

 

397

 

Total liabilities

 

170,048

 

52,023

 

Equity:

 

 

 

 

 

Common shares, $0.01 par value, 500,000,000 shares authorized, 21,632,863 and 21,548,597 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively.

 

216

 

215

 

Additional paid-in capital

 

213,833

 

213,359

 

Accumulated deficit

 

(16,630

)

(8,670

)

Total shareholders’ equity

 

197,419

 

204,904

 

Noncontrolling interests:

 

 

 

 

 

Operating partnership

 

33,749

 

35,310

 

Partially owned properties

 

635

 

623

 

Total noncontrolling interest

 

34,384

 

35,933

 

Total equity

 

231,803

 

240,837

 

Total liabilities and equity

 

$

401,851

 

$

292,860

 

 

18



 

 

CONSOLIDATED STATEMENTS OF OPERATION

(In thousands, except share and per share data)

 

 

 

Three Months Ended

 

 

 

March 31, 2014

 

 

 

 

 

Predecessor

 

 

 

2014

 

2013 (1)

 

Revenues:

 

 

 

 

 

Rental revenues

 

$

6,808

 

$

2,497

 

Expense recoveries

 

1,070

 

814

 

Interest income on real estate loans and other

 

113

 

5

 

Total revenues

 

7,991

 

3,316

 

Expenses:

 

 

 

 

 

Interest expense, net

 

1,281

 

1,166

 

General and administrative

 

2,014

 

120

 

Operating expenses

 

1,609

 

1,188

 

Depreciation and amortization

 

2,416

 

979

 

Acquisition expenses

 

4,287

 

 

Management fees

 

 

238

 

Total expenses

 

11,607

 

3,691

 

Other income:

 

 

 

 

 

Change in fair value of derivative

 

41

 

74

 

Equity in income of unconsolidated entity

 

17

 

 

Net loss

 

(3,558

)

$

(301

)

Less: Net loss attributable to noncontrolling interests — operating partnership

 

531

 

 

 

Less: Net income attributable to noncontrolling interests — partially owned properties

 

(66

)

 

 

Net loss attributable to common shareholders

 

$

(3,093

)

 

 

Net loss per share:

 

 

 

 

 

Basic and diluted

 

$

(0.15

)

 

 

Weighted average common shares:

 

 

 

 

 

Basic and diluted

 

21,298,597

 

 

 

 

 

 

 

 

 

Dividends and distributions declared per common share and unit

 

$

0.225

 

 

 

 

(1)          The results of operation for the three months ended March 31, 2013 reflect the results of operations of the Predecessor Ziegler Funds.

 

19



 

 

GLOSSARY

 

Adjusted Earnings Before Interest Taxes, Depreciation and Amortization (Adjusted EBITDA): We define Adjusted EBITDA for DOC as net (loss) income computed in accordance with GAAP plus depreciation, amortization, interest expense and net change in the fair value of derivative financial instruments, net (loss) included from discontinued operations, stock based compensation, and acquisition-related expenses. We consider Adjusted EBITDA an important measure because it provides additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

 

Annualized Base Rent: Annualized base rent is calculated by multiplying contractual base rent for December 2013 by 12 (but excluding the impact of concessions and straight-line rent).

 

Earnings Before Interest Taxes, Depreciation, Amortization and Rent (EBITDAR): We define EBITDAR for DOC as net (loss) income computed in accordance with GAAP plus depreciation, amortization, interest expense and net change in the fair value of derivative financial instruments, net (loss) included from discontinued operations, stock based compensation, acquisition-related expenses and lease expense. We consider EBITDAR an important measure because it provides additional information to allow management, investors, and our current and potential creditors to evaluate and compare our tenants ability to fund their rent obligations.

 

Funds From Operations (FFO): Funds from operations, or FFO, is a widely recognized measure of REIT performance. Although FFO is not computed in accordance with generally accepted accounting principles, or GAAP, we believe that information regarding FFO is helpful to shareholders and potential investors because it facilitates an understanding of the operating performance of our initial properties without giving effect to real estate depreciation and amortization, which assumes that the value of real estate assets diminishes ratably over time. Because real estate values have historically increased or decreased with market conditions, we believe that FFO provides a more meaningful and accurate indication of our performance. We calculate FFO in accordance with the April 2002 National Policy Bulletin of the National Association of Real Estate Investment Trusts, or NAREIT, which we refer to as the “White Paper.” The White Paper defines FFO as net income (computed in accordance with GAAP) before noncontrolling interests of holders of OP units, excluding gains (or losses) on sales of depreciable operating property and extraordinary items (computed in accordance with GAAP), plus real estate related depreciation and amortization (excluding amortization of deferred financing costs). Our FFO computation may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with the White Paper definition or that interpret the White Paper definition differently than we do. The GAAP measure that we believe to be most directly comparable to FFO, net income (loss), includes depreciation and amortization expenses, gains or losses on property sales and noncontrolling interests. In computing FFO, we eliminate these items because, in our view, they are not indicative of the results from the operations of our properties. To facilitate a clear understanding of our historical operating result, FFO should be examined in conjunction with net income (determined in accordance with GAAP) as presented in our financial statements. FFO does not represent cash generated from operating activities in accordance with GAAP, should not be considered to be an alternative to net income (loss) (determined in accordance with GAAP) as a measure of our liquidity and is not indicative of funds available for our cash needs, including our ability to make cash distributions to shareholders.

 

Gross Leasable Area (GLA): Gross leasable area (in square feet)

 

Gross Real Estate Investments: Based on acquisition price (and includes lease intangibles).

 

Health System-Affiliated: Properties are considered affiliated with a health system if one or more of the following conditions are met: 1) the land parcel is contained within the physical boundaries of a hospital campus; 2) the land parcel is located adjacent to the campus; 3) the building is physically connected to the hospital regardless of the land ownership structure; 4) a ground lease is maintained with a health system entity; 5) a master lease is maintained with a health system entity; 6) significant square footage is leased to a health system entity; 7) the property includes an ambulatory surgery center with a hospital partnership interest; or (8) a significant square footage is leased to a physician group that is either employed, directly or indirectly by a health system, or has a significant clinical and financial affiliation with the health system.

 

Hospitals: Hospitals generally include acute care hospitals, inpatient rehabilitation hospitals and long-term acute care hospitals. Acute care hospitals provide a wide range of inpatient and outpatient services, including, but not limited to, surgery, rehabilitation, therapy and clinical laboratories. Long-term acute care hospitals provide inpatient services for patients with complex medical conditions who require more intensive care, monitoring or emergency support than that available in most skilled nursing facilities.

 

Medical Office Building: Medical office buildings are office and clinic facilities, often located near hospitals or on hospital campuses, specifically constructed and designed for use by physicians and other health care personnel to provide services to their patients. They may also include ambulatory surgery centers that are used for general or specialty surgical procedures not requiring an overnight stay in a hospital. Medical office buildings may contain sole and group physician practices and may provide laboratory and other patient services.

 

Net Operating Income (NOI): NOI is a non-GAAP financial measure that is defined as net income or loss, computed in accordance with GAAP, generated from DOC’s total portfolio of properties before general and administrative expenses, acquisition-related expenses, depreciation and amortization expense, REIT expenses, interest expense and net change in the fair value of derivative financial instruments, and gains or loss on the sale of discontinued properties. DOC believes that NOI provides an accurate measure of operating performance of its operating assets because NOI excludes certain items that are not associated with management of the properties. Additionally, DOC’s use of the term NOI may not be comparable to that of other real estate companies as they may have different methodologies for computing this amount.

 

Cash Net Operating Income (NOI): Cash NOI is a non-GAAP financial measure which excludes from NOI straight-line rent adjustments, amortization of acquired below and above market leases and other non-cash and normalizing items. Other non-cash and normalizing items include items such as the amortization of lease inducements. DOC believes that Cash NOI provides an accurate measure of the operating performance of its operating assets because it excludes certain items that are not associated with management of the properties. Additionally, DOC believes that Cash NOI is a widely accepted measure of comparative operating performance in the real estate community. However, DOC’s use of the term Cash NOI may not be comparable to that of other real estate companies as such other companies may have different methodologies for computing this amount.

 

20



 

 

GLOSSARY CONTINUED

 

Normalized Funds Available for Distribution (Normalized FAD): DOC defines Normalized FAD, a non-GAAP measure, which excludes from Normalized FFO, non-cash compensation expense, straight-line rent adjustments, amortization of acquired above market leases, amortization of deferred financing costs and amortization of lease inducements. DOC believes Normalized FAD provides a meaningful supplemental measure of its ability to fund its ongoing distributions. In order to understand and analyze DOC’s liquidity, Normalized FAD should be compared with cash flow (computed in accordance with GAAP). Normalized FAD should not be considered as an alternative to net income or loss attributable to controlling interest (computed in accordance with GAAP) as an indicator of DOC’s financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of DOC’s liquidity. Normalized FAD should be reviewed in connection with other GAAP measurements.

 

Normalized Funds From Operations (Normalized FFO): Changes in the accounting and reporting rules under GAAP have prompted a significant increase in the amount of non-operating items included in FFO, as defined. Therefore, DOC uses Normalized FFO, which excludes from FFO acquisition-related expenses, net change in fair value of derivative financial instruments, non-controlling income from operating partnership units included in diluted shares, acceleration of deferred financing costs, and other normalizing items. However, DOC’s use of the term Normalized FFO may not be comparable to that of other real estate companies as they may have different methodologies for computing this amount. Normalized FFO should not be considered as an alternative to net income or loss attributable to controlling interest (computed in accordance with GAAP) as an indicator of DOC’s financial performance or to cash flow operating activities (computed in accordance with GAAP) as an indicator of DOC’s liquidity, nor its indicative of funds available to fund DOC’s cash needs, including its ability to make distributions. Normalized FFO should be reviewed in connection with other GAAP measurements.

 

Occupancy:   Occupancy represents the percentage of total gross leasable area that is leased, including month-to-month leases and leases that are signed but not yet commenced, as of the date reported.

 

Off-Campus:   A building portfolio that is not located on or adjacent to key hospital based-campuses and is not affiliated with recognized healthcare systems.

 

On-Campus / Affiliated: On-campus refers to a property that is located on or within a quarter mile to a healthcare system. Affiliated refers to a property that is not on the campus of a healthcare system, but anchored by a healthcare system.

 

21